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CD137 is a member of the TNF receptor family, and is involved in the regulation of 
activation, proliferation, differentiation and cell death of leukocytes. Bidirectional 
signaling exists for the CD137 receptor / ligand system as CD137 ligand which is 
expressed as a transmembrane protein, can also transduce signals into the cells it is 
expressed on. In this study we have identified the expression of CD137 and CD137 
ligand on small subsets of bone marrow cells. Activation of hematopoietic progenitor 
cells – CD34+ cells in the human system and Lin-, CD117+ cells in the murine system 
– through CD137 ligand induces activation, prolongation of survival, proliferation and 
colony formation. Concomitantly to proliferation, the cells differentiate to colony 
forming units granulocyte macrophage (CFU-GM), and then to monocytes and 
macrophages but not to granulocytes or dendritic cells. Hematopoietic progenitor cells 
differentiated in the presence of CD137 protein display enhanced phagocytic activity, 
secrete high levels of IL-10 but no IL-12 in response to LPS, and can partially 
suppress T cell activation and proliferation in an allogeneic mixed lymphocyte 
reaction. CD137 and G-CSF cooperatively induce survival and proliferation of murine 
bone marrow cells, while they compete for inducing monocytic and granulocytic 
differentiation, respectively. The number of CD137
+
 cells in the bone marrow is 
positively regulated during infection and inflammation. These data uncover a novel 
function of CD137 and CD137 ligand by showing their participation in hematopoiesis, 
in particular, myelopoiesis and monocytosis.  
 
 xi 
LIST OF TABLES 
Table 1 Structure features of human CD137 protein. 14 
Table 2 Biological functions of reverse signaling through CD137L in 
hematopoietic cells. 
28 
Table 3 Differential cytokine profiles between CD137-Fc- and Fc-treated 
bone marrow cells on day 7 detected by cytokine antibody array. 
109 
Table 4 CD137 expression on AA101 cells is proportional to the cell density. 136 
   
   
   
   
   
   
   
 xii 
LIST OF FIGURES 
Figure 1.1 Overview of hematopoiesis and the role of cytokines in vivo. 4 
Figure 1.2 Classification of macrophage populations. 8 
Figure 1.3 Schematic diagram of the structure of murine and human CD137 mRNA and protein. 13 
Figure 1.4 Schematic diagram of the structure of murine and human CD137L mRNA and protein. 20 
Figure 1.5 Schematic diagram of bidirectional signal transduction of the CD137 receptor / ligand system. 21 
Figure 2.1 Schematic diagram of the structure of recombinant CD137-Fc protein. 35 
Figure 2.2 Schematic diagram of coating proteins or antibodies onto the tissue culture plates. 37 
Figure 3.1 CD137 and CD137L expression. 50 
Figure 3.2 CD137 induces morphological changes of CD34
+
 cells. 52 
Figure 3.3 CD137 maintains survival and induces proliferation of CD34
+
 cells. 54 
Figure 3.4 CD137L agonists immobilized on beads induce proliferation of CD34
+
 cells. 55 
Figure 3.5 CD137L signaling promotes colony formation. 57 
Figure 3.6 Flow cytometric analysis of CD137-induced differentiation of CD34
+
 cells. 60 
Figure 3.7 Morphological comparison of CD137 differentiated cells, DCs and macrophages. 63 
Figure 3.8 RT-PCR of macrophage- and DC-specific genes. 64 
Figure 3.9 Flow cytometric analysis of DC / macrophage cell surface marker expression on CD137-treated cells. 67 
 xiii 
Figure 3.10 Phagocytic function analysis. 68 
Figure 3.11 IL-10 and IL-12p70 ELISA. 69 
Figure 3.12 MLR. 70 
Figure 3.13 IL-8 ELISA. 71 
Figure 3.14 CD137-induced survival and proliferation of CD34
+
 cells are partially dependent on IL-8. 73 
Figure 3.15 CD137-induced proliferation of CD34
+
 cells increases exponentially with the increasing initial cell density. 74 
Figure 3.16 CD137 is unable to induce proliferation of human MoDCs. 76 
Figure 3.17 CD137L crosslinking increases cell numbers of murine bone marrow cells. 79 
Figure 3.18 CD137L crosslinking induces proliferation of bone marrow cells. 80 




 cells. 82 
Figure 3.20 Tracking of cell division. 83 
Figure 3.21 Morphological changes induced by CD137 protein. 85 
Figure 3.22 Colony formation from bone marrow cells in response to CD137. 87 




 cells in response to CD137. 89 
Figure 3.24 Effect of neutralizing anti-GM-CSF antibody on CD137-induced morphological changes, proliferation, and colony 
formation. 
90 
Figure 3.25 Expression of CD137 and CD137L in the bone marrow. 92 
 xiv 
Figure 3.26 Functional equivalence of human and murine CD137. 94 
Figure 3.27 CD137L signaling induces differentiation of bone marrow cells to monocytic cells. 99 




 cells to monocytic cells. 103 
Figure 3.29 Phagocytosis assay. 105 
Figure 3.30 Allogeneic MLR. 107 
Figure 3.31 ELISA of IL-10 and IL-12p70. 108 
Figure 3.32 Cytokine profile. 109 




 macrophages partially suppress T cell proliferation in an allogeneic MLR. 111 
Figure 3.34 CD137 does not induce proliferation of mouse ES cells. 113 
Figure 3.35 CD137 does not induce apoptosis of bone marrow granulocytes. 116 
Figure 3.36 Ethidium bromide and acridine orange staining. 117 
Figure 3.37 G-CSF and CD137 synergizes to induce proliferation and survival of bone marrow cells. 118 
Figure 3.38 Cell morphology. 119 
Figure 3.39 G-CSF and CD137 compete for inducing granulocytic and monocytic differentiation, respectively. 122 
Figure 3.40 Dose response of the combination of G-CSF and CD137 protein. 125 
Figure 3.41 Esterase staining. 126 
Figure 3.42 CD137 and Flt3L cooperatively induce morphological changes of bone marrow cells. 129 
 xv 
Figure 3.43 Flt3L and CD137 additively induce survival and proliferation of bone marrow cells. 130 
Figure 3.44 CD137 supports Flt3L induced bone marrow derived DCs differentiation. 131 






 cells. 132 
Figure 3.46 AA101 cells express CD137 and CD137L. 134 
Figure 3.47 ST-2 and MS-5 cells express neither CD137 nor CD137L. 136 
Figure 3.48 B. pertussis infection leads to an increase of CD137
+
 cells in the bone marrow. 138 
Figure 3.49 Influenza A infection leads to an increase of CD137
+
 cells in the bone marrow. 139 
Figure 3.50 I.p. injection of LPS leads to an increase of CD137
+
 cells in the bone marrow. 141 
Figure 3.51 Activated T cells could induce bone marrow cell proliferation. 143 
Figure 4.1 Proposed schematic summary of CD137-induced myelopoiesis. 151 
   
 xvi 
LIST OF ABBREVIATIONS 
 
APC   Antigen presenting cells 
BM    Bone marrow 
bp    Base pair 
CBA   Cytokine beads array 
CD137L  CD137 ligand 
CFSE   Carboxyfluorescein diacetate, succinimidyl ester 
CFU-G   Colony forming unit-granulocyte 
CFU-GM  Colony forming unit-granulocyte/macrophage 
CFU-M   Colony forming unit-macrophage  
CPM   Count per minute 
CMP   Common myeloid progenitors  
DC    Dendritic cells 
EDTA    Ethylenediamine tetraacetic acid  
ELISA   Enzyme-linked immunosorbent assay 
EPO   Erythropoietin 
ES    Embryonic stem 
FACS    Fluorescence activated cell sorting 
Fc     Fc portion of an antibody 
FITC    Fluorescein isothiocyanate 
Flt3L   Fms-like tyrosine kinase 3 (Flt3) ligand 
G-CSF   Granulocyte colony stimulating factor 
GM-CSF  Granulocyte macrophage colony stimulating factor 
GMP   Granulocyte macrophage progenitors 
HPC   Hematopoietic progenitor cells 
HRP   Horseradish peroxidase 
HSC   Hematopoietic stem cells  
HSPC   Hematopoietic stem / progenitor cells 
ICC    Immunocytochemistry 
IFN    Interferon  
IHC   Immunohistochemstry 
IL     Interleukin 
ILA    Induced by lymphocyte activation 
i.p.    Intra-peritoneal  
IRB    Institutional review board   
i.v.    Intra-venous  
KC    Keratinocyte cytokine 
KO    Knockout 
LIF    Leukemia inhibitory factor 
LPS   Lipopolysaccarides 
mAb    Monoclonal antibody 
MACS   Magnetic activated cell sorting 
 xvii 
mCD137-Fc  Murine CD137-Fc 
MCP-1   Monocyte chemoattractant protein-1 
M-CSF   Monocyte colony stimulating factor 
MDSC   Myeloid derived suppressor cells 
MoDC   Monocyte derived dendritic cells 
MFI   Mean fluorescence intensity 
MLR   Mixed lymphocyte reaction 
NK    Natural killer 
PBMC   Peripheral blood mononuclear cells 
PBS    Phosphate buffered saline 
PBST   PBS + 0.05% Tween-20 
PE    Phycoerythrin 
PFA   Paraformaldehyde 
RBC   Red blood cells 
RT-PCR  Reverse transcription – polymerase chain reaction 
SCF   Stem cell factor 
SD    Standard deviation  
SE    Standard error 
TAE   Tris-acetate-EDTA 
TAM   Tumor associated macrophages 
TECK   Thymus-expressed chemokine 
TNF    Tumor necrosis factor 
TNFR    Tumor necrosis factor receptor 
TPO   Thrombopoietin 
WT    Wide type 
 1 
CHAPTER 1  INTRODUCTION 
 
1.1 Hematopoietic stem and progenitor cells (HSPC) 
Stem cells hold great promise for regenerative medicine and the study of cell and 
tissue differentiation. Hematopoietic stem and progenitor cells (HSPC) are to date the 
best-studied stem cell population, and are already used for several clinical 
applications.  
 
First, HSPCs are an indispensable source of replenishment of blood and immune cells. 
All adult hematopoietic lineages are derived from very small numbers of 
self-replicating hematopoietic stem cells (HSC). This breathtaking ability to 
reconstitute the hematopoietic system makes transplantation of HSPCs after ablative 
chemotherapy the gold standard of care for treatment of leukaemia and lymphoma 
nowadays. These chemotherapy and radiation therapies inevitably destroy actively 
dividing healthy cells of the hematopoietic system along with the cancer cells. 
Patients thus often become immune deficient and highly susceptible to opportunistic 
infections which may even be fatal. The traditional treatment regiment involves the 
use of granulocyte colony-stimulating factor (G-CSF / Neupogen), but the short half 
life of this factor demands for daily injections. Furthermore, this treatment is specific 
for the augmentation of granulocytes. HSPCs with their multipotential seem to offer a 
better alternative solution for shortening the period of profound pancytopenia 
following chemotherapy or chemo-radiotherapy. This may in turn lessen the chances 
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of opportunistic infections and improve the patients' quality of life. Engraftment of 
HSPCs to cancer patients following chemotherapy also means that patients can be 
treated more aggressively, thereby increasing the potential for complete remission 
(Elias, 1995). Therefore, in the recent decade, transplantation of HSPCs have been 
more frequently used in autologous and allogeneic settings to restore the immune 
functions (Corringham and Ho, 1995; Sorrentino, 2004; Heike et al., 2002). 
 
More recently, there are emerging clinical applications of HSPCs for other malignant 
and non-malignant diseases. For example, HSPCs are capable of trans-differentiation 
to non-hematopoietic tissues to replace damaged or lost tissues (Orlic et al., 2001; 
Bailey et al., 2004). Recent cardiac clinical trials of introducing autologous 
hematopoietic progenitor cells during coronary artery bypass grafting demonstrated 
that patients had significantly improved circulation into infarct area and cardiac 
functions (Stamm et al., 2003). Clinical applications for hematopoietic progenitor 
cells are therefore no longer restricted to hematopoietic and immune reconstitution.  
 
This enormous clinical potential of HSPCs is, however, limited by their low 
availability. It is therefore of great importance to find ways to effectively and 
efficiently amplify the numbers of these cells. Hematopoietic growth factors and 
cocktails of such factors are an essential part of the ex vivo or in vivo amplification 
protocols of HSPCs. Unfortunately, the effective expansion of HSPCs has yet to be 
attained in spite of over 20 years of research in animal models and human clinical 
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trials (Devine et al., 2003).  
 
 
1.2 Hematopoiesis and myeloid cells 
1.2.1 Overview of hematopoiesis 
Hematopoiesis is a complex and tightly regulated process, and is essential for the 
homeostasis of tissue oxygenation and immune functions. Deepening our 
understanding of the regulation and mechanisms of hematopoiesis is expected to 
continue to offer new and effective therapies.  
 
Hematopoiesis (Fig. 1.1) starts with HSCs, cells that can renew themselves and can 
differentiate to a variety of specialized cells. HSCs can be further divided into three 
groups, long term (LT)-HSC, short term (ST)-HSC and multi-potential progenitor 
(MPP). LT-HSCs are very rare and usually in a quiescent state, while MPPs are in a 
more active state. The MPPs commit to common myeloid progenitors (CMP) in the 
presence of stem cell factor (SCF) and thrombopoietin (TPO), or to common 
lymphoid progenitors (CLP) in the presence of IL-7. (Robb, 2007). 
 
CMPs further differentiate to megakaryocyte erythroid progenitors (MEP) or 
granulocyte-macrophage progenitors (GMP). MEPs give rise to megakaryocytes 
(platelets) under the influence of TPO, or erythrocytes (red blood cells) under the 
influence of erythropoietin (EPO) (Robb, 2007). GMPs have potential to give rise to 
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monocytes, which further differentiate to macrophages or myeloid DCs in the 
peripheral tissues depending on the microenvironment; or to granulocytes, including 
neutrophils, eosinophils and basophils. This process is called myelopoiesis, and 
colony stimulating factors, such as GM-CSF, G-CSF and M-CSF, are crucial 
regulators of myelopoiesis (Fig. 1.1).   
 
CLPs undergo lymphopoiesis and give rise to B cells, T cells and NK cells, depending 
on the presence of various interleukins as shown in Fig. 1.1. (Robb, 2007).   
 
Figure 1.1. Overview of hematopoiesis and the role of cytokines in vivo. HSC, 
hematopoietic stem cells; CMP, common myeloid progenitor; CLP, common 
lymphoid progenitor; MEP, megakaryocyte erythroid progenitor; GMP, 
granulocyte-macrophage progenitor; MkP, megakaryocyte progenitor; EP, erythroid 
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progenitor; TNK, T-cell natural killer cell progenitor; BCP, B-cell progenitor. IL, 
interleukin; SCF, stem cell factor; TPO, thrombopoietin; EPO, erythropoietin; 
GM-CSF, granulocyte-macrophage-colony stimulating factor; G-CSF, 




1.2.2 Monocytes / Macrophages 
Macrophages have long been considered to be important immune effector cells. 100 
years ago (1908), Elie Metchnikoff who won the Nobel Prize for his description of 
phagocytosis, proposed that the key to immunity was to “stimulate the phagocytes” 
(Gordon, 2008). Macrophages are present in virtually all tissues. During monocyte 
development, GMPs sequentially give rise to monoblasts, pro-monocytes and finally 
monocytes, which are released from the bone marrow into the bloodstream. 
Monocytes migrate from the blood into tissues to replenish long-lived tissue-specific 
macrophages of the bone (osteoclasts), alveoli, central nervous system (microglial 
cells), connective tissue (histiocytes), gastrointestinal tract, liver (Kupffer cells), 
spleen and peritoneum (Gordon and Taylor, 2005). 
 
In innate immunity, resident macrophages provide immediate defense against foreign 
pathogens and coordinate leukocyte infiltration (Martinez et al., 2008). Macrophages 
contribute to the balance between antigen availability and clearance through 
phagocytosis and subsequent degradation of apoptotic cells, microbes and possibly 
neoplastic cells (Gordon, 2003). In adaptive immunity, macrophages collaborate with 
T and B cells, through both cell-to-cell interactions and fluid phase-mediated 
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mechanisms, based on the release of cytokines, chemokines, enzymes, arachidonic 
acid metabolites, and reactive radicals (Gordon, 2003; Martinez et al., 2008). 
 
Macrophages display remarkable plasticity and can change their physiology in 
response to environmental cues. These changes can give rise to different populations 
of cells with distinct functions. Now, it is commonly accepted that activated 
macrophages can be classified into two main groups (Fig. 1.2 A): classically activated 
macrophages (or M1), whose prototypical activating stimuli are IFN-γ and LPS; and 
alternatively activated macrophages (or M2), further subdivided into M2a (after 
exposure to IL-4 or IL-13), M2b (immune complexes in combination with IL-1β or 
LPS) and M2c (IL-10, TGF-β or glucocorticoids) (Martinez et al, 2008). M1 
macrophages exhibits potent microbicidal properties and promote strong 
IL-12-mediated Th1 responses, whilst M2 macrophages support Th2-associated 
effector functions. Beyond infection, M2-polarized macrophages play a role in the 
resolution of inflammation through high endocytic clearance capacities and trophic 
factor synthesis, accompanied by reduced pro-inflammatory cytokine secretion 
(Martinez et al, 2008). In the tumor microenvironment, M2 macrophages could be 
redirected to tumor-associated macrophages (TAM), which are believed to facilitate 
tumor growth, angiogenesis and metastasis by secreting various growth factors and 




More recently, a new grouping of macrophage populations has been suggested, based 
on the three different homeostatic activities – host defense, would healing and 
immune regulation (Fig. 1.2 B) (Mosser and Edwards, 2008). It is proposed that 
similarly to primary colors these three basic macrophage populations can blend into 
various other “shades” of activation. Compared to the linear polar classification of M1 
/ M2, this classification better illustrates how macrophages can evolve to exhibit 
characteristics that are shared by more than one macrophage population. The concept 
of “regulatory macrophages” is raised in this new classification. Regulatory 
macrophages, which are anti-inflammatory, can arise following innate or adaptive 
immune responses. This population of macrophages produces high levels of the 
immunosuppressive cytokine IL-10, and also downregulates IL-12 production (Gerber 
and Mosser, 2001). Therefore, the ratio of IL-10 to IL-12 could be used to define 
regulatory macrophages. Unlike wound-healing macrophages, these regulatory 
macrophages do not contribute to the production of extracellular matrix, and many of 
these regulatory cells express high levels of costimulatory molecules (CD80 and 
CD86) and therefore can present antigens to T cells (Edwards et al., 2006). So, there 
are clear functional, as well as biochemical differences between regulatory and 




Figure 1.2. Classification of macrophage populations. (A) A monochromatic 
depiction of the nomenclature showing the linear scale of the two macrophage 
designations, M1 and M2. (B) The three populations of macrophages that are 
classified based on the three different homeostatic activities – classically activated 




1.2.3 Myeloid dendritic cells  
Dendritic cells (DCs), the so-called “conductor of the immune orchestra”, are 
professional antigen presenting cells (APCs) endowed with the unique
 
capacity to 
activate naive T cells. DCs also have important effector
 
functions during innate 
immune responses, such as pathogen
 
recognition and cytokine production. Therefore, 
DCs are a bridge between innate and adaptive immunity.  
 
Similar as monocytes and macrophages, bone marrow derived myeloid DCs (also 
called conventional DCs) consist of a complex and heterogeneous population of cells 
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with distinctive stages of cell development, activation and maturation. Various subsets 
endowed with
 
specific pathogen recognition mechanisms, locations, phenotypes,
 
and 
functions have been described. DCs can be immunogenic or tolerogenic (Steinman et 
al., 2003; Morelli and Thomson, 2007; Rossi and Young, 2005). The immunogenic 
DCs, in the adaptive immunity, influence the type of subsequent immune response by 
secreting specific cytokines. For example, IL-12 produced by DCs favors a Th1 
response that is highly effective against viral infections and neoplastic cells; while 
IL-4 production drives T cell polarization towards a Th2 response that is more 
advantageous during infections by extracellular bacteria (Steinman, 2003). Differing 
from their immunogenic counterparts, tolerogenic DCs can sufficiently suppress the 
activities of effector T cells and induce regulatory T cells (Menges et al., 2002). Thus, 
they are important in keeping the balance of the immune system by preventing 
harmful autoimmune responses and excessive inflammation and tissue damage during 
anti-pathogen immune responses. In spite of their regulatory roles, however, the 
tolerogenic DCs sometimes can render the immune system unresponsive to infections 
or malignancies and hence cause pathogenesis. 
 
1.2.4 Granulocytes 
Granulocytes are essential cells of the innate immune system. As neutrophil and 
eosinophil granulocytes they form the first defense line against bacteria and 
multicellular parasites, respectively. Through release of cytotoxic and inflammatory 
mediators granulocytes participate in the elimination of pathogens, recruitment of 
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additional immune cells and perpetuation of the inflammatory reaction (Hogan et al., 
1988). The activity of granulocytes is partly regulated via their life span which is 
short under normal conditions. Neutrophils, which constitute about 95% of all 
granulocytes, have a half life of a just few hours in circulation. At sites of 
inflammation proinflammatory cytokines such as G-CSF, GM-CSF, TNF and IFN- 
extend the life span of granulocytes by preventing apoptosis (Simon et al., 1997; 
Savill, 1997). Numbers of granulocytes can also be increased by enhancing the 
proliferation rate of hematopoietic progenitor cells and their differentiation rate to 
granulocytes. G-CSF is the single most important factor for inducing the generation of 
new granulocytes from bone marrow. G-CSF is also used to treat neutropenia induced 
by cancer chemo or radiation therapy (Moore, 1990).  
 
1.2.5 Myeloid derived suppressor cells  
The myeloid derived suppressor cells (MDSC) are a group of myeloid cells comprised 
of precursors of macrophages, granulocytes, dendritic cells and myeloid cells at 
earlier stages of differentiation (Talmadge, 2007). The accumulation of MDSC in 
lymphoid organs, tumor masses and peripheral blood has been observed in 
tumor-bearing individuals and is often associated with large tumor burdens. In mice 




 cells. They have a very rapid turnover 
and accumulate in large numbers in lymphoid tissues of tumor-bearing mice as well as 
in mice with infectious diseases, sepsis, and trauma (Delano et al., 2007; MacDonald 
et al., 2005; Youn et al., 2008). MDSC have also been described in cancer patients. In 
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a recent study circulating MDSC were found to be significantly increased in cancer 
patients of all stages relative to healthy volunteers. A significant correlation between 
circulating MDSC and clinical cancer stage was also observed. Among stage IV 
patients, those with extensive metastatic tumor burden had the highest percentage and 
absolute number of MDSC (Diaz-Montero et al., 2009). The main feature of these 
cells is their ability to suppress T cell responses in Ag-specific or nonspecific manners 
depending on the condition of T cell activation (Youn et al., 2008; Movahedi et al., 
2008). MDSCs can suppress T cell sensitization in tumor-draining lymph nodes in 
vivo (Watanabe et al., 2008). Furthermore, it is reported that MDSC quickly 
differentiate to tumor-associated macrophages (TAM) (Serafini and Bronte, 2007; 
Mantovani et al., 2009). Sinha and colleagues have demonstrated that cross-talk 
between MDSC and macrophages further subverts tumor immunity by increasing 
MDSC production of IL-10, and by decreasing macrophage production of IL-12 
(Sinha et al., 2007). Therefore, MDSCs are now considered as one of the major 
factors responsible for tumor associated immune defects and are an attractive target 




1.3.1. Expression of CD137 
CD137 (TNFRSF9 / 4-1BB / ILA), is a member of the tumor necrosis factor (TNF) 
receptor family, and it has originally been identified as a potent T cell costimulatory 
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molecule (Kwon et al., 1989; Schwarz et al., 1993). It is a type I transmembrane 
glycoprotein expressed by activated T cells (Schwarz et al., 1995, 1996), activated 
NK cells (Melero et al., 1998), monocytes (Kienzle et al., 2000), follicular dendritic 
cells (FDCs) in germinal centres (Pauly et al., 2002), and a small fraction of 
neutrophils (Simon, 2001). Its expression on primary immune cells is strictly 
activation-dependent and transient (Schwarz et al., 1995), and is involved in the 
regulation of multiple and diverse types of immune responses (Watts, 2005).  
 
Besides immune cells, primary articular chondrocytes express CD137 after 
stimulation by proinflammatory factors (von Kempis et al., 1997). The walls of blood 
vessels at sites of inflammation (Drenkard et al., 2007) and in certain cancer cells 
(Lisignoli et al., 1998; Ringel et al., 2001). 
 
1.3.2 Structure of CD137 
The murine CD137 gene is located on chromosome 4 (Kwon et al., 1989). The human 
CD137 gene has been mapped to chromosome band 1p36, where the genes of four 
other members of the TNFRSF, TNFRII, CD30, OX40 and TRAMP/Apo3, are also 
found (Schwarz et al., 1993). Both human and murine CD137 are made up of eight 
exons. Exon VII encodes the transmembrane domain (Fig. 1.3 A, C). A smaller 
mRNA isoform lacking this exon is generated by differential splicing, and leads to the 
production of soluble CD137 (sCD137) (Setareh et al., 1995; Michel et al., 1998).    
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Murine and human CD137 proteins (Fig. 1.3 B, D) are 60% homologous and have 
similar topological structures. CD137 protein is comprised of a signal peptide, an 
extracellular domain, a transmembrane domain, and a cytoplasmic domain, which is 
necessary for signal transduction into the cell. Within the extracellular region lie four 
cysteine-rich domains (CRDs), which are characteristic for TNFR superfamily 
members. In the cytoplasmic domain, five regions are conserved between mouse and 
man, indicating that they might be important for the function of CD137. All the 




Figure 1.3. Schematic diagram of the structure of murine and human CD137 
mRNA and protein. (A) murine CD137 mRNA, accession number: NM_011612; (B) 
murine CD137 protein, accession number: P20334; (C) human CD137 mRNA, 
accession number: NM_001561; and (D) human CD137 protein, accession number: 
Q07011. STS, sequence-tagged site; CDS, coding sequence. All the information of 
sequences and primary structures is from NCBI Entrez Nucleotide and Entrez Protein 
databases (As in May 2009).   
 
 
Table 1. Structure features of human CD137 protein.  
Position (amino acid) Structure feature 
1-23  signal peptide 
24-255  mature peptide 
19-106  TNFR domain  
24-186  extracellular domain 
187-213  transmembrane domain 
214-255  cytoplasmic domain, interaction with LRR-1  
24-45 cysteine rich domain 
47-86 cysteine rich domain 
87-118 cysteine rich domain 
119-159  cysteine rich domain 
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LRR-1: Leucine rich repeat protein.  
 
 
1.3.3 Biological functions of CD137 
High levels of CD137 can be found on activated T cells, and crosslinking of CD137 
delivers potent costimulatory signals to T cells. Recombinant CD137 ligand or 
agonistic anti-CD137 antibodies enhance both T cell and NK cell activities, such as 
vigorous proliferation and IFN-γ secretion (Melero et al., 1997, 1998; Wilcox et al., 
2002). These enhaced immune responses lead to induce complete or partial regression 
of established tumors in various mouse models (Sica and Chen, 2000; Croft, 2003; 
Watts, 2005; Zhu et al., 2009). Humanized anti-CD137 antibodies are currently 
undergoing phase I clinical trials for cancer immunotherapy (Hong et al., 2000; Son et 
al., 2004). 
 
29-36, 43-47, 79-81 protein binding site 
19, 29, 33, 35, 44, 47, 57 parallel homodimerization interface 
53, 63, 72, 94, 102  antiparallel homodimerization interaface  
56-57, 62,64 50’s loop TNF binding site what is that? 
94, 102-106 90’s loop TNF binding site 
138, 149 glycosylation site 
56  variant (A  T) 
115 variant (K  N) 
176 variant (A  D) 
250 variant (E  G) 
28, 37 disulfide bond 
31, 45 disulfide bond 
48, 62 disulfide bond 
65, 78  disulfide bond 
68, 86 disulfide bond 
88, 94 disulfide bond 
99, 106 disulfide bond 
102, 117 disulfide bond 
121, 133 disulfide bond 
139, 158  disulfide bond 
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The CD137 signal to T cells is able to substitute the CD28 costimulatory signal, and 
CD137 agonists have been proven to be effective immune stimulators, leading to 
elimination of mastocytoma, sarcoma, colon carcinoma and melanoma in mice (Croft, 
2003; Sica et al., 2000; Watts, 2005).  
 
Stimulation of CD137 also enhances protective immune responses against pathogen 
infections. Agonistic anti-CD137 antibodies have been shown to enhance the efficacy 
of vaccines against influenza and poxvirus (Halstead et al., 2002; Munks et al., 2004). 
Inclusion of a CD137 ligand-expressing vector in a vaccine, or engineered expression 
of CD137 ligand on monocytes enhanced their ability to induce anti-HIV responses 
(Harrison et al., 2006; Wang et al., 2007). Therefore, the induction of CD137 
expression on immune cells is part of the anti-pathogen immune response. 
 
Interestingly, CD137 agonists can also dampen immune responses and ameliorate 
autoimmune diseases under certain conditions (Mittler, 2004; Myers et al., 2005). The 
underlying mechanism is still not elucidated.   
 
A few studies have investigated the role of CD137 in granulocytes. Neutrophils from 
human and mouse are found to constitutively express CD137 (Simon, 2001; Lee et al., 
2005). In human, CD137 expression on eosinophils could be observed in patients 
suffering from IgE-mediated allergic responses, but not in normal subjects or those 
patients suffering from non-IgE-mediated eosinophilic disorders (Heinisch et al., 
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2001). In both neutrophils and eosinophils, CD137 stimulation promotes apoptosis in 
these cells, even in the presence of the survival factors GM-CSF and / or IL-5 
(Heinisch et al., 2000). In mouse, however, ligation of CD137 on neutrophils by 
anti-CD137 antibody was reported to induce intracellular Ca
2+
 influx, and to enhance 
the reactive oxygen species generation and phagocytic activities, which was very 
important for the host defense against intracellular pathogens such as Listeria 
monocytogenes (Lee et al., 2005). Nishimoto et al. found CD137 expression is 
inducible in mast cells upon the stimulation through the high-affinity receptor for IgE 
(FcRI). Agonistic anti-CD137 antibodies can enhance FcRI-induced cytokine 
production and secretion from mast cells (Nishimoto et al., 2005). Despite the 
discrepancy, the consensus is that CD137 stimulation seems to play an important role 
in regulating granulocyte function during the initiation and resolution of an 
inflammatory response.  
 
1.3.4 Diseases associated with CD137  
CD137 is expressed as a neoantigen by several types of tumor cells, such as in Reed- 
Sternberg cells in Hodgkin’s lymphoma (personal communication, Schwarz H), 
osteosarcoma (Lisignoli et al., 1998), rhabdomyosarcoma (personal communication, 
Schwarz H) and pancreatic cancer (Ringel et al., 2001). Elevated sCD137 levels have 
been reported in sera of patients with chronic lymphocytic leukemia (CLL) (Furtner et 
al., 2005).  
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CD137 in both membrane-bound form and soluble form is also reported to be 
involved in or associated with some autoimmune diseases, such as herpetic stromal 
keratitis (HSK) (Seo et al., 2003), rheumatoid arthritis (RA) (Michel et al., 1998; Seo 
et al., 2004), multiple sclerosis (MS) (Sharief, 2002; Jung et al., 2004), systemic lupus 
erythematosus (SLE) and Behcet’s disease (Shao et al., 2008; Jung et al., 2004).  
 
 
1.4 CD137 ligand  
1.4.1 Expression of CD137 ligand 
CD137 ligand (CD137L / TNFSF9 / 4-1BBL), also known as CD137 counter-receptor, 
is a type II membrane protein of the TNF superfamily (Goodwin et al., 1993; 
Alderson et al., 1994). CD137L is expressed mainly on APCs, including B cells, DCs 
and monocytes/macrophages. Human and murine transformed B cells express 
CD137L protein constitutively while activation may be required for primary B cells 
(Pollok et al., 1994; Zhou et al., 1995; DeBenedette et al., 1997; Palma et al., 2004). 
CD137L is also expressed constitutively on peripheral monocytes and 
monocyte/macrophage cell lines (Pollok et al., 1994; Futagawa et al., 2002; Ju et al., 
2003; Laderach et al., 2003). In DCs, CD137L is expressed at low levels in both the 
murine and human system. However, it can be enhanced by proinflammatory stimuli, 
including IL-1, CD40 ligand, LPS and double stranded RNA (Futagawa et al., 2002; 
Laderach et al., 2003; Kim et al., 2002; Lee et al., 2003). Progress in understanding 




1.4.2 Structure of CD137L 
The gene for CD137L is located on chromosome 17 in mouse (Goodwin et al., 1993) 
and on chromosome 19p13.3 in man (Alderson et al., 1994), (Fig. 1.4 A, C). The 
CD137 protein has a TNF domain, whose tertiary structure is very similar to that of 
TNF and lymphotoxin (LT)-(Fig. 1.4 B, D). Like other members of the TNF 
superfamily, it is present in a trimeric or oligometric form on cell surfaces (Rabu et al., 
2005).  
 
Sequence analysis of the human CD137L protein has revealed only 36% aminoc acid 
homology to the mouse CD137L, compared to 70–80% of homology between human 
and murine ligands reported for other members of the TNF family (Alderson et al., 
1994). In addition, there is almost no homology of human CD137L to other members 
of the human TNF cytokine family (Smith et al., 1994). Chalupny et al. reported that, 
besides CD137, a murine CD137-Fc fusion protein could bind to various extracellular 
matrix proteins, including fibronectin, vitronectin, laminin, and collagen VI 






Figure 1.4. Schematic diagram of the structure of murine and human CD137L 
mRNA and protein. (A) murine CD137L mRNA, accession number: NM_009404; 
(B) murine CD137L protein, accession number: NP_033430; (C) human CD137L 
mRNA, and accession number: NM_003811; (D) human CD137L protein, accession 
number: NP_003802. STS, sequence-tagged site; CDS, coding sequence. All the 
information of sequences and primary structures is from NCBI Entrez Nucleotide and 
Entrez Protein databases (As in May 2009).   
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1.4.3 Bidirectional signaling of CD137 receptor / ligand system 
The CD137 receptor / ligand system has the ability to signal bidirectionally. CD137L 
is expressed as a type II transmembrane protein and it too can transduce signals into 
the cells it is expressed on, a process referred to as reverse signaling or bidirectional 
signal transduction (Schwarz, 2005). The ability of reverse signaling is common 
among other members of TNFR and TNF families (Eissner et al., 2004). During 
APC-T cell interactions, the signals through CD137L are activating or costimulatory 
for APCs. Together with CD137, which can deliver costimulatory signals to T cells, 
the bidirectional signals escalate the activation process for both APCs and T cells and 
therefore, form a potent proinflammatory system (Fig. 1.5).  
 
Figure 1.5. Schematic diagram of bidirectional signal transduction of the CD137 
receptor / ligand system. (Schwarz, 2005). 
 
 
1.4.4 Biological functions of reverse signaling through CD137L   
The biological functions of reverse signaling through CD137L in hematopoietic cells 
are summarized in Table 2.  
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1.4.4.1 Reverse signaling through CD137L in monocytes 
Reverse signaling through the CD137L in monocytes has been well studied. 
Crosslinking of the CD137L on peripheral monocytes induces a specific signaling 
cascade involving protein tyrosine kinases (PTK), p38 mitogen activated protein 
kinase (MAPK), extracellular signal-regulated kinase (ERK)-1/2,  phosphoinositide 
-3-kinase (PI3K) and protein kinase A (PKA) (Sollner et al., 2007). Signaling through 
CD137L leads to activation of the monocytes with induction of adherence, 
morphological changes and enhanced expression of proinflammatory cytokines (TNF, 
IL-6, IL-8 and IL-12) and activation markers (ICAM-1). Concurrently, it inhibits the 
expression of anti-inflammatory cytokines (IL-10) and differentiation markers 
(FcyRIII) in monocytes (Langstein et al., 1998, 2000; Laderach et al., 2003). In 
addition, it significantly prolongs monocyte survival via induction of M-CSF 
(Langstein et al., 1999b), and it induces a profound proliferation and endomitosis of 
human peripheral monocytes (Langstein et al., 1999a). The potency of CD137L in 
stimulating proliferation of monocytes is profoundly higher than that of other 
monocyte growth factors such as M-CSF or GM-CSF (Langstein et al., 1999a; Ju et 
al., 2003). Recently, the activating effects of CD137L on monocytes have been 
confirmed in vivo. Transgenic mice overexpressing CD137 ligand on APC develop a 
threefold increased number of macrophages (Zhu et al., 2001). CD137-deficient mice 
on the other hand have an increased number of myeloid progenitor cells in the 
peripheral blood, bone marrow, and spleen (Kwon et al., 2002). It seems these cells 
cannot fully mature to monocytes, macrophages, and possibly dendritic cells due to 
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the lack of CD137L signaling. 
 
CD137L provides potent migration signals to peripheral monocytes (Drenkard et al., 
2007). Since the expression of CD137 is strictly activation-dependent, monocytes 
would encounter CD137 in tissues where activated immune cells or endothelial cells 
are present (Schwarz et al., 1995; Drenkard et al., 2007; Broll et al., 2001). Therefore, 
reverse signaling by CD137L into monocytes is expected to induce proliferation, 
activation, and migration, i.e. amplifying and regulating an ongoing immune 
response. 
 
1.4.4.2 Reverse signaling through CD137L in DCs 
DCs are professional and potent APCs in the initiation of an immune response and 
adaptive immunity. CD137L is expressed at low levels on murine and human DCs, 
which were derived in vitro from monocytes or hematopoietic progenitor cells 
(Laderach et al., 2003; Kim et al., 2002; Futagawa et al., 2002). Crosslinking of 
CD137L on DCs enhances the expression of CD11c, CD80, CD86, MHC class II, and 
CCR7, and induces cellular adherence and the release of IL-6, IL-12, and TNF(Kim 
et al., 2002; Futagawa et al., 2002; Laderach et al., 2003; Lippert et al., 
2008).CD137L-activated DCs are able to induce the proliferation of autologous T 
cells in antigen-specific manner, the release of IL-12p70 and IFN-, and the 
differentiation to potent Th1 effectors (Lippert et al., 2008). This implies that CD137L 
signaling induces the maturation, activation and migration of immature DCs. The 
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cross-linking of CD137L and CD137 allows simultaneous costimulation of T cells 
and DCs when they interact, thereby endowing the CD137 receptor / ligand system 
with potent proinflammatory activities. 
 
Interestingly, Wilcox et al. also reported that freshly isolated murine splenic DCs and 
bone marrow-derived DCs express CD137 on the cell surface and in soluble form. 
Triggering CD137 increased the secretion of IL-6 and IL-12 from DCs and enhanced 
the ability of DCs to stimulate T cell proliferation in vitro (Wilcox et al., 2002). This 
implies that DCs can express both CD137L and CD137 on their surface, and both 
signals are activating. However, it is not clear whether both signaling can occur at the 
same time and whether there is a positive feedback loop in the DCs that express both 
CD137L and CD137.  
 
The physiological function of CD137L signal in DCs is an induction or enhancement 
of their antigen-presenting capacity, and consequently an initiation or enhancement of 
immune response. However, it is still controversial whether CD137L signal alone is 
sufficient to induce DC activation or whether it only works in combination with 
additional signals such as CD40L. In addition, it is still unclear whether CD137L 
alone can induce DC differentiation directly from monocytes or hematopoietic 
progenitors. 
 
1.4.4.3 Reverse signaling through CD137L in B cells 
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Human and murine transformed B cells express CD137L protein constitutively while 
activation may be required for primary B cells (Pauly et al., 2002; Pollok et al., 1994). 
Unlike in the case of monocytes and DCs, signals through CD137L do not initiate 
activation of B cells. Rather, they enhance proliferation and immunoglobulin 
synthesis of preactivated B cells (Pauly et al., 2002; Pollok et al., 1994). In contrast to 
these in vitro data, constitutive expression of CD137L on APC in transgenic mice 
causes a gradual elimination of peripheral B cells (Zhu et al., 2001). This could 
indicate that initially the signals through CD137L are activating for B cells, while 
prolonged CD137L signals may be deleterious for B cells, possibly due to the 
activation induced cell death. Indeed, it has been shown that crosslinking of CD137 
on monocytes causes them to induce apoptosis in B cells (Kienzle et al., 2000). The 
findings of CD137 expression on follicular DCs in germinal centers support 
CD137L-mediated B cell activation. The expression of CD137 on follicular DCs 
provide costimulatory and survival signals to those B cells in the germinal centers, 
which have rearranged their immunoglobulin genes resulting in a high affinity 
binding to the antigen (Pauly et al., 2002; Lindstedt et al., 2003). This implicates that 
the CD137 / CD137L system plays a role in B cells affinity maturation. 
 
1.4.4.4 Reverse signaling through CD137L in bone marrow cells 
The expression of CD137L and CD137 in the bone marrow (Saito et al., 2004; Jiang 
et al., 2008a, 2008b; Lee et al., 2008) suggests CD137L signaling takes place not only 
in differentiated hematopoietic cells but also in bone marrow progenitor cells. 
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Proliferation of murine bone marrow cells treated with M-CSF is enhanced when cells 
are exposed to immobilized CD137 protein (Saito et al., 2004). CD137L signals also 
inhibit RANK ligand-induced differentiation of bone marrow cells towards 
osteoclasts (Saito et al., 2004; Shin et al., 2006a, 2006b). These data indicate that 
CD137L signals direct differentiation of bone marrow cells away from osteoclast and 
towards the myeloid lineage. However, total bone marrow cells are unable to provide 
a clean system to study the effects of CD137 ligand signaling in HSPCs, because bone 
marrow cells are a mixture of various cell populations, including those differentiated 
APCs mentioned above.  
 
1.4.4.5 Reverse signaling through CD137L in T cells 
Reverse signaling also takes place in T cells, and contrary to the situation in APCs, the 
CD137L signal has been shown to inhibit proliferation and to induce apoptosis in 
human T cells (Schwarz et al., 1996; Ju et al., 2003; Michel et al., 1999). A recent 
study however, found that CD137L signaling in murine T cells induces IFN- release, 
contributing to immune deviation and an inhibition of Th2-mediated allergic lung 
inflammation (Polte et al., 2007). 
 
 
In conclusion, except in T cells, the reverse signaling through CD137L into APCs and 
probably their progenitors leads to activation, maturation and even proliferation. This 
leads to the initiation or amplification of immune responses. Together with the 
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costimulatory signal through CD137 into T cells, the bidirectional signaling of the 
CD137 receptor / ligand system allows a more coordinated immune response and its 
fine-tuning.  
 
To date, very limited data are available that support a role of CD137L signaling in 
hematopoiesis. In fact, some other members of the TNF family have already been 
shown to regulate survival and expansion of hematopoietic precursor cells. According 
to Greil and colleagues, CD95 and TNF related apoptosis inducing ligand (TRAIL) 
are of critical importance for lymphopoiesis and myelopoiesis (Greil et al., 2003). 
TNF can induce or inhibit hematopoiesis, depending on its dose and its interaction 





Table 2. Biological functions of reverse signaling through CD137L in hematopoietic cells. 
Cell type Species  Activity System References 
Monocytes Human Induction of TNF, IL-6, IL-8, IL-12, ICAM, and 
adherence. Inhibition of FcRIII and IL-10 
In vitro Langstein et al., 1998, 2000; 
Laderach et al., 2003 
 Human Induction of M-CSF and prolongation of survival In vitro Langstein et al., 1999b 
 Human Induction of proliferation and endomitosis In vitro Langstein et al., 1999a; Ju et al., 2003 
 Human Enhanced migration and extravasation. In vivo Drenkard et al., 2007 
 Mouse Amplification of cell numbers CD137L-trg mice Zhu et al., 2001 
Macrophages Mouse Downstream of TLR, sustained TNF production CD137L-trg mice Kang et al., 2007 
Dendritic cells Human Maturation, induction of CD11c, CD86, CD137L,     
MHC-II, IL-12, and cellular adherence  
In vitro Laderach et al., 2003; 
Kim et al., 2002 
 Mouse Induction of IL-6, IL-12, CD80 and CD86 In vitro Futagawa et al., 2002 
 Human Maturation by induction of TNF-, migration by 
induction of CCR7, induce T cell proliferation 
and release of IL-12p70 and IFN- 
In vitro  
Lippert et al., 2008 
B cells Human Costimulation of proliferation and Ig secretion In vitro Pauly et al., 2002 
 Mouse Costimuation of proliferation In vitro Pollok et al., 1994 
 Mouse Elimination of peripheral B cells (after 3 months) CD137L-trg mice Zhu et al., 2001 
Bone marrow cells Mouse Induction of proliferation In vitro Saito et al., 2004 
 Mouse Inhibition of osteoclast differentiation In vitro Saito et al., 2004; Shin et al., 2006a 
 Mouse Enhanced osreoclastogenesis caused by reduced 
IL-10 
CD137-def mice Shin et al., 2006b 
T cells Human Inhibition of proliferation and induction of 
apoptosis 
In vitro Schwarz et al., 1996; Ju et al., 2003 
IL: interleukin, ICAM: intercellular adhesion molecule, FCγR: Fc receptor for IgG, M-CSF: macrophage-colony stimulating factor, CD137L-trg: 
CD137 ligand-transgenic, MHC: major histocompatibility complex, CD137-def: CD137-deficient. Modified from Schwarz, 2005.
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1.5 Scope and objectives of the study 
The data of reverse signaling through CD137L in hematopoietic cells described above 
imply a role of CD137L signaling in hematopoiesis. In addition, preliminary evidence 
has shown that immobilized recombinant CD137 protein can induce proliferation of 
human and murine HSPCs. However, this activity of CD137L signaling has not been 
experimentally proven. This study aims to look at the involvement of CD137L 
signaling in the proliferation and differentiation of HSPCs in both the murine and the 
human system.  
 
The specific objectives of this study are, 
1. Investigate the effects of CD137 on HSPC proliferation and differentiation in both 
the murine and the human system; 
2. Investigate the lineage and the functions of HSPCs differentiated by CD137; 
3. Explore potential synergistic or additive effects of CD137 with other 
hematopoietic growth factors on HSPC proliferation and differentiation; 
4. Identify the CD137L- and CD137-expressing cells in the bone marrow; 
5. Investigate the regulation of CD137 expression in the bone marrow. 
 
The data obtained are expected (1) to increase our knowledge of the CD137 / CD137L 
biology and CD137L signaling in hematopoiesis, (2) to lay the basis for ex vivo or in 
vivo expansion of HSPCs with CD137, and (3) to explore the potential to use CD137 
as a candidate for future clinical applications in terms of immunotherapy.   
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CHAPTER 2  MATERIALS AND METHODS 
 
2.1 Preparations of animal and human samples 
 
2.1.1 Mice  
BALB/c or C57/BL6 wide type and CD137-deficient mice between 16 and 20 weeks 
of age were used as a source of bone marrow cells or splenocytes. Animals were 
specific pathogen free, and kept with free access to food and water in the animal care 
facility at the National University of Singapore under the institutional guidelines for 
usage of experimental animals. 
 
2.1.2 Preparation of murine bone marrow cells and splenocytes 
BALB/c or C57/BL6 mice were sacrificed by CO2 inhalation. The femur bones were 
dissected and the bone marrow was flushed out aseptically with phosphate-buffered 
saline (PBS), 2 mM EDTA using a 10 ml syringe and 27G needle. Total bone marrow 
cells were passed through a 30 µm filter (Miltenyi Biotec, Bergisch Gladbach, 
Germany), washed with PBS containing 2 mM EDTA and resuspended in complete 
medium (RPMI1640 (Sigma), supplemented with 10% fetal bovine serum (FBS), 100 
U/ml penicillin and 100 μg/ml streptomycin).  
 
Spleens were aseptically removed from the abdominal cavity and minced through a 
40-μm nylon cell strainer (BD Falcon) with a 5-ml syringe core in 10 ml of PBS. Red 
 31 
blood cells were depleted with Tris-NH4Cl lysis buffer (0.144 M NH4Cl, 0.017 M 
Tris-HCl). Splenocytes were washed with PBS containing 2 mM EDTA and 
resuspended in complete medium.  
 











 progenitor cells were isolated by immunomagnetic separation 
(MACS) using the mouse lineage cell depletion kit and mouse CD117 selection kit 
(Miltenyi) following the manufacturer’s instructions. Briefly, the fresh bone marrow 
cells were labeled with a cocktail of biotinylated antibodies against a panel of 
antigens (CD5, CD45R (B220), CD11b, anti-Ly-6G (Gr-1), 7-4, and Ter119 
antibodies) expressed on mature cells, followed by anti-biotin microbeads. The cell 
suspension was passed through a LD column in a strong magnetic field, and the 
lineage negative (Lin
-
) cells were collected in the effluent. These Lin
-
 cells were then 





 cells was >90% as determined by flow cytometry using a FITC-conjugated 




 cells were also isolated by MACS. Briefly, the fresh bone marrow cells 
were treated with mouse FcR blocker (Miltenyi Biotec) and labeled with biotinylated 
anti-mouse Gr-1 antibody (Biolegend) followed by anti-biotin microbeads (Miltenyi 
Biotec). The cell suspension was passed through a LS column (Miltenyi Biotec) in a 
strong magnetic field. The Gr-1
+
 cells were retained in the column. After three washes, 
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the column was removed from the magnetic field and the Gr-1
+
 cells were flushed out. 
The purity of the Gr-1
+
 cells was >95% as determined by flow cytometry using a 
PE-conjugated anti-Gr-1 antibody (eBioscience). 
 
2.1.4 Isolation of pan T cells from mouse splenocytes 
Splenic T cells were isolated by MACS using the mouse Pan T Cell isolation kit 
(Miltenyi). Briefly, the fresh splenocytes were labeled with a cocktail of 
biotin-conjugated antibodies against CD45R (B220), CD49b (DX5), CD11b (Mac-1), 
and Ter-119 expressed on non-T cells (B cells, NK cells, DCs, macrophages, 
granulocytes and erythroid cells), followed by anti-biotin microbeads. The cell 
suspension was passed through a LS column in a strong magnetic field, and the 
untouched T cells were collected in the effluent. The purity of the T cells was >90% 
as determined by flow cytometry using a PE-conjugated anti-CD3 antibody 
(eBioscience). 
 
2.1.5 Isolation of CD34
+
 cells and monocytes from human cord blood 
Human umbilical cord blood was obtained from the Singapore Cord Blood Bank and 
the protocols were approved by IRB (Yong Loo Lin School of Medicine, National 
University of Singapore). CD34
+
 cells were isolated from cord blood by 
immunomagnetic selection (MACS) using the Direct CD34 Progenitor Kit (Miltenyi 
Biotech). Briefly, the layer of mononuclear cells was obtained from cord blood by 
Ficoll-Hypaque density (1.077g/dl) (Sigma) gradient centrifugation. These 
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mononuclear cells were labeled with microbeads which were conjugated to the 
monoclonal mouse anti-human CD34 antibody, QBEND/10, in the presence of FcR 
blocking reagent (Miltenyi) to prevent non-specific binding. The magnetic labeled 
cells were passed through a LS column in a strong magnetic field. The column was 
then removed from the magnetic field and the retained CD34
+ 
cells were flushed out.    
The purity of CD34
+
 cells was >90% as determined by flow cytometry using 
FITC-conjugated mouse anti-human CD34 monoclonal antibody, AC136 (Miltenyi). 
The purified CD34
+
 cells were resuspended in RPMI1640 culture medium (Sigma) 
supplemented with 10% FBS, 50 µg/ml streptomycin and 50 IU/ml penicillin, or in 
serum-free expansion medium (SFEM) from StemCell Technologies (Vancouver, 
British Columbia, Canada). 
 
Monocytes were purified from umbilical cord blood with the monocyte isolation kit II 
(Miltenyi). The purity was higher than 95% as determined by flow cytometric 
analysis after CD14 staining. 
 
2.1.6 Intra-peritoneal (i.p.) injection of LPS 
8 – 10 weeks old healthy C57/BL6 mice, of around 20 g of weight were divided into 
three groups (2 mice per group). Dosing solutions of LPS from E. coli 0111:B4 
(Sigma) were prepared in PBS. Mice were anesthetized with xylazine (5 mg/kg), and 
then dosed with 100 L of 1 mg/ml LPS (high dose = 5 mg/kg = 100 g/mouse) or 
0.2 mg/ml LPS (low dose = 1 mg/kg = 20 g/mouse) or PBS by intraperitoneal (i.p.) 
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injection. Mice were sacrificed after 24 h. Femur bones were collected, and EDTA 
decalcified, formalin fixed, paraffin embedded bone sections were used for IHC 
staining. 
 
2.1.7 Adoptive transfer of T cells  
T cells were isolated from spleens of C57/BL6 wide type (WT) or CD137-deficient 
(CD137-KO) mice by MACS using the Pan T cell isolation kit (Miltenyi). The cells 
were seeded at a density of 2 – 3 × 106 per ml per well into 12-well plates that were 
precoated with 5 g/ml of anti-mouse CD3 mAb (Clone 17A2) and 5 g/ml of 
anti-mouse CD28 mAb (Clone 37.51) or their isotypes, rat IgG2b and Syrian hamster 
IgG, respectively, both at 5 g/ml. Cells were harvested after culturing for 48 h, and 
labeled with CFSE (Invitrogen) at a final concentration of 5 M. Cells were incubated 
for 5 min in 2 mM EDTA in PBS to dissociate any aggregates. After washing twice, 
the CSFE labeled isotype Abs treated or anti-CD3 and anti-CD28 treated T cells from 
WT or CD137-KO C57/BL6 mice were resuspended in serum-free RPMI medium at 
2 × 10
7
/ml. 2 × 10
6
 cells in a volume of 100 L or 100 L of serum-free RPMI 
medium were aseptically i.v. injected into the lateral tail veins of 5 healthy C57/BL6 
mice. Mice were sacrificed after 24 h. Bone marrow cells, splenocytes and peripheral 





2.2 Molecular and biochemical techniques  
 
2.2.1 Recombinant proteins and chemicals 
Recombinant human CD137-Fc protein, comprising the extracellular domain of 
human CD137 and Fc portion of human IgG1 (Fig. 2.1), was purified from 
supernatants of stable transfected CHO cells by protein G sepharose, as described 
previously (Schwarz, et al 1996). The endotoxin concentration in the CD137-Fc 
protein is 55 I.U./mg. Recombinant murine CD137-Fc protein, comprising the 
extracellular domain of murine CD137 and Fc portion of human IgG1, was purchased 
from R&D systems (Minneapolis, MN USA). Human IgG1 Fc protein was purchased 
from Accurate Chemical and Scientific Corporation (Westbury, NY, USA). 
Recombinant murine GM-CSF, IL-4, M-CSF, G-CSF, Flt3L, LIF, SCF and 
recombinant human GM-CSF, IL-4, M-CSF were purchased from PeproTech (Rocky 
Hill, NJ, USA). Recombinant human G-CSF and LPS (E. coli 0111:B4) were obtained 
from Sigma (St. Louis, MO, USA). 
 






Total RNA from murine bone marrow cells was extracted using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. RT-PCR was 
performed in a Mastercycler® gradient thermal cycler (Eppendorf, Hamburg, 
Germany). cDNA was reverse transcribed from total RNA using the RevertAid
TM
 first 
strand cDNA synthesis kit (Fermentas, Hanover, MD, USA). Amplification of the 
murine GAPDH gene or human Cyclophilin gene was used to verify equal amounts of 
cDNA in the murine or human cDNA samples, respectively. The target genes, primer 
sequences, annealing temperatures, cycle numbers, and the length of PCR products 
are listed in Appendix III. The cycling parameters for a PCR amplification usually 
included 1 cycle at 95°C for 5 min, followed by 25 - 40 cycles at 95°C for 30 sec, 
indicated annealing temperature for 30 sec and 72°C for appropriate time based on 1 
min for every 1000 bp, and a final extension at 72°C for 10 min.  
 
 
2.3 Cell biology techniques  
 
2.3.1 Coating of recombinant proteins and antibodies 
In the experiments that require precoating of recombinant proteins or antibodies, 
tissue culture plates were incubated with coating solution at 4ºC overnight, and the 
wells were washed with PBS before cells were seeded (Fig. 2.2). The final 
concentrations of coating solutions were: 10 g/ml (Langstein et al., 1998, 1999a, 
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1999b, 2000; unless otherwise stated) for human or mouse CD137-Fc protein and 
their control protein, Fc of human IgG1 in PBS; 10 g/ml for anti-human CD137L 
(clone 5F4 and C65-485) and their isotype control mouse IgG1 (clone MOPC-21) in 
PBS; 5 g/ml for anti-mouse CD3 (clone 17A2), anti-mouse CD28 (clone 37.51) and 
their isotype control rat IgG2b (clone RTK4530), Syrian hamster IgG (clone SHG-1) 
in PBS. The volumes of coating solutions per well for different tissue culture plates 
were: 100 L for 96-well plates, 300 L for 24-well plates, 500 L for 12-well plates 
and 1 ml for 6-well plates (unless otherwise stated). When the recombinant proteins or 
antibodies were added as soluble, the plate wells were precoated with 3% BSA at 4ºC 
overnight.    
 
 
Figure 2.2. Schematic diagram of coating proteins or antibodies onto the tissue 
culture plates.  
 
 
2.3.2 Cell count 
2.3.2.1 Manual cell count with Trypan blue 
Cells were harvested after incubation with 10 mM EDTA for 10 min. Cells were 
centrifuged and resuspended in PBS. The numbers of viable cells were assessed by 
0.4% Trypan blue (Sigma) staining and counted using a haemocytometer (Neubauer). 
 
2.3.2.2 Differential Cell Count 
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For cytological examination, cytospin preparations were prepared using a Cytospin 
(Thermo Shandon, Pittsburgh, PA), fixed, and stained in a modified Wright stain (Bao, 
et al 2007). Differential cell count was then performed on at least 500 cells in each 
cytospin slide. 
 
2.3.2.3 Cell count by FACS with counting beads 
Cell samples were stained with 0.5 μg/ml 7-AAD for 15 min at room temperature in 
the dark. After washing for three times, cells were resuspended in 450 μl PBS. 50 μl 
of Sphero AccuCount Blank Particles (about 50,000 beads per 50 l) (ACBP-100-10, 
Spherotech, IL, USA) were added to the suspension and mixed well. Samples were 
analyzed by flow cytometry with CyAn™ ADP Analyzer (Beckman Coulter, CA, 
USA). 7-AAD negative cells were gated as live cells. The population of beads and 
target cells were gated separately on the forward/side scatter plot based on different 
sizes. The number of cells in each sample was calculated by the following formula.  
 
 
2.3.3 Flow cytometry analysis and antibodies 
Aliquots of cultured cells (2 – 3 × 105 cells) were stained with respective 
fluorochrome conjugated antibodies in PBS containing 0.5% BSA and 0.1% sodium 
azide (FACS buffer) together with mouse or human FcR blocker (Miltenyi Biotech, 
Bergisch Gladbach, Germany) for 1 h at 4°C in the dark. Cells were then washed 
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twice and resuspended in 500 µl of FACS buffer. If fixation was required, the cells 
were fixed with 1% PFA at 4ºC for 1 h. Flow cytometry was performed either on a 
FACSCalibur (BD Biosciences, San Diego, CA, USA) with CellQuest data 
acquisition and analysis software, or on a Cyan flow cytometer (Dako, Denmark) with 
Summit software. Nonspecific staining was controlled by isotype-matched antibodies. 
All the antibodies used in the study were listed in Appendix II. 
 
2.3.4 CFSE labeling 
Fresh bone marrow cells at a concentration of 10
6
 cells/ml were labeled with 5 µM 
Carboxyfluorescein diacetate, succinimidyl ester (CFSE) using the CellTrace
TM
 CFSE 
Cell Proliferation Kit (Invitrogen, CA) according to the manufacturer’s protocol. 
Labeled cells were cultured in plates precoated with 10 μg/ml Fc or CD137-Fc. The 
cells were harvested on day 7 and 14, and analyzed by flow cytometry.  
 
2.3.5 Proliferation assay 
Cell proliferation was determined by 
3
H-thymidine incorporation. Cells were pulsed 
with 0.5 Ci of 3H-thymidine (PerkinElmer, Boston, MA) for the last 24 h of the 
culture period. The cells were then harvested onto a Packard Unifilter Plate using a 
MicroMate 196 Cell Harvester and counted using a TopCount Microplate Scintillation 
Counter (Packard Instruments, Meriden, CT).  
 
For immobilization of CD137L agonists on beads, protein A-coupled polystyrene 
 40 
beads (Spherotech, IL, USA) were incubated with CD137-Fc, Fc, anti-CD137L 
antibody (clone 5F4) or isotype control mouse IgG1 (clone MOPC-21) at a ratio of 50 
μg beads (~ 1.3 × 106 beads) to 1.5 g protein or antibody for 1 h at 4°C. The coated 
beads were washed three times with PBS before seeded into round-bottom 96-well 
plates (Nunc) at 50 g beads per well. 
 
2.3.6 Colony-forming assay 





Freshly isolated bone marrow cells at density of 5 × 10
4





at density of 10
4
 cells/ml were cultured in 35 mm dishes in triplicates in 1 ml of 
semi-solid methylcellulose based medium (MethoCult® SF
BIT
 M3236, StemCell 
Technologies) supplemented with 10% bovine calf serum. Dishes were cultured at 
37°C in a humidified atmosphere containing 5% CO2. Colonies were counted under 




 cells. The 
number of colonies consisting of more than 50 cells was counted, and the average 
numbers of colonies and standard deviations were calculated from triplicate plates. 
The types of colonies were identified based on their morphological characteristics 
(Yoon et al. 2006, Coutinho et al. 2003).  
 





 cells were cultured in 35 mm dishes in triplicates at a density of 2 × 10
3
 
cells/ml in 1 ml of semi-solid methylcellulose based medium (StemCell Technology) 
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supplemented with 10% bovine calf serum (BCS). Dishes were cultured at 37°C in a 
humidified atmosphere containing 5% CO2. Colonies were counted under the 
microscope 14 days after culture. The number of colonies consisting of more than 30 
cells was counted, and the average number of colonies and standard deviations were 
calculated from triplicates.  
 
2.3.7 Apoptosis assay 
Cells were labeled with Annexin V-FITC and 7-AAD (BD Bioescience) following the 
the manufacturer’s instructions. The percentage of apoptotic cells was determined by 
flow cytometry. 
 
2.3.8 Phagocytosis assay 













 cells per well were cultured in 
plates that had been precoated with 10 µg/ml of Fc or CD137-Fc for 7 days. 
Subsequently, 1 µm yellow-green fluorescent carboxylate-modified microspheres 
(FluoSpheres, Molecular Probes) were added at a ratio of 50 beads per cell. The plates 
were incubated for 1 h at 37°C in the dark. Cells that had undergone the same 
treatment but without addition of beads served as negative controls. After 1 h 
incubation, 1 ml of cold PBS was added into each well to stop phagocytosis. Cells 
were washed and trypsin-EDTA was added to dislodge surface adherent beads. Cells 
were washed again and resuspended in FACS buffer for analysis by flow cytometry.  
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2.3.8.2 Phagocytosis assay for human cord blood CD34
+





 cells or 5 × 10
5
 cord blood monocytes per well were cultured in 
plates that had been precoated with 10 µg/ml of Fc or CD137-Fc. Monocytes were 
cultured for 3 days and CD34
+
 cells were cultured for 10 days. Subsequently, 1 µm 
yellow-green fluorescent carboxylate-modified microspheres were added and then 
analyzed by flow cytometry, same as described above.  
 
2.3.9 Allogeneic mixed lymphocyte reaction 





Bone marrow cells were isolated from femurs of 12-week old BALB/c mice. 2 × 10
6
 






 cells per well were cultured in plates that 
had been precoated with 10 µg/ml of Fc or CD137-Fc. In parallel, cells were treated 
with 100 ng/ml GM-CSF + 25 ng/ml IL-4 (Peprotech) to generate immature DCs. 
Maturation of DCs was induced on day 6 by addition of 1 μg/ml LPS (Sigma). Cells 
were treated with 50 g/ml mitomycin C at 37°C for 2 h to disable the proliferation 
on day 7. Subsequently, cells were harvested by incubation with 10 mM EDTA at 
room temperature for 10 min and washed twice with PBS, and served as stimulator 
cells. T cells were isolated from splenocytes of 8-week old C57/BL6 mice by 
magnetic selection using the mouse Pan T cell isolation kit (Miltenyi) to a purity 
of >90%, as analyzed by flow cytometry for mouse CD3. 10
5
 T cells were cocultured 
with stimulator cells at a 10:1 ratio in 96-well round bottom plates for 3 days and 
pulsed with 0.5 Ci 3H-thymidine per well for the last 18 h. The rate of T cell 
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proliferation was determined with a scintillation counter (Packard).  
 
2.3.9.2 Allogeneic MLR for human cord blood CD34
+





 cells or 5 × 10
5
 cord blood monocytes per well were cultured in 
plates that had been precoated with 10 µg/ml of Fc or CD137-Fc for 7 days. In 
parallel, cells were treated with 100 ng/ml GM-CSF + 25 ng/ml IL-4 (Peprotech) to 
generate immature DCs. Maturation of DCs was induced on day 6 by addition of 1 
g/ml LPS (Sigma). Cells were treated with 50 g/ml mitomycin C at 37°C for 2 h to 
disable the proliferation on day 7. Subsequently, cells were harvested by incubation 
with 10 mM EDTA at room temperature for 10 min and washed twice with PBS, and 
served as stimulator cells. CD3
+
 T cells were isolated from another unit of buffy coat 
by magnetic selection using the human CD3 MicroBeads (Miltenyi) to a purity 




 T cells were 
cocultured with stimulator cells at a 10:1 ratio in 96-well round bottom plates for 3 
days and pulsed with 0.5 Ci 3H-thymidine per well for the last 18 h. The rate of T 
cell proliferation was determined with a scintillation counter (Packard).  
 
2.3.9.3 MLR for suppressor cell function 




 cells were isolated from BALB/c mice as 
described above. Bone marrow derived DCs were generated by culturing bone 
marrow cells with 100 ng/ml GM-CSF and 25 ng/ml IL-4 for 7 days with 1 g/ml 




 cells were cultured in 12-well plates that were 
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precoated with 10 g/ml CD137-Fc or Fc proteins for 7 days at a density of 5 × 10 
cells per well. Cells and supernatants were harvested on day 7. Supernatants were 
used for ELISA. Bone marrow derived DCs were used as stimulator cells, and 
CD137-Fc or Fc treated cells were used as suppressor cells. T cells were isolated from 
C57/BL6 mice spleen by MACS using the Pan T cell isolation kit (Miltenyi). T cells, 
stimulator cells (bone marrow derived DCs) and suppressor cells were cocultured in 
round-bottom 96-well plate at indicated ratios, with a constant T cell number of 10
5
 
per well, in a total volume of 200 L complete medium. Single cell types of T cells or 
stimulator cells or suppressor cells were used as negative controls. Cells were 
cocultured for 4 days and pulsed with 0.5 μCi 3H-thymidine per well for the last 18 h. 
The rate of T cell proliferation was determined with a scintillation counter (Packard).  
 
2.3.10 ELISA 
The concentrations of murine IL-10, IL-12p70, G-CSF, M-CSF, GM-CSF, IL-3, IL-6, 
and SCF in cell supernatants were determined by mouse IL-10 ELISA MAX set 
(BioLegend), mouse IL-12p70 DuoSet ELISA kit (R&D systems) and mouse G-CSF, 
M-CSF, GM-CSF, IL-3, IL-6, SCF ELISA Development kits (Peprotech), respectively. 
The concentrations of human IL-10, IL-12p70, IL-6 and IL-8 in cell supernatants 
were determined by human IL-10 ELISA MAX set (BioLegend), human IL-12p70, 
IL-6, IL-8 DueSet ELISA kits (R&D systems) according to the manufacturer’s 




MCF-7 cells were plated in 6-well plates at a density of 2 × 10
5
 cells/well, and 
cultured to 80% confluency. The cells were transiently transfected with 10 µg of 
human or murine CD137 ligand expression vector or the empty vector pcDNA3.1 
(Invitrogen), together with 10 µl of Lipofectamine
TM
 2000 (Invitrogen) in serum-free 
medium. The culture medium was changed to complete medium after 4 h of 
transfection. Cells were harvested after 48 h of transfection using 10 mM EDTA in 
PBS for flow cytometric analysis.  
  
2.3.12 Cytokine antibody array  
Mouse bone marrow cells were cultured for 14 days in plates that were precoated with 
10 g/ml CD137-Fc or Fc. Supernatants were harvested on day 7 and 14, and 
analyzed with using the RayBio
 
Mouse Cytokine Antibody Array III (RayBiotech, GA, 
USA) according to the manufacturer's instructions. Briefly,
 
cytokine array membranes 
were blocked in blocking
 
buffer for 30 min and then incubated with 1 ml of samples 
at
 
room temperature for 2 h. After five times washing, membranes
 
were incubated at 
room temperature with biotinylated primary
 
antibodies for 2 h and then with 
streptavidin-HRP for 1 h. Membranes were washed thoroughly
 
for 5 min in the dark 
before imaging. Membranes
 
were exposed to X-ray film (Kodak X-OMAT AR film) 
within 30
 
min of exposure to the substrate. Signal intensities were scanned with the 
Typhoon 9400 blot imager (Amersham Biosciences, CA, USA) and quantified with 
ImageQuant TL v2005 (Amersham). Data were analyzed by RAYBIO analysis tool 
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(RayBiotech). The signal intensities on different membranes were normalized based 
on six positive control spots on each membrane.  
 
2.3.13 Cytometric bead array (CBA) 
Tissue culture plates were precoated with 10 g/ml CD137-Fc or Fc protein at 4 ºC 
overnight. 2 × 10
6
 BALB/c bone marrow cells were cultured in 6-well plates for 7 
days or 5 × 10
5
 human cord blood CD34
+
 cells were cultured in 12-well plates for 10 
days. Supernatants were collected and concurrently assayed for IL-6, IL-10, MCP-1, 
IFN-, TNF, and IL-12p70 using the BD™ Cytometric Bead Array (CBA) mouse 
inflammation kit; or IL-8, IL-1, IL-6, IL-10, TNF, and IL-12p70 using the human 
inflammation kit (BD Biosciences), respectively, according to the manufacturer's 
protocol.   
 
Six bead populations with distinct fluorescence intensities had been coated with 
capture antibodies specific for the above mentioned cytokine proteins and were 
detected on the FL3 channel of the Calibure flow cytometer (Becton Dickinson, 
Mountain View, CA). The antibody-coated bead mixture was then tagged to a 
PE-conjugated detection-antibody system and the fluorescence signals were read on 
the FL2 channel. Standard curves for each cytokine were plotted and the unknown 
values for each of the test samples were calculated using the CBA software. Results 
are represented as mean fluorescence intensity obtained on the FL2 channel. 
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2.3.14 Microscopy and photography 
Morphological changes of cells were documented by using a Zeiss Axiovert 40 
inverted microscope (Zeiss, Göttingen, Germany) and Canon PowerShot G6 digital 




2.4 Staining procedures 
 
2.4.1 Immunocytochemistry 
2 – 5 × 106 cells were smeared onto the TBS-coated glass slides. The air-dried slides 
were fixed with ice cold absolute methanol. After blocking with 3% skim milk for 30 
min and 3% H2O2 for 10 min, the slides were incubated with 1 µg/ml biotinylated 
primary antibodies for 1 h and subsequently with 1 µg/ml streptavidin-peroxidase 
polymer (Sigma) for 30 min. After three washes, the slides were incubated with liquid 
DAB
+
 substrate (Dako, Denmark) for 5 - 10 min in the dark. Then the slides were 
counterstained with hematoxylin (Sigma), and mounted in DPX mounting media 
(Sigma). All incubations were done at room temperature.  
 
2.4.2 Immunohistochemistry 
Formalin fixed paraffin embedded human bone marrow tissue slides were purchased 
from Spring Bioscience (Fremont, CA, USA). After deparaffinization in Xylene, and 
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hydration in a graded series of alcohol, the slides were pretreated with citrate buffer 
(Dako) in a pressure cooker at 109ºC for 15 min for antigen retrieval. Endogenous 
peroxidases were inactivated by 3% hydrogen peroxide for 15 min. Unspecific 
staining was blocked by 3% dry milk in PBS for 30 min. 2 µg/ml of anti-CD137 
(clone BBK-2, Bioscource) or an isotype control antibody (MOPC21, Sigma) in TBS 
were used as primary antibodies and hybridized overnight. The secondary 
HRP-conjugated anti-mouse antibody (Dako) was added for 30 min, followed by 
DAB
+
 substrate (Dako). The entire procedure was carried out at room temperature and 
after each step the samples were washed three times with PBS. Finally, the tissue 
sections were counterstained with hematoxylin and mounted.  
 
2.4.3 Esterase stain 
2 - 5 × 10
6
 cells were smeared onto glass slides. Esterase staining was performed 
successively with the α-Naphyl Acetate Esterase kit (Sigma) for non-specific esterase 
and the Naphthol AS-D Chloroacetate Esterase kit (Sigma) for specific esterase 
following the manufacturer’s instructions. 
 
 
2.5 Statistics  
Data are expressed as means ± SD for replicates in an independent experiment, or 
mean ± SE for repeats of several independent experiments. Unless otherwise stated, 
two tailed unpaired Student’s t-tests were used to determine statistical significance. 
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CHAPTER 3  RESULTS 
 
Since CD137 agonists (recombinant CD137 protein and anti-CD137L antibodies) 
have been shown to induce proliferation and endomitosis in peripheral monocytes, a 
cell population which was believed not to be able to proliferate (Langstein et al., 
1999a; Ju et al., 2003) we hypothesized that they may also be able to induce 
proliferation in the precursor of monocytes, the hematopoietic progenitor cells. We 





3.1 Induction of proliferation and monocytic differentiation of human CD34
+
 
cells by CD137L signaling 
 
3.1.1 CD137 and its ligand are expressed in the bone marrow 
CD137 is expressed on few but distinct cells in the human bone marrow as detected 
immunohistochemically (Fig. 3.1 A). CD137L is expressed on a small subset of 
hematopoietic progenitor cells. 1.9% and 3.2% of freshly isolated CD34
+
 cells stained 
positive with an anti-CD137L antibody and a recombinant CD137 protein, 
respectively (Fig. 3.1 B). Confirming data on CD137L protein expression we detected 
CD137L mRNA in CD34
+
 cells by RT-PCR (Fig. 3.1 C).  
 
Expression of both, CD137 and CD137L by bone marrow cells suggested a function 
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for this receptor/ligand pair in the bone marrow. Since CD137L crosslinking has been 
shown to induce proliferation of peripheral monocytes and maturation of immature 
DCs we suspected similar functions for the CD137L-expressing hematopoietic 






Figure 3.1. CD137 and CD137L expression. (A) Immunohistochemical detection of 
CD137 expression (brown stain) in human bone marrow. CD137 was detected by 
staining with anti-CD137 antibody (clone BBK-2); and mouse IgG (clone MOPC-21) 





 cells) were stained with PE-labeled anti-CD137L antibody, clone 5F4 (1:10), 
or 1.2 g of CD137-Fc protein followed by anti-human IgG1-PE. Mouse IgG1 and Fc 
protein were used as isotype controls for 5F4 and CD137-Fc, respectively. CD34 was 
detected by an FITC-labeled anti-CD34 antibody, clone AC136 (1:10). Cells were 
analyzed by flow cytometry, and the resulting dot blot analyses are depicted. 
Percentages of cells are stated in each quadrant. (C) Expression of CD137L mRNA 
was determined by RT-PCR using cDNAs from purified CD34
+
 cells of two donors. 
Cloned human CD137L cDNA (CD137L plasmid) and cDNA from Raji cells were 
used as positive controls. Reactions with no template (water) or RNA from CD34
+
 
cells that was not reverse-transcribed served as negative controls. Comparable 
amounts of cDNA were verified by amplification of cyclophilin. GeneRuler DNA 
ladder (Fermentas) was used as a size standard. PCR products were analyzed on a 1% 
TAE agarose gel. These experiments were performed three times with same results. 
 
 
3.1.2 CD137 induces morphological changes of CD34
+
 cells 
Hematopoietic progenitor cells were isolated from umbilical cord blood via their 
CD34 expression. The purity of enriched CD34
+
 cells was higher than 90%. The cells 
were cultured in tissue culture plates that were coated with a fusion protein consisting 
of the extracellular domain of CD137 and the constant domain (Fc) of IgG1 
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(CD137-Fc) or an Fc control protein.  
 
CD137-Fc protein induced attachment and spreading of subsets of CD34
+
 cells 
whereas other cells appeared to attach only lightly or not at all. Cells in the control 
wells resembled this latter group as they too remained round and did not attach. 
Attachment and spreading in response to CD137 protein was accompanied by 
morphological changes of the cells, which became apparent on the days 5 – 7, and 
were the most prominent on day 14. Besides a general increase in cell size, the 
following three types of morphological changes were observed: (1) Elongation to 
spindle-shaped cells, formation of (2) lamelopodia and filopodia, and (3) dendrites 
(Fig. 3.2).  
 
 
Figure 3.2. CD137 induces morphological changes of CD34
+




cells at a density of 5 × 10
5
 /ml were cultured in RPMI, 10% FBS (complete medium) 
in wells coated with 10 g/ml Fc or CD137-Fc protein. Photographs were taken on 
day 14 at room temperature at magnifications of 400× and 630×. Scale bars: 25 m. L: 
Lamellopodia. F: Filopodia. D: Dendrites. 
 
 
3.1.3 CD137 induces proliferation of CD34
+
 cells 
We noticed that besides morphological changes CD137-Fc protein also enhanced the 




 cells were cultured on Fc- 
or CD137-Fc-coated plates and numbers of live cells were counted on days 3, 7, 10 
and 14. More than half of the cells died during the first 3 days. CD137-Fc induced an 
amplification of live cell numbers that peaked at day 14 at around 4 × 10
4
 cells. At 
that time point CD137-Fc had increased cell numbers 4-fold over the Fc control and 
above the original cell number plated (Fig. 3.3 A). The cell number did not increase 
further after day 14, likely due to exhaustion of nutrients in the culture (not shown). 
The increase in cell number was accompanied by cellular proliferation in response to 
CD137-Fc protein as measured by 
3
H-thymidine incorporation (Fig. 3.3 B, C). The 
time course curve of cell numbers showed a delayed kinetics compared to that of cell 
proliferation which peaked at day 10. CD137-Fc added as soluble protein could not 
induce proliferation of CD34
+
 cells (Fig. 3.3 B). This demonstrates that CD137-Fc 
works by crosslinking CD137L on a subset of CD34
+
 cells, and excludes that the 










 cells at a density of 2.5 × 10
5
 cells/ml were cultured in complete 
medium in wells coated with 10 g/ml Fc or CD137-Fc protein or the proteins were 
added soluble. (A) Live cells were counted after trypan blue staining on days 3, 7, 10, 
14, 17, and 21. Depicted are means ± SD of four representative fields of each of 
duplicate cultures. (B) Proliferation was determined on day 10 after cells had been 
labeled for the last 24 h with 0.5 Ci of 3H-thymidine. (C) Proliferation was 
determined on day 3, 7, 10, 14, 17, 21 after cells had been labeled for the last 24 h 
with 0.5 Ci of 3H-thymidine. Depicted are means ± SD of triplicate measurements. *, 




In order to verify that the observed effects of CD137-Fc protein on CD34
+
 cells are 
indeed due to CD137L crosslinking we performed several control experiments. 
Immobilization of CD137-Fc was prevented by prior coating of the culture dishes 
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with BSA. Immobilized but not soluble CD137-Fc protein induced morphological 
changes (Fig. 3.2; personal communication by Yue P. S. and Schwarz H.), and 
proliferation (Fig. 3.3 B). In addition, two monoclonal antibodies specific for CD137L 
induced identical morphologies as CD137-Fc protein (not shown), and enhanced 
proliferation of CD34
+
 cells (Fig. 3.4 A). Further, CD137-Fc and anti-CD137L 
antibody (clone 5F4), but not the Fc or MOPC-21 isotype controls, immobilized on 
protein-A coated polystyrene beads enhanced proliferation of CD34
+
 cells (Fig. 3.4 B), 
similar as they did when immobilized on the culture plates. This rules out the 
possibility that the Fc portion of the fusion protein provides synergistic effect to 
CD137L signaling.   
 
 





 cells at a density of 2 × 10
5
/ml were cultured in complete 
medium. Proliferation was determined on day 10 after cells had been labeled for the 
last 24 h with 0.5 Ci of 3H-thymidine. (A) Cells were treated with 10 g/ml 
immobilized monoclonal anti-CD137L antibodies (clone 5F4 or C54-485) or isotype 
control (mouse IgG1, clone MOPC-21). (B) Cells were cocultured with 50 g of 
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protein-A coated polystyrene beads (labeled as B on x-axis) conjugated with 1.5 g of 
Fc, CD137-Fc, MOPC-21, or 5F4 in round-bottom 96-well plates. Depicted are means 
± SD of triplicate measurements. **, p < 0.01. This experiment was performed three 
times with similar results. 
 
 
3.1.4 CD137 induces colony formation of CD34
+
 cells 
CD137L crosslinking also induced colony formation by hematopoietic progenitor 




cells were seeded in Fc- or CD137-Fc-coated 35 mm dishes with 
methylcellulose medium supplemented with 10% serum. No other growth factors 
were added. Due to the high viscosity of methylcellulose medium only a fraction of 
the plated CD34
+ 
cells are expected to come in contact with the plate-bound Fc or 
CD137-Fc protein. By day 20, 3 - 4 colonies had emerged in the Fc-coated control 
dishes, but more than 40 colonies had formed in response to CD137-Fc. While 
Fc-induced colonies were comparatively small containing less than 50 cells, CD137 
protein had induced larger colonies, with some containing up to 500 cells (Fig. 3.5). 
The colonies formed in response to CD137L crosslinking were of the CFU-GM type 










were cultured in 1 ml methylcellulose medium, 10% BCS, on 35 mm dishes which 
were coated with 10 µg/ml Fc or CD137-Fc protein. (A) At day 14, the numbers and 
sizes of the colonies were counted. Depicted are means ± SD of triplicate 
measurements. * p<0.05. (B) Photographs of colonies in CD137-Fc-coated dishes 




3.1.5 CD137 ligand signaling induces differentiation towards the myeloid lineage 
Generally, growth factors which induce proliferation of hematopoietic progenitor cells 
also induce differentiation to a specific lineage. We therefore investigated whether 
CD137L signaling also influences differentiation using flow cytometry.  
 
Differentiation is characterized by a decreased expression of the CD34 antigen 
(Fackler et al. 1995). Among freshly isolated cells, more than 90% stained positive for 
CD34 by flow cytometry. However, after culturing the cells for 10 days on Fc- or 
CD137-Fc-coated dishes the expression of CD34 had decreased to around 12%, 
indicating that differentiation of the cells had occurred (Fig. 3.6).  
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We analyzed expression of lineage-associated cell surface markers to determine to 
which lineage CD137 agonists are driving differentiation of the CD34
+
 cells. 
Antibodies to CD3, CD19, CD41 and CD235a were used to identify T cells, B cells, 
megakaryocytic and erythroid cells, respectively. CD11b and CD14 served as markers 
for the myeloid lineage and monocytes/macrophages, respectively. No influence of 
CD137-Fc on T and B cell survival or differentiation could be detected. T cells and B 
cells which each made up close to 5% of freshly isolated CD34
+
 cells were strongly 
reduced or had completely disappeared at day 10 (Fig. 3.6 A, B). 
 
Similarly, CD137-Fc had no influence on the megakaryocytic and erythroid lineages. 
Around 60% of the freshly isolated CD34
+ 
cells expressed CD41. After the 10 day 
culture, the percentage of CD41
+
 cells was reduced to 5 – 10%. The percentage of 
CD235a
+
 cells had decreased from around 16% to 1 – 2% by day 10 (Fig. 3.6 A, B). 
There were no significant differences in CD3, CD19, CD41 and CD235 expression 
for the cells cultured on Fc- or CD137-Fc-coated plates.  
 
CD137-Fc however, promoted differentiation to myeloid cells. Among freshly 
isolated CD34
+
 cells 5.7±2.7% expressed CD11b. After the cells were cultured for 10 
days, CD11b expression had increased significantly, to 16.2±3.4% and 29.3±3.8% 
CD11b
+
 cells for Fc- and CD137-Fc-treated cells, respectively (Fig. 3.6 A, B). More 
pronounced was the effect of CD137-Fc on the absolute number of live CD11b
+
 cells. 




 in the Fc control conditions 
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but had increased 18-fold to (946.4±122.7)×10
3
 in the CD137-Fc conditions (Fig. 3.6 
A, B).  
 
The monocytic marker CD14 was expressed on 3.3±1.2% of the freshly isolated 
CD34
+ 
cells. After the 10 day culture, the percentage of Fc-treated cells which stained 
positive for CD14 had increased to 18.6±3.5% while that for CD137-Fc-treated cells 
had increased to 30.4±3.9%. The absolute number of CD14
+





 in the Fc controls, and to (991.9±126)×10
3
 in the 
CD137-Fc conditions (Fig. 3.6 A, B).   
 
These data indicate that CD137L signaling drives differentiation of CD34
+
 cells to the 
myeloid lineage, especially to monocytes/macrophages, but has no effect on the 







Figure 3.6. Flow cytometric analysis of CD137-induced differentiation of CD34
+
 
cells. Freshly isolated CD34
+
 cells or CD34
+
 cells which had been cultured on dishes 
coated with 10 μg/ml Fc or CD137-Fc protein for 10 days. (A) Cells were stained for 
CD34, CD11b, CD3, CD19, CD14, CD41 and CD235a expression and analysed by 
flow cytometry. Black line: Isotype. Gray, filled curve: Marker-specific antibody. (B) 
Depicted are means ± SE for absolute numbers of live cells (left column) and 
percentages (right column) of data in (A) for indicated subpopulations at days 0 and 
10 of eight independent experiments.  
 
 
3.1.6 CD137 induces differentiation to macrophages 
Previous experiments show CD137L crosslinking by recombinant CD137 protein on 
CD34
+
 cells and subsequent CD137L signaling in CD34
+
 cells causes (1) activation 
resulting in attachment and morphological changes, (2) survival and/or proliferation, 
and (3) induces differentiation of CD34
+
 cells to monocytic cells. Monocytic cells 
include monocytes, macrophages, and myeloid DCs. Circulating monocytes can 
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differentiate to DCs or macrophages in the peripheral tissues upon stimulation. The 
next question we want to address is whether the monocytic cells differentiated by 
CD137 are DCs or macrophages.  
 
First, we started with cell morphology since DCs and macrophages adopt different 
morphologies. When comparing CD137-differentiated CD34
+
 cells to cells exposed to 
M-CSF or GM-CSF + IL-4, classical macrophage or DC differentiation factors, 
respectively, we noticed the presence of elongated or ovoid macrophages, and of 
smaller, round, detached cells with DCs morphology, implying that CD137 may 
support macrophage as well as DC differentiation (Fig. 3.7). 
 
For reference we included cord blood monocytes from the same donor. 
CD137-Fc-treated monocytes resembled more macrophages than DCs but contained 
more cells than M-CSF-treated monocytes. This observation is in line with the known 
activities of CD137 as a monocyte survival and growth factor (Langstein et al. 1999a, 
b). Further, CD34
+
 cells and monocytes exposed to CD137 differed profoundly in 
morphology indicating that it were progenitor cells that responded to CD137. It 
excludes the possibility that the observed effects are due to contaminating monocytes 




Figure 3.7. Morphological comparison of CD137 differentiated cells, DCs and 
macrophages. Human CD34
+
 cells or cord blood monocytes were cultured for 10 
days in complete medium in wells coated with 10 g/ml Fc or CD137-Fc protein. 100 
ng/ml of GM-CSF + 25 ng/ml of IL-4 and 50 ng/ml of M-CSF were used as controls 
for DCs differentiation and macrophage differentiation, respectively. Photographs 




Next, gene expression analysis was carried in order to gain a more detailed 
understanding of CD137-induced differentiation of hematopoietic progenitor cells. 
We checked the expression of DC- and macrophage-specific genes. It is reported that 
during differentiation of human monocytes to macrophages or DCs, FcR1A and 
TCF7L2 are macrophage-specific, and WNT5A, FceR1A, Fibronectin, SOCS1, and 
TGG- are DC-specific (Lehtonen et al. 2007). The expression profile of these genes 
was analyzed and compared in the cultures of CD137-Fc- and Fc-treated CD34
+
 cells 
and cord blood monocytes by RT-PCR. The expression of FcR1A and TCF7L2 were 
higher in M-CSF-treated CD34
+
 cells and monocytes than in GM-CSF + IL-4-treated 
monocytes, indicating that they are indeed macrophage-specific genes. 
CD137-Fc-treated cells showed higher expression of these two genes than Fc-treated 
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counterparts, and the expression levels were similar as in M-CSF-treated cells (Fig. 
3.8). This suggested that CD137-treated CD34
+
 cells and monocytes were in the 
process of macrophage differentiation. SOCS1 was expressed in GM-CSF + 
IL-4-treated cells but not in M-CSF-treated cells, indicating it was a DC-specific gene. 
CD137-Fc-treated CD34
+
 cells expressed no or much less SOCS1 than Fc-treated 
cells on day 7 and 13 (Fig. 3.8). This suggested that CD137 drives differentiation 
away from DCs. The rest of the DC-specific genes failed to give a clear result. From 




Figure 3.8. RT-PCR of macrophage- and DC-specific genes. CD34
+
 cells and 
monocytes isolated from human cord blood were cultured in complete medium in 
wells coated with 10 g/ml Fc or CD137-Fc protein. 100 ng/ml of GM-CSF + 25 
ng/ml of IL-4 and 50 ng/ml of M-CSF were used as controls for DC and macrophage 
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differentiation, respectively. Total RNA was extracted and converted to cDNA from 
these cultures on day 7 and 13. Expression of FcR1A, TCF7L2, WNT5A, FceR1A, 
Fibronectin, SOCS1 and TGG- mRNA were determined by RT-PCR. Reactions with 
no template (water) or RNA from GM-CSF + IL-4-treated monocytes that was not 
reverse-transcribed served as negative controls. Comparable amounts of cDNA were 
verified by amplification of cyclophilin. GeneRuler DNA ladder (Fermentas) was 
used as a size standard. PCR products were analyzed on a 1% TAE agarose gel. These 
experiments were performed twice with similar results. The numbers indicate the 
lengths of the PCR products for the respective genes.  
   
 
In the next step, we analyzed CD137-induced changes in cell surface marker 
expression to assess DC and macrophage differentiation phenotypically. CD1a and 
CD83 were not detectable or expressed at low levels, respectively, on 
CD137-differentiated CD34
+
 cells (not shown). CD209 (DC-SIGN) was neither 
expressed on CD137-Fc-treated CD34
+
 cells nor monocytes, but was expressed 
slightly by GM-CSF + IL-4-treated CD34
+
 cells (9% positive), and strongly by 
GM-CSF + IL-4-treated monocytes (95% positive), (Fig. 3.9). HLA-DR levels were 
high (>75% positive) but not affected by CD137L signaling on CD34
+
 cells, and 
interestingly, were reduced on cord blood monocytes from the same donor (85% vs. 
53.8%), (Fig. 3.9). CD14 expression was increased by exposure of CD34
+
 cells to 
CD137 protein (31% vs. 43%), but was lower than in monocytes (around 80%), (Fig. 
3.9). These data from the analysis of cell surface marker expression were more 
compatible with macrophage than DC differentiation. 
 
Though expression of cell surface markers could indicate cellular differentiation, a 




 cells that had been cultured for 10 days on CD137-Fc or Fc protein. 
Stimulation by CD137 protein more than doubled the percentage of cells 
phagocytosing flourescent latex beads (8.1% vs 18.6%). In contrast, in cord blood 
monocytes CD137 reduced the number of phagocytic cells to less than half (38.3% vs 





Figure 3.9 Flow cytometric analysis of DC / Macrophage cell surface marker 
expression on CD137-treated cells. Human CD34
+
 cells or cord blood monocytes 
were cultured in complete medium in wells coated with 10 µg/ml Fc or CD137-Fc 
protein. 100 ng/ml of GM-CSF + 25 ng/ml of IL-4 and 50 ng/ml of M-CSF were used 
as controls for DCs differentiation and macrophage differentiation, respectively. Cells 
were harvested on day 10 and stained for CD14, HLA-DR and CD209 expression and 
analysed by flow cytometry. Black line: Isotype. Gray, filled curve: Marker-specific 




Figure 3.10 Phagocytic function analysis. Human CD34
+
 cells were cultured for 10 
days and cord blood monocytes were cultured for 3 days in complete medium in wells 
coated with 10 g/ml Fc or CD137-Fc protein. Phagocytosis was measured by a 1 h 
pulse with fluorescent latex beads (black curves) at 50 beads per cell, followed by 
flow cytometry. White lines: Control without beads. This data is representative of 
three independent experiments. The percentage of beads containing cells and mean 
fluorescence intensity (MFI) were shown in the upper right corner for each sample.  
 
In addition, we analyzed secretion of cytokines associated with DC and macrophage 
differentiation. CD137-Fc differentiated CD34
+
 cells produced low levels of IL-10, 
and secretion of this cytokine was strongly induced by LPS. The same pattern was 
found in CD34
+
 cells differentiated with the Fc control protein, or in immature DCs, 
differentiated with GM-CSF + IL-4. In cord blood monocytes from the same donor 
CD137 protein as well as GM-CSF + IL4 induced moderate IL-10 secretion while 
high levels were obtained after LPS stimulation (Fig. 3.11 A). IL-12 was secreted in 
moderate and high amounts by GM-CSF + IL-4 treated monocytes and CD34
+
 cells, 
respectively, upon LPS maturation. CD137-Fc treatment could only give rise to low 
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levels of IL-12 in monocytes but not in CD34
+
 cells after LPS maturation. Without 
LPS treatment CD137L signaling had actually slightly reduced basal IL-12 levels in 
monocytes and CD34
+
 cells (Fig. 3.11 B).  
 
 
Figure 3.11. IL-10 and IL-12p70 ELISA. Human CD34
+
 cells or cord blood 
monocytes were cultured for 10 days in RPMI, 10% FBS in wells coated with 10 
g/ml Fc or CD137-Fc protein. 100 ng/ml of GM-CSF + 25 ng/ml of IL-4 were used 
as controls for DC differentiation. LPS was added for the last 24 h at 1 g/ml. IL-10 
(A) and IL-12p70 (B) in cell culture supernatants were measured by ELISA. Depicted 
are means ± SD of triplicate measurements. * p<0.05; ** p<0.01. These experiments 
were repeated three times with similar results. 
 
 
The ability to activate and induce clonal expansion of T cells is one of the most 
important signatures and functions of DCs. We tested this by using CD137-Fc-treated 
CD34
+
 cells and cord blood monocytes as stimulator cells in an allogeneic mixed 
lymphocyte reaction (MLR). Compare with Fc-treated monocytes, CD137-Fc-treated 
ones induced T cell proliferation (Fig. 3.12); however, CD137-Fc-treated CD34
+
 cells 





Figure 3.12. MLR. Human CD34
+
 cells or cord blood monocytes were cultured for 
10 days in RPMI, 10% FBS in wells coated with 10 g/ml Fc or CD137-Fc protein. 
After mitomycin C treatment, the cells were used as stimulators in an allogeneic MLR 
with T cells from another buffy coat PBMC at a stimulator:responder cell ratio of 1:10. 
T cell proliferation was measured 
3
H-thymidine incorporation. Depicted are means ± 
SD of triplicate measurements. **, p<0.01. This experiment was performed three 
times with similar results. 
 
 
Taken together, the absence of DC markers (SOCS1, CD1a, CD83, CD209, IL-12p70, 
and inability to induce allogeneic T cell proliferation), expression of macrophage 
markers (IL-10 and enhanced phagocytosis) argue that CD137L signaling induces 
macrophage rather than DC differentiation in hematopoietic progenitor cells. 
 
 
3.1.7 Maintenance of cell survival and induction of cell proliferation on CD34
+
 
cells by CD137 were partially dependent on IL-8 and cell density 
Next, we wanted to investigate the underlying mechanism of CD137-induced 
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proliferation and differentiation of hematopoietic progenitor cells (HPC). We noticed 
that immobilized CD137L agonists-treated CD34
+
 cells had significantly elevated 
IL-8 secretion in the presence (Fig. 3.13 A) or absence of serum (Fig. 3.13 B), 




Figure 3.13. IL-8 ELISA. 2 × 10
5
 of human CD34
+
 cells at density of 4 × 10
5
 / ml 
were cultured in complete medium for 8 days (A) or serum free medium for 10 days 
(B) in wells coated with 10 g/ml Fc or CD137-Fc protein, 10 g/ml MOPC-21 or 
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anti-CD137L mAb (clone C65-485 and 5F4), or CD137-Fc was added soluble. 
Supernatants were collected at day 3, 8 and 10, respectively. The concentration of 
IL-8 in the supernatants was measured by ELISA. Depicted are means ± SD of 
triplicate measurements. *, p<0.05, **, p<0.01. These experiments were repeated 
three times with similar results. 
 
 
Since IL-8 is associated with activation and proliferation of cells such as monocytes / 
macrophages (Milara et al. 2009), endometriotic stromal cells (Takemura et al. 2007), 
epithelial cells (Li et al. 2003; Joh et al. 2005), and carcinoma cells (Itoh et al. 2005), 
it may also play a role in CD137-induced HPC activation and proliferation. We tested 
this possibility by adding neutralizing anti-human IL-8 antibody or the isotype control 
antibody (MOPC-21) into the culture. 0.5 g/ml and 5 g/ml of anti-IL-8 neutralizing 
antibody but not the isotype control could significantly reduce the viable cell numbers 
of CD137-Fc-exposed CD34
+
 cells (Fig. 3.14). However, the cultures with anti-IL-8 
neutralizing antibody still had statistically significant more viable cells than the cells 
treated with Fc protein (Fig. 3.14). Therefore, blocking IL-8 could partially abolish 
the effects of CD137L reserves signaling in CD34
+
 cells. It suggested that CD137L 
agonists induced survival and proliferation of CD34
+
 cells were partially dependent 




Figure 3.14. CD137-induced survival and proliferation of CD34
+
 cells are 
partially dependent on IL-8. Human CD34
+
 cells at a density of 5 × 10
5 
/ml were 
cultured in complete medium in wells coated with 10 g/ml Fc or CD137-Fc protein. 
Anti-human IL-8 neutralizing antibody at 0.5 g/ml and 5 g/ml or isotype control 
antibody (MOPC-21) at 5 g/ml were added into the respective wells. The cells were 
harvested on day 10 and the numbers of viable cells were determined by cell counting 
after trypan blue staining. Depicted are means ± SD of four representative fields of 
each of duplicate cultures. *, p<0.05; **, p<0.01. This experiment was performed 
twice with the same result. 
 
During the culture, we also noticed that the initial cell density affected the magnitude 
of the effects on CD34
+
 cells induced by CD137L agonists. A proliferation assay of 
CD137-Fc-treated CD34
+
 cells was set up with different initial seeding densities. The 
cell proliferation increased exponentially with the increasing initial cell density (Fig. 
3.15). Hence, the initial cell density plays a role in CD137L agonist-induced 
proliferation of CD34
+
 cells. This suggests that some cytokines (e.g. IL-8) with 
autocrine or paracrine properties or cell-cell interactions are crucial in the CD137L 
reverse signaling pathway in HPC.   
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Figure 3.15. CD137-induced proliferation of CD34
+
 cells increases exponentially 
with the increasing initial cell density. Human CD34
+
 cells were cultured in 
complete medium in wells coated with 10 g/ml CD137-Fc at 0.5 × 104, 1 × 104, 2 
×10
4
, 5 × 10
4
, 10 × 10
4 
per well, respectively. Proliferation was determined on day 8 
after cells had been labeled for the last 24 h with 0.5 Ci of 3H-thymidine. Depicted 
are means ± SD of triplicate measurements. This experiment was performed twice 
with similar results.  
   
 
3.1.8 CD137 is unable to induce the proliferation of DCs 
Previous studies have demonstrated that crosslinking of CD137L induces proliferation 
and activation of peripheral monocytes (Langstein et al., 1999a; Langstein et al., 
2000). It can also induce the maturation of the immature DCs and enhance the DCs 
activity. (Wilcox et al., 2002; Kim et al., 2002; Laderach et al., 2003; Lippert et al. 
2008). We therefore investigated whether CD137L signaling also induces the 
proliferation of DCs. 
 
Monocytes were isolated from fresh peripheral blood (Fig. 3.16), buffy coat (not 
shown) or cord blood (not shown) and were cultured with GM-CSF + IL-4 for 7 days 
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to induce the differentiation of immature monocyte derived DCs (MoDCs). The 
maturation was pulsed by LPS or LPS + IFN-. Morphologically, the cells were 
semi-adherent and tended to form aggregates, and the cells treated with LPS + IFN- 
extended long dendrites (Fig. 3.16 A). Phenotypically, they all expressed high levels 
of DC markers DC-SIGN (CD209) and HLA-DR. The costimulatory molecules CD80 
and CD86, the DC activation marker CD83 were upregulated, especially in LPS + 
IFN- treated cells (Fig. 3.16 B). Therefore, these cells were indeed immature and 
mature MoDCs.  
 
These cells were then transferred to wells that had been coated with CD137-Fc or Fc 
in the presence or absence of conditioned medium from the DCs culture. There was 
no proliferation detectable in these cells by day 3 (not shown) and 6 (Fig. 3.16 C), 
except that the immature MoDCs in fresh medium had a basal level of DNA synthesis 
with no difference in CD137-Fc or Fc treatment. Therefore, no evidence could be 
obtained for CD137L signaling inducing the proliferation of the terminally 








Figure 3.16. CD137 is unable to induce proliferation of human MoDCs. 
Monocytes purified from fresh peripheral blood at the density of 1 × 10
6
 /ml were 
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cultured for 7 days in complete medium supplemented with 100 ng/ml of GM-CSF + 
25 ng/ml of IL-4. 1 g/ml LPS and 100 ng/ml IFN- were added in the corresponding 
wells for the last 24 h. (A) Photographs were taken on day 7 at room temperature at 
magnifications of 200× (scale bars: 100 m) and 630× (scale bars: 50 m). (B) Cells 
were harvested and stained for CD209, HLA-DR, CD80, CD86 and CD83 expression, 
and analyzed by flow cytometry. Black line: Isotype; blue line: GM-CSF + IL-4; 
orange line: GM-CSF + IL-4 + LPS; red line: GM-CSF + IL-4 + LPS + IFN-. (C) 
Culture supernatants were harvested as conditioned medium (CM) together with the 
cells. The cells were transferred to wells that had been precoated with 10 g/ml Fc or 
CD137-Fc protein with 5 × 10
4
 cells per well in fresh medium or complete medium 
that contained 50% CM. Cells were cultured for another 6 days and proliferation was 
determined after cells had been labeled for the last 24 h with 0.5 Ci of 3H-thymidine. 
Depicted are means ± SD of triplicate measurements. These data are representatives 
of three independent experiments. 
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3.2 CD137 induces proliferation of murine hematopoietic progenitor cells and 
differentiation to macrophages 
 
3.2.1 CD137 ligand signaling regulates survival and proliferation of murine bone 
marrow cells 
In the experiments described in the previous section, our hypothesis that CD137 
agonists are able to induce proliferation and differentiation of HSPCs proved to be 
true in the human system. We wanted to confirm these activities of CD137 agonists 
also in the murine system in order to use murine animal models.  
 
Bone marrow cells were isolated from the femur bones of BALB/c mice. The cells 
were cultured on tissue culture plates that had been coated with CD137-Fc. Fc protein 
was used as a negative control. Coating was performed overnight at 4°C and plates 
were washed with PBS afterwards. Cell numbers were determined by counting using 
a haemocytometer and viability was determined by trypan blue staining twice a week. 
2 × 10
6
 bone marrow cells were plated per condition and about 90% of the cells died 
during the first three days. But from day three onwards the number of live cells started 
to increase in the wells which had been coated with CD137-Fc protein until day 10 
after which the live cell number declined again. By that time all cells in the other 
conditions had died. This and the decline of cell numbers in the CD137-Fc-treated 
wells after day 10 may be due to exhaustion of nutrients.  
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But more live cells were present in the CD137-Fc-coated wells compared to Fc-coated 
wells or untreated wells (PBS) throughout the experiment. Even at day 21 when the 
experiment was terminated CD137-treated conditions contained >10
5
 live cells. 
G-CSF which had been added daily to the cells until day 21 resulted in a less rapid 
decline in cell numbers during the first seven days, but had no effect afterwards (Fig. 
3.17 A). Enhancement of cell numbers by CD137 protein was dose-dependent. 
Saturation was reached at a coating concentration of 20 g/ml CD137-Fc but a 
significant enhancement in live cell numbers could already be observed at 1.2 g/ml 
(Fig. 3.17 B). 
 
 
Figure 3.17. CD137L crosslinking increases cell numbers of murine bone marrow 
cells. Murine bone marrow cells at a density of 10
6
 cells/ml were cultured on plates 
coated with indicated concentrations of Fc or CD137-Fc protein or on uncoated plates 
(PBS). (A) Time course. 2 × 10
6
 cells were plated, and the number of live cells was 
determined by trypan blue staining and counting at indicated time points. PBS: yellow 
ovals; Fc (10 g/ml): blue squares; CD137-Fc (10 g/ml): red diamonds; G-CSF (0.1 
ng/ml daily): green triangles. Depicted are means ± SD of 4 countings. (B) Dose 
response. Experimental conditions as in A, but the number of live cells in B was 
determined at day 12. *, p<0.05. The experiments were performed at least 3 times 




The increase in numbers of living cells by CD137-Fc could be due to survival, 
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proliferation or a combination of both. We determined therefore the rate of 
CD137-induced proliferation by measuring DNA synthesis and cell division using 
3
H-thymidine and CFSE labeling, respectively. Concentrations of Fc and CD137-Fc 
protein ranging from 0.15 to 40 g/ml were used to coat plates before 105 bone 
marrow cells were added for 7 days. CD137-Fc induced a significant proliferation of 
bone marrow cells in both complete medium (Fig. 3.18 A) and serum free medium 
(Fig. 3.18 B) at concentrations as low as 1.2 g/ml and reached its maximum activity 
at 20 g/ml. Proliferation of cells in the Fc-coated wells was not different from that of 
cells in uncoated wells (PBS), (Fig. 3.18). Both, the number of live cells and the 
3




Figure 3.18. CD137L crosslinking induces proliferation of bone marrow cells. 10
5
 
bone marrow cells per well at the density of 10
6
 cells/ml were cultured either in 
complete medium (A) or serum free medium (B) on plates coated with indicated 
concentrations of Fc or CD137-Fc protein or on uncoated plates (PBS) or indicated 
concentrations of soluble CD137-Fc protein. Cells were cultured for 7 days and 
labeled for the last 24 h with 0.5 Ci 3H-thymidine. The rate of proliferation was 
determined as 
3
H-thymidine incorporation with a scintillation counter. Depicted are 
means ± SD of triplicate measurements. *, p<0.05. The experiments were performed 3 
times with similar results. 
 
 
CD137-Fc needs to be immobilized onto the tissue culture plates in order to induce 
proliferation and survival of bone marrow cells. CD137-Fc in its soluble form is not 
active. When CD137-Fc was added to the cells as a soluble protein and its 
immobilization to the tissue culture plates was prevented by precoating the plates with 
serum, no increase in cell numbers was observed (Fig. 3.18). This demonstrates that 
CD137-Fc works by crosslinking CD137L on bone marrow cells or a subset of these 
cells, and excludes that the observed effects are due to potential contaminants in the 
protein preparation. 
 
The subset of bone marrow cells that is considered to be most enriched for 
hematopoietic progenitor cells is negative for lineage-specific markers (Lin
-
) and 










 cells to the same extend (about five fold) than that of total bone 
marrow cells, and soluble CD137-Fc was inactive (Fig. 3.19). But total cell 




 cells than in unfractionated 
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bone marrow cells.  
 











 cells per well were cultured on plates coated with 10 g/ml Fc or 
CD137-Fc protein or on uncoated plates (PBS) or 10 g/ml soluble CD137-Fc protein. 
Cells were cultured for 7 days and labeled for the last 24 h with 0.5 Ci 3H-thymidine. 
The rate of proliferation was determined as 
3
H-thymidine incorporation with a 
scintillation counter. Depicted are means ± SD of triplicate measurements. *, p<0.01. 





 bone marrow cells were labeled with 5 M CFSE. Labeling efficacy was 
verified by flow cytometry and the area of CFSE-negative cells was defined as M1 
(Fig. 3.20). Only 0.9 % of the CFSE-labeled cells were in M1. The CFSE-labeled 
cells were cultured for 14 days on immobilized CD137-Fc or Fc protein, or treated 
daily with 0.1 ng/ml of G-CSF. Flourescence of CSFE-labeled bone marrow cells 
which were cultured in the presence of Fc control protein had diminished by day 14, 
indicating some cell division had occurred but only 0.9% of the cells were in M1 
which was the same percentage as for freshly labeled cells (Fig. 3.20). In contrast, 
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CD137-Fc induced strong proliferation causing 44% of the cells to shift into the M1 
region. G-CSF also induced cell division, and 9.1% of the G-CSF-treated cells were in 
M1 (Fig. 3.20). This data was adopted from my colleague Chen Yifeng to solidify the 
proliferation of bone marrow cells induced by immobilized CD137-Fc protein (Jiang 
et al., 2008a).  
 
 
Figure 3.20. Tracking of cell division. Freshly isolated bone marrow cells were 
either not treated or stained with 5 M CFSE and were immediately (day 0) analyzed 
by flow cytometry. CFSE-stained bone marrow cells were incubated for 14 days on 
immobilized Fc or CD137-Fc protein, or were treated daily for 14 days with 0.1 ng/ml 
of G-CSF and analyzed by flow cytometry for CFSE flourescence. Depicted are 
histograms with percentages of CFSE-negative cells (gated in M1). This experiment 
was performed twice by Chen Y. with similar results. (Jiang et al., 2008a).  
 
 






Concomitant with survival and proliferation CD137-Fc protein induced adherence and 
morphological changes. These morphological changes were of the same type in the 
















responded to the CD137L crosslinking. Many more cells attached to 
CD137-Fc-coated plates than to the Fc-coated or untreated control plates (Fig. 3.21 B). 
During the first three days CD137-Fc induced spreading in the attached cells, and 
some grew a tail-like extension on one end and lamellopodia on the opposite end. By 
day seven, the tails had grown longer, sometimes reaching five times the length of the 
cell body, while the lamellopodia were changing to filopodia. Some cells had several 
branches and displayed star-like shapes. From day 10 - 17, some cells adopted round 
and flat ovoid shapes. Several morphological characteristics described above 
coexisted in the culture. From day 21 onwards, filopodia disappeared and tails 
shortened, the cells adopted spindle-like shapes (Fig. 3.21 B). The appearance of the 
tail-like extensions and the lamellopodia and filopodia coincided with the phase of 
cell growth. They disappeared after day 21 when the cells stopped proliferating and 
the cell numbers started to decline. Soluble CD137-Fc protein (sCD137-Fc) did not 






Figure 3.21. Morphological changes induced by CD137 protein. (A) 2×10
6
 murine 
bone marrow cells at a density of 10
6






 cells at a 
density of 5×10
5
 cells/ml were cultured on plates coated with 10 g/ml of Fc or 
CD137-Fc protein. Photographs were taken at indicated times at a magnification of 





3.2.3 CD137 ligand signaling induces colony formation in hematopoietic progenitor 
cells 
Proliferation induced by CD137L stimulation was also confirmed by colony assays. 
Bone marrow cells were cultured for 14 days in methylcellulose medium containing 
10% bovine calf serum on tissue culture plates with immobilized CD137-Fc or Fc 
protein. There were in average only 3  1 colonies in the Fc-coated dishes compared 
to 40  10 in the CD137-Fc-coated dishes. In addition, colonies on Fc protein 
contained fewer than 100 cells whereas colonies on CD137-Fc protein were 
composed of up to 5,000 cells (Fig. 3.22).  
 
Figure 3.22. Colony formation from bone marrow cells in response to CD137. 
5×10
4
 bone marrow were cultured in methylcellulose medium containing 10% bovine 
calf serum on 35 mm dishes which were coated with 10 µg/ml Fc or CD137-Fc 
protein. (A) A photograph of the edge of a large colony grown on CD137-Fc-coated 
plates were taken at day 14 at a magnification of 200×. (B) Numbers and seizes of the 
colonies were counted on day 14. *, p<0.05; **, p<0.01. The cell numbers in the 
colonies larger than 50 were determined by counting representative sections of the 
colony. Depicted are means ± SD of triplicate measurements. This experiment was 












 cell colonies had grown to confluency by day 14 they had to be 
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assessed already at day 7 (Fig. 3.23).  
 









 cells among the bone marrow cells that 
responded to CD137. Most colonies (80.81.9%) were colorless with dark, dense 
cores or consisted of granular or foamy cells. Based on these morphological 
characteristics they were identified as colony forming unit granulocyte-macrophage 
(CFU-GM), (Yoon et al., 2006, Coutinho et al., 1993). CFU macrophage (CFU-M), 
recognizable by their larger and individually identifiable cells were also induced by 
CD137 and constituted 16.91.4% of the colonies. Very few (2.30.5%) CFU 
granulocyte (CFU-G), (smaller and more tightly packed cells) could be identified (Fig. 
3.23 B-D). No additional growth factors besides CD137 were present in this assay to 



















 cells were cultured in methylcellulose medium containing 10% bovine 
calf serum on 35 mm dishes which were coated with 10 g/ml Fc or CD137-Fc 




 cells on day 8. (A) Quantitative evaluation. 
Depicted are means ± SD of triplicate measurements. (B) – (D) Photographs of 
CFU-GM, CFU-M and CFU-G, respectively, at a magnification of 50×. **, p<0.01. 
The cell numbers in the colonies larger than 50 were determined by counting 
representative sections of the colony. This experiment was performed twice with 
similar results.  
 
 
Since CD137L signaling induced formation of myeloid colonies and of cells with 
myeloid morphology it was possible that CD137 protein exerted its activities through 
induction of GM-CSF. However, a neutralizing anti-GM-CSF antibody had no 
influence on the appearance (Fig. 3.24 A), proliferation rate (Fig. 3.24 B), nor on the 









Figure 3.24. Effect of neutralizing anti-GM-CSF antibody on CD137-induced (A) 
morphological changes, (B) proliferation, and (C) colony formation. Rat IgG2a: 
isotype control. Scale bar in (A) is 50 m. Concentration of antibodies in (C) is 300 
ng/ml. **, p<0.01; n.s.: not significant. The cell numbers in the colonies larger than 
50 were determined by counting representative sections of the colony. Depicted in (B) 
and (C) are means ± SD of triplicate measurements. This experiment was performed 




3.2.4 Expression of CD137 and CD137 ligand on bone marrow cells 
The above described proliferative response of bone marrow cells to CD137L agonists 
implied CD137L expression by bone marrow cells. Further, if the CD137L induced 
proliferation were to occur in the bone marrow then CD137 should also be expressed 
there.  
 
Indeed, CD137L is expressed constitutively by a subset of murine bone marrow cells. 
By immunocytochemical staining with a polyclonal or a monoclonal anti-CD137L 
antibody 8.9±3.8% or 6.8±0.7%, respectively, of freshly isolated and untreated bone 
marrow cells were found to express CD137L (Fig. 3.25 A). Also, the expression of 
CD137 on few (4.2±0.4%) but distinct cells in the murine bone marrow was detected 
immunocytochemically (Fig. 3.25 B). Expression of CD137L and CD137 mRNAs 
could also be verified by RT-PCR (Fig. 3.25 C, D). Bone marrow cells from healthy 
naïve C57/BL6 mice express very little CD137, but the expression elevated 
significantly after nasal infection of Bordetella pertussis bacteria (Fig. 3.25 D). The 
details of regulation of CD137 expression in the bone marrow upon infection will be 





Figure 3.25. Expression of CD137 and CD137L in the bone marrow. Fresh bone 
marrow cell smears were fixed and immunocytochemically stained (brown). (A) 
CD137L expression was detected with a polyclonal and a monoclonal anti-CD137L 
antibody (clone TKS-1). (B) CD137 expression was detected by staining with 
anti-CD137 antibody (clone 17B5). Magnification: 200×. Expression of (C) CD137L 
and (D) CD137 mRNA was determined by RT-PCR using cDNA from bone marrow 
cells as a template. Cloned CD137L cDNA (CD137L plasmid) and cDNA from 3B3 
cells were used as positive controls for CD137L. Cloned CD137 (pcDNA-mCD137) 
and cDNA from mCD137 transfected CHO cells (CHO::mCD137) were used as 
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positive controls for CD137. Reactions with no template (water) or RNA form bone 
marrow cells which was not reverse transcribed served as a negative control. 
Comparable amounts of cDNA were verified by amplification of GAPDH. GeneRuler 
DNA ladder (Fermentas) was used as a marker. PCR products were analyzed on a 1% 
TAE agarose gel and stained by ethidium bromide. These experiments were 
performed 3 times with similar results. 
 
 
3.2.5 Murine CD137 elicits same effects as human CD137 on murine bone marrow 
cells  
We have detected the expression of both murine CD137L and CD137 on bone marrow 
cells; however, the CD137-Fc recombinant protein we used here contains the 
extracellular domain of human CD137. Therefore, we wanted to determine whether 
murine CD137 was functionally equivalent to human CD137 on nurine bone marrow 
cells.  
 
Murine bone marrow cells adopted the same morphological changes in response to 
murine CD137-Fc as was observed with human CD137-Fc protein (Fig. 3.26 A). Both 
proteins induced a similar increase in viable cell numbers (Fig. 3.26 B) and 
proliferation (Fig. 3.26 D, compared with Fig. 3.18 A); and both proteins were 
inactive when they were added as soluble proteins (Fig. 3.26 B). Interestingly, 
anti-human CD137L mAb (clone 5F4 and C65-485) could induce similar 
morphological changes and a similar increase in viable cell number too (Fig. 3.26 A, 
C), while their isotype control (clone MOPC-21) and the antagonistic anti-mouse 
CD137L mAb (clone TKS-1) could not. Moreover, anti-human CD137 mAbs (clone 
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BBK-2, M127, and 4B4-1) had no such activities (Fig. 3.26 C and not shown) further 
proving that the signal was transduced through CD137L.  
 
Further more, the human or murine CD137 expressed on CHO cells could also induce 
the proliferation of cocultured bone marrow cells with similar extend (Fig. 3.26 E). 
Again, it proved functional equivalence between human and murine CD137, and it 







Figure 3.26. Functional equivalence of human and murine CD137. (A) 2×10
6
 
murine bone marrow cells were cultured on uncoated plates (PBS) or on plates coated 
with 10 g/ml Fc or human CD137-Fc or murine CD137-Fc protein; anti-human 
CD137L mAbs (clone 5F4 and C65-485) or their isotype control (clone MOPC-21) or 
antagonistic anti-mouse CD137L mAb (clone TKS-1) or anti-human CD137 mAbs 
(clone BBK-2, M127, and 4B4-1). In addition, human or murine CD137-Fc proteins 
were added as soluble proteins. Photographs were taken at day 14. Scale bar = 25 m, 
magnification = 630×. (B) 3×10
5
 or (C) 2×10
6
 bone marrow cells were undergone 
same treatment in (A) and viable cell numbers were counted after trypan blue staining 
on day 7. (D) 1×10
5
 bone marrow cells at density of 1×10
6
 /ml were cultured for 7 
days on uncoated plates (PBS) or on plates coated with indicated concentration of 
murine CD137-Fc or Fc, or with indicated concentration of soluble murine CD137-Fc. 
(E) CHO cells stably transfected with murine CD137 (CHO-pcDNA-mCD137) or 
human CD137 (CHO-pcDNA-hCD137) on pcDNA3.1 vector or empty vector 
(CHO-pcDNA) were arrested by treating overnight with 100 g/ml Mitomycin C or 
fixed overnight with 1% paraformaldehyde (PFA). 1×10
5




 /ml were cocultured with arrested or fixed CHO cells for 7 days. For 
proliferation assessment, cells were labeled for the last 24 h with 0.5 Ci 
3
H-thymidine, and the rate of proliferation was determined with a scintillation counter 
(Packard). Depicted are means ± SD of triplicate measurements. *, p<0.05; **, 
p<0.01; n.s., not significant. These experiments were performed three times with 
similar results.  
 
 
3.2.6 CD137 ligand signaling induces differentiation to monocytic cells 
Induction of colony formation, especially of the CFU-GM type had already implied 





 cells to the myeloid lineage. We confirmed this by analyzing cell marker 
expression by flow cytometry.  
 
Among freshly isolated bone marrow cells the most prominent subpopulations were 
Gr-1
+
 granulocytes (46.7%), and CD11b
+
 myeloid cells (36.8%). However, most of 
the myeloid cells seemed to be immature since CD14 and F4/80, markers for 
monocytes and macrophages, were present only on 0.1% and 9.2% of the cells, 
respectively. CD11c a marker for DCs was found only on 2.6% of the cells. 1.2% and 
11.6% of the cells were T and B cells, respectively, as determined via CD3 and CD19 
expression (Fig. 3.27 A, B).  
 
At day seven, only 12 % of the CD137-Fc-treated cells and 3.2% of the Fc-treated 
cells had survived. T and B cells and granulocytes had disappeared (0.4%, 0.6% and 
3.2%, respectively), indicating that lymphocyte and granulocyte survival and/or 
differentiation are not supported under these conditions. Among the CD137-Fc-treated 
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cells, the percentages of cells positive for CD11b, CD14, and F4/80 had increased to 
91.4%, 43.9% and 82.2%, respectively. However, since the total cell number had 
dropped to 12% by day 7 this increase in percentage did not translate into an increase 




 cells. The number of myeloid cells 
(CD11b
+
) actually decreased while the F4/80
+
 population remained at the same level. 
The only cell population that was increased in relative proportion (>400-fold) and 
absolute numbers (50-fold) were the CD14
+
 cells. Among the Fc-treated cells, the 
percentages of cells positive for CD11b, CD14, F4/80 had also increased (79.8%, 
27.7% and 67.7%, respectively) compared to fresh bone marrow cells, but to a lesser 
degree compared to CD137-Fc-treated cells. Also, there was only an increase in 
percentage, not in absolute cell numbers for any of these cell populations (Fig. 3.27 A, 
B). 
 
At day 14 the absolute cell numbers had further decreased to 9.3% and 0.4% in the 
CD137-Fc and Fc conditions, respectively. Among the CD137-Fc-treated cells the 
F4/80
+
 population was unchanged compared to day 7, the CD11b
+
 population had 
slightly declined in percentage and absolute numbers, while the CD14
+
 population 







 populations were lower in percentage and absolute 
numbers (Fig. 3.27 A, B).  
 
The absolute number of DCs as detected by CD11c was the same in fresh bone 
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marrow cells and CD137-Fc-treated cells throughout the experiment but their 
percentage in the overall population had increased from 2.6% to 21.8%. The Fc 
control protein was not able to support DCs survival or differentiation (Fig. 3.27 A, 
B).  
 
These findings were confirmed by immunofluorescent staining. CD137-Fc-treated 








 cells than 









Figure 3.27. CD137L signaling induces differentiation of bone marrow cells to 
monocytic cells. (A) Bone marrow cells were analyzed immediately after isolation 
(day 0) for cell surface marker expression by flow cytometry, or 6×10
6
 bone marrow 
cells were cultured in T25 flasks coated with 1 ml of 10 g/ml of Fc or CD137-Fc 
protein and analyzed on days 7 and 14. Black line: Isotype. Gray, filled curve: 
Marker-specific antibody. (B) Depicted are absolute numbers of live cells (left column) 
and percentages (right column) of data in (A) for indicated subpopulations at days 0, 7 
and 14. This experiment was performed three times with identical results. (C) 1×10
6
 
bone marrow cells were cultured in 6-well plate coated with 1 ml of 10 g/ml of Fc or 
CD137-Fc protein. On day 7 supernatants were removed and cells were stained with 
PE-conjugated antibodies. Photos were taken under light phase contrast or 





Since the total bone marrow cells contain mature myeloid cells, such as monocytes 
and macrophages, which are known to respond to CD137L signals with survival and 
proliferation (Langstein et al. 1999a, 1999b, Ju et al. 2003), it is possible that these 
mature cells had influenced the differentiation results we had obtained. Hence, we 










 cells were entirely depleted of mature cells assuring that any mature 
cells present after CD137L stimulation would necessarily have to have differentiated 




 cells cultured for 7 









 cells while expression of these markers on the Fc 
control cells was negligible (Fig 3.28 B). The numbers of live cells expressing these 
















 cells to 




 cells were analyzed immediately after isolation for 
expression of mature cell markers (CD5, CD45R (B220), CD11b, anti-Ly-6G (Gr-1), 




 cells at a density of 
5×10
5
 cells/ml were cultured on plates coated with 10 g/ml of Fc or CD137-Fc 
 104 
protein, and expression of cell surface marker was analyzed by flow cytometry on day 
7. Black line: Isotype. Gray, filled curve: Marker-specific antibody. (C) Depicted are 
absolute numbers of live cells of data in (B). This experiment was performed 3 times 
with similar results. 
 
 









 cells respond more strongly than the total 
bone marrow cells suggest that the small subpopulation in the bone marrow cells 





cells.   
 
 
3.2.7. CD137 ligand signaling induces macrophage differentiation 
The comparable numbers of cells expressing macrophage markers (CD14, F4/80) and 





 cells were compatible with macrophage and DC differentiation. In 
order to clarify the nature of cells that had been derived from hematopoietic 
progenitor cells after differentiation with CD137 protein, we assessed their biological 
functionalities, including the phagocytotic ability, the ability to induce allogeneic T 
cell proliferation, and the cytokine profile.  
 
Bone marrow cells that were exposed for seven days to CD137-Fc exhibited an 
enhanced phagocytosis compared to Fc-treated cells (71.6% vs. 56.7%), (Fig. 3.29 A). 
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Bone marrow cells that had been treated with M-CSF as a positive control for 
inducing macrophage differentiation, displayed a similar phagocytic activity as 
Fc-treated control cells (60.0% vs. 56.7%) but surprisingly were not as active as 
CD137-Fc-treated cells (60.0% vs. 71.6%). The cells that had been treated with 
GM-CSF + IL-4 as a positive control for inducing DC differentiation, displayed a 




 cells that 
were exposed for seven days to CD137-Fc exhibited an enhanced phagocytosis 
compared to Fc-treated cells (57.9% vs. 28.1%), (Fig. 3.29 B). This increased 
phagocytic activity suggested a macrophage differentiation. In addition, almost all the 
phagocytotic CD137-treated bone marrow cells were F4/80
+
 (99.1%), further 
confirming macrophage differentiation. Interestingly, 30.7% of the phagocytic cells 





Figure 3.29. Phagocytosis assay. (A) 2 × 10
6







 cells were cultured for 7 days in complete medium in wells coated with 10 
g/ml Fc or CD137-Fc protein. Or the cells were treated with 100 ng/ml GM-CSF + 
25 ng/ml IL-4, or 50 ng/ml M-CSF as the controls for DC and macrophage 
differentiation, respectively. Phagocytosis was measured by a 1 h pulse with 
fluorescent latex beads (gray shade) at 50 beads per cell, followed by flow cytometry. 
White lines: Control without beads. (C) After being pulsed with fluorescent beads, the 
CD137-Fc-treated bone marrow cells in (A) were harvested and stained with 
PE-conjugated antibodies for CD14, F4/80, CD11c or their isotype control rat IgG2b, 
and were analyzed by flow cytometry. These data are representative of three 
independent experiments.   
 
 




 cells that had 
been differentiated with CD137-Fc were phagocytically active, and since CD137-Fc 
treatment had induced expression of CD11c, it was possible that some of the 




 cells had differentiated to 
DCs. We tested this possibility by using CD137-Fc-treated cells as stimulator cells in 





 cells (Fig. 3.30 B) did not enhance T cell proliferation and neither did the Fc 
control protein nor M-CSF (Fig. 3.30 B). However, cells that had been treated with 
GM-CSF + IL-4, standard conditions for DCs generation, induced significant T cell 
proliferation (Fig. 3.30 A, B).  
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cells were cultured for 7 days in wells coated with 10 g/ml Fc or CD137-Fc protein, 
or in wells containing 50 ng/ml M-CSF or 100 ng/ml GM-CSF + 25 ng/ml IL-4. After 
mitomycin C treatment, the cells were used as stimulators in an allogeneic MLR with 
T cells from C57/BL6 mice at the indicated stimulator:responder (S:R) cell ratios. T 
cell proliferation was measured by 
3
H-thymidine incorporation. Depicted are means ± 




DCs also differ from macrophages in their ability to secrete IL-12 (Smith et al., 1998). 




 cells secreted large amounts of IL-10 
upon LPS stimulation but little IL-12 (Fig. 3.31). GM-CSF + IL-4-treated cells had 
the reverse pattern with high levels of IL-12 and low levels of IL-10. CD137L signals 








 cells were cultured for 7 
days in wells coated with 10 g/ml Fc or CD137-Fc protein, or in wells containing 50 
ng/ml M-CSF or 100 ng/ml GM-CSF + 25 ng/ml IL-4. LPS was added for the last 24 
h at 1 g/ml. Supernatants were harvested on day 7. (A) IL-10 and (B) IL-12p70 were 
measured by ELISA. Depicted are means ± SD of triplicate measurements. *, p<0.05; 













 cells also secreted significantly higher levels of macrophage associated 
cytokines compare to the Fc treated counterparts, such as MCP-1, TNF, M-CSF, KC, 
MCP-5, and TECK, detected by cytokine bead array (BD Biosciences) (Fig. 3.32 A) 
and by cytokine antibody array (RayBiotech) (Fig. 3.32 B; Table 3). The bone marrow 
cells released cytokines with fold change ≥ 2 detected by cytokine antibody array are 




Figure 3.32. Cytokine profile. 2×10
6







were cultured in plate that had been coated with 10 mg/ml Fc or CD137-Fc. 
Supernatants were harvested on day 7. (A) Cytokine levels in supernatants from bone 




 cells were analyzed by cytokine bead array for murine 
TNF and MCP-1 (IL-12p70, IFN-, IL-10, and IL-6 were lower than detection limit). 
(B) Cytokine levels in supernatants from bone marrow cells were analyzed by 
cytokine antibody array. Membranes
 
were exposed to X-ray film, and signal 
intensities were scanned and quantified with ImageQuant TL v2005 (Amersham). The 
cytokines of the corresponding dots on the membrane were listed in Appendix IV. The 
cytokines with fold change ≥ 2 were listed in Table 3.  
 
 
Table 3. Differential cytokine profiles between CD137-Fc- and Fc-treated bone 
marrow cells on day 7 detected by cytokine antibody array.  
Cytokines Signal (Fc) Signal (CD137-Fc) Fold change (CD137-Fc / Fc) 
sTNF-RII 64.47 647.93 10.1 
sTNF-RI 102.82 867.56 8.4 
TNF 117.82 621.51 5.3 
TPO 351.92 1,068.38 3.0 
TECK 116.81 306.46 2.6 
MCP-1 469.40 1,130.27 2.4 
KC 115.11 268.95 2.3 
M-CSF 362.79 748.09 2.1 
MCP-5 261.16 511.29 2.0 
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IL-13 194.90 396.87 2.0 
SCF 216.56 48.91 –4.4 
TPO, thrombopoietin; TECK, thymus-expressed chemokine; MCP-1, monocyte 
chemoattractant protein-1; KC, keratinocyte cytokine; SCF, stem cell factor.  
 
 










are in agreement with the enhancement of phagocytosis and the inability to induce T 
cell proliferation in an allogeneic MLR, and demonstrate that CD137L signaling 




3.2.8. Macrophages induced by CD137L signaling are immunosuppressive 




 profile and inability to simulate T cells in an allogenic 
MLR in previous experiments, it hinted that the cells induced by CD137 may be 
suppressive instead of inflammatory. To test the potential suppressive properties of 
CD137-treated cells, and to identify the cells they influence, we cocultured GM-CSF 
+ IL4 generated bone marrow derived DCs from BALB/c, splenic T cells from 




 cells from BALB/c. The MLR showed 
that mature bone marrow derived DCs could induce robust T cell proliferation (Fig. 





 cells. This suppression was dose -dependent, as less 
CD137-Fc-treated cells resulted less suppression. The T cell proliferation was restored 
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when the ratio of CD137-Fc-treated cells : DCs : T dropped to 0.05 : 1 : 5 (i.e. 10
3
 
CD137-Fc-treated cells per 2 × 10
4
 DCs and 10
5
 T cells) (Fig. 3.33). The 
paraformaldehyde fixed CHO in the DCs and T cells coculture failed to elicit the 
similar suppression on T cell proliferation (Fig. 3.33) indicated that the suppressive 
effect of CD137-Fc-treated cells was specific and not due to the spatial blockage of 
interaction between DCs and T cells. Therefore, the in vitro differentiated 
macrophages induced by CD137L signaling were immunosuppressive.  
 
 




 macrophages partially suppress T cell 




 cells were isolated from BALB/c 
bone marrow cells by MACS using the lineage depletion kit followed by CD117 
selection kit (Miltentyi). Bone marrow derived DCs were generated by culturing fresh 
BALB/c bone marrow cells with 100 ng/ml GM-CSF and 25 ng/ml IL-4 for 7 days 
with 1 g/ml LPS for the last 24 h. Lin-, CD117+ cells were cultured in 12-well plates 
that were precoated with 10 g/ml CD137-Fc proteins for 7 days at a density of 5 × 
10
5
 cells per well. T cells were isolated from C57/BL6 mice spleen by MACS using 
the Pan T cell isolation kit (Miltenyi). Bone marrow derived DCs were used as 
effector cells, and and T cells were used as target cells. CD137-Fc-treated cells were 
co-cultured with DCs and T cells in round-bottom 96-well at various ratios as 
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indicated, with a constant T cell number of 10
5
 per well, in a total volume of 200 L 
complete medium. 2% paraformaldehyde fixed CHO cells were used as negative 
control for CD137-Fc-treated cells in coculture. Single cell types of T cells or 
stimulator cells or CD137-Fc-treated cells were used as negative controls for 
proliferation. Cells were cocultured for 4 days and pulsed with 0.5 μCi 3H-thymidine 
per well for the last 18 h. The rate of T cell proliferation was determined with a 
scintillation counter (Packard). Depicted are means ± SD of triplicate measurements. 
DC, GM-CSF + IL-4 + LPS treated BM-derived DC; CHO, 2% paraformaldehyde 





*, p<0.05; **, p<0.01; n.s., not significant. This experiment was performed three 




3.2.9. CD137 does not induce proliferation of murine embryonic stem cells 
Since CD137 can induce proliferation and differentiation of hematopoietic stem / 
progenitor cells (HSPC), we wanted to investigate whether CD137 has similar effects 
on the more primitive pluripotent embryonic stem (ES) cells.  
 
Mouse ES cells AB2.2 (a gift from Dr. Wang Nai Di, Dept. of Physiology, NUS) were 
cultured in DMEM supplemented with 15% FBS, 2 mM L-Glutamine, 1% 
Penicillin-Streptomycin, 100 M -mercaptoethanol and 1000 U/ml LIF (ESC culture 
medium) for 4 passages. Cells from each passage were seeded into wells that were 
precoated with CD137-Fc or murine CD137-Fc (mCD137) or Fc proteins, or 
CD137-Fc was added as a soluble protein. On day 2, embryoid bodies were formed in 
each condition. There were no significant differences in proliferation among the 
different treatment groups in any passage (Fig. 3.34). Hence, CD137 may have no 




Figure 3.34. CD137 does not induce proliferation of mouse ES cells. AB2.2 ES 
cells were cultured for four passages and then seeded into wells coated with 10 g/ml 
Fc or CD137-Fc or mCD137-Fc protein or in uncoated wells (PBS) or 10 g/ml 
soluble CD137-Fc protein were added. Cells were cultured for 3 days and labeled for 
the last 24 h with 0.5 Ci 3H-thymidine. The rate of proliferation was determined as 
3
H-thymidine incorporation with a scintillation counter. Depicted are means ± SD of 
triplicate measurements. The experiments were performed 4 times for AB2.2 cells 
harvested in each passage 1-4 with similar results. 
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3.3 G-CSF and CD137 cooperatively induce proliferation of bone marrow cells 
but antagonize each other in promoting granulocytic or monocytic 
differentiation 
 
3.3.1 CD137 ligand signaling in bone marrow cells leads to an increase in myeloid 
cell numbers except granulocyte numbers  
As showed in Section 3.2.6, CD137L signaling can induce the colony formation of 
CFU-GM type. This implied that CD137L signaling could induce the differentiation 
of HSPC to myeloid cells, which are mainly comprised of two major groups, the 
monocytic cells and the granulocytic cells. After treating bone marrow cells with 




 cells, markers for 
monocytes and macrophages, were increased from 0.1% and 9.2% to 43.9% and 
82.2%, respectively, and higher than in the Fc treated cultures (27.7% and 67.7%, 
respectively). Gr-1
+
 cells, a pan marker for bone marrow granulocytes dropped from 
46.7% to 3.2%, and even lower in the Fc treated cells (9.9%) (Fig. 3.27 A, B in 




 cells were 
increased to 64.2% and 94.6%, respectively, in CD137-Fc-treated bone marrow cells, 
accompanied by a substantial increase in absolute cell numbers. In contrast, the Gr-1
+
 
cells were decreased to 0.7% (Fig. 3.27 A, B in Section 3.2.6).  
 
 
3.3.2 CD137 does not induce apoptosis of bone marrow granulocytes 
CD137 protein has been shown to induce T cell death by apoptosis and crosslinking 
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of CD137 on granulocytes can also induce apoptosis (Schwarz et al. 1996, Michel et 
al. 1999, Heinisch et al. 2000, Heinisch et al. 2001). Since a possible explanation for 
the decrease in the percentage of granulocytes could be CD137-induced granulocyte 
apoptosis, we tested the effects of CD137 on granulocyte survival and death. Cell 
death in granulocytes among bone marrow cells (Fig. 3.35 A) or in purified 
granulocyte populations (Fig. 3.35 B, C) were not different between Fc and 
CD137-Fc conditions (p = 0.48 in Fig. 3.35 A; p = 0.45 in Fig. 3.35 B), evaluated by 
Annexin v / 7-AAD apoptosis assay. This was confirmed by ethidium bromide and 
acridine orange staining. Cell death (yellow or red fluorescent) could be found in both 
Fc and CD137-Fc-treated Gr-1
+
 bone marrow cells (Fig. 3.36 A). Although the latter 
one had a slightly higher death rate, the differences were statistically not significant 
(Fig. 3.36 B). The cell blebbing and chromatin condensation (Fig. 3.36 C) and the 
externalization of phosphatidylserine (PS) to the outer membrane (Annexin V staining 
in Fig. 3.35) indicated that the cells had undergone apoptosis, which may due to the 
short half-life of neutrophils, the main component of granulocytes.  
 
Since CD137 does not influence granulocyte survival, the reduction of granulocytes in 
the bone marrow cell population must be due to a suppression of granulocytic 







Figure 3.35. CD137 does not induce apoptosis of bone marrow granulocytes. 
2×10
6
 (A) BALB/c bone marrow cells or (B) MACS purified Gr-1
+
 cells at a density 
of 10
6
 cells/ml were cultured on plates coated with 10 g/ml Fc or CD137-Fc protein 
for 4 h. Cells were stained with Gr-1-PE, Annexin V-FITC and 7-AAD and analyzed 
by flow cytometry. Depicted are Annexin V and 7-AAD analysis on Gr-1
+
 cells. (C) 
Gr-1
+
 cells were purified from BALB/c bone marrow cells by MACS using biotin 
conjugated anti-Gr-1 antibody and anti-biotin microbeads. Depicted histogram shows 
the purity of enriched cells after MACS separation. Black line: Isotype (rat IgG2b). 
Gray, filled curve: anti-Gr-1 antibody. These experiments were performed three times 










 cells at 
a density of 10
6
 cells/ml were cultured on plates coated with 10 g/ml Fc or 
CD137-Fc protein for 40 h. Cells were harvested and stained with 10 g/ml Ethidium 
Bromide and 3 g/ml Acridine Orange, and examined and counted under fluorescent 
microscope. (A) Representative photos for Fc and CD137-Fc-treated Gr-1
+
 cells after 
staining. Green cells, live; Red cells, late apoptosis or secondary necrosis; yellow, 
early apoptosis. Magnification: 50×; scale bar: 100 m. (B) Depicted are the cell 
counts of the different fluorescent colors as mean ± SD of 10 fields. n.s.: not 
significant. (C) Photos were taken at magnification of 400×, scale bar: 5 m.   
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3.3.3 G-CSF and CD137 cooperatively induce survival and proliferation and 
morphological changes of bone marrow cells 
Since CD137 supports monocyte but not granulocyte survival and/or differentiation 
we investigated the interaction of CD137 with G-CSF, the classical granulocyte 
growth and differentiation factor, in regulating bone marrow cell survival, 
proliferation and differentiation.  
 
Bone marrow cells were treated with immobilized CD137-Fc or G-CSF, which was 
added daily at a concentration of 1 ng/ml, or with both. Cells treated with Fc or Fc + 
G-CSF were used as controls. Both CD137-Fc and G-CSF increased cell proliferation 
(Fig. 3.37 A) and numbers (Fig. 3.37 B), with CD137 being more potent. Comparing 
with CD137-Fc or G-CSF alone, the combination of CD137-Fc and G-CSF further 
increased cell proliferation and cell numbers (Fig 3.37). 
1 
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Figure 3.37. G-CSF and CD137 synergizes to induce proliferation and survival of 
bone marrow cells. 2×10
6
 murine bone marrow cells at a density of 10
6
 cells/ml were 
cultured for 7 days with respective treatment. 10 g/ml of Fc or CD137-Fc protein 
were pre-coated on the flask, 1 ng/ml of G-CSF was added daily in respective wells. 
(A) Cells were labeled for the last 24 h with 0.5 Ci 3H-thymidine, and the rate of 
proliferation was determined with a scintillation counter (Packard, Meriden, CT). 
Depicted are means ± SD of triplicate measurements. (B) 10
5
 bone marrow cells were 
treated as in (A). The cells were harvested on day 7, and cell counts were determined 
by trypan blue staining of 4 representative microscopic fields. *, p<0.05; **, p<0.01. 
Depicted are means and standard errors of 7 independent experiments.  
 
G-CSF and CD137 had more than additive effects on cell morphology. Treatment of 
bone marrow cells with CD137 protein resulted in a population of adherent and 
spread-out cells with few cells remaining in suspension. G-CSF treatment resulted in 
the opposite phenotype. However, the combination of G-CSF + CD137-Fc resulted in 
an enhanced cell adherence and spreading of the cells, yet more cells remained in 
suspension compared to CD137 alone (Fig. 3.38).  
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Figure 3.38. Cell morphology. 2×10
6
 BALB/c bone marrow cells were cultured in 
wells that had been precoated with 10 g/ml CD137-Fc or Fc, in the presence or 
absence of daily added 1 ng/ml G-CSF. Photographs were taken on day 7 at a 
magnification of 200×. Scale bar: 50 m. 
 
 
Adherence is a characteristic of monocytic cells while granulocytes are non-adherent 
cells. The observed morphologies are therefore in line with the expected effects of 
CD137 and G-CSF. The presence of adherent as well as suspension cells in conditions 
that were treated with G-CSF + CD137 indicated that none of the factors exerted a 
dominant influence over the differentiation of bone marrow cells.  
 
 
3.3.4 CD137 and G-CSF antagonize each other in inducing differentiation of bone 
marrow cells 
Granulocytic versus monocytic differentiation of bone marrow cells was investigated 
by differential cell counting. Data in Figure 3.28 had implied that CD137 inhibits 
granulocyte differentiation. This could indeed be verified since treatment of bone 
marrow cells with CD137-Fc for 7 days resulted in a decrease in granulocytes (9.6 vs 
16.1 %), and an concomitant increase of macrophages (87.0 vs 41.9 %) as determined 
by differential cell counting (Fig. 3.39 A). As expected, the treatment of bone marrow 
cells with G-CSF increased granulocytes numbers. However, the combination of 
CD137 and G-CSF resulted in a smaller increase of macrophages than with CD137 
alone (66.2 vs 87.0 %), and in a lesser increase in granulocytes than with G-CSF 
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alone (28.6 vs 62.4 %), implying that CD137 and G-CSF inhibit each other in 
inducing granulocytic vs monocytic differentiation (Fig. 3.39 A).  
 
The antagonistic activities of G-CSF and CD137 in myelopoiesis of bone marrow 
cells could be confirmed by flow cytometry via Gr-1 and CD14 and F/4/80 expression, 
markers for granulocytes and monocytes/macrophages, respectively (Fig. 3.39 B). 
Bone marrow cells treated for 7 days with CD137-Fc contained a significantly lower 
percentage of Gr-1
+
 cells than the Fc control condition (7.2 ± 1.2% vs. 25.4 ± 3.9%), 
(Fig. 3.39 C). In bone marrow cells treated with G-CSF 41.5 ± 6.2% of the cells were 
Gr-1
+
, demonstrating the expected induction of granulocyte differentiation by G-CSF. 
The presence of CD137 however prevented this G-CSF-induced granulocyte 
differentiation and the percentage of Gr-1
+
 cells in the cultures treated with G-CSF + 
CD137 was 21.5 ± 3.6%. The Fc control protein had no influence on the percentage of 
Gr-1
+
 cells (40.7 ± 6.6%) (Fig. 3.39 C). Reciprocally, G-CSF also interfered with 
CD137-induced monocytic cell differentiation. Of CD137-Fc-treated bone marrow 
cells 65.4 ± 5.4% and 77.9 ± 2.4% expressed CD14 and F4/80, respectively, and these 
number dropped to 36.1 ± 5.3% and 50.6 ± 4.2%, respectively, when G-CSF was 
added (Fig. 3.39 D). 
 
The antagonism of G-CSF to CD137-induced monocytic differentiation also 
manifested itself in the absolute number of cells. G-CSF reduced the number of 
CD14
+
 cells by 38.4% from (137 ± 15.2) ×10
3
 to (84.5 ± 14.3) ×10
3




 cells by 24.9%, from (166.4 ± 13.6) ×10
3
 to (125 ± 11.9) ×10
3
 (Fig. 3.39 E). 
When bone marrow cells were cultured with G-CSF the number of Gr-1
+
 cells was 
not different from cultures stimulated with G-CSF and CD137. This was unexpected 
as CD137 had reduced the percentage of Gr-1
+








Figure 3.39. G-CSF and CD137 compete for inducing granulocytic and 
monocytic differentiation, respectively. 2×10
6
 BALB/c bone marrow cells at a 
density of 10
6
 cells/ml were cultured for 7 days on plates that had been coated with 10 
g/ml of Fc or CD137-Fc protein. Where indicated, G-CSF was added daily at 10 
ng/ml or other stated concentrations. Differential cell counts (A) with a modified 
Wright stain were performed on a minimum of 500 cells. These data are 







 cells (D), as well as absolute cell numbers (E), determined by 
flow cytometry on day 7, are depicted as means ± SE of 7 independent experiments, 
with (B) shown as a representative. *, p<0.05; **, p<0.01.   
 
 
G-CSF induced granulocytic differentiation and CD137-induced monocytic 
differentiation are dose-dependent. Bone marrow cells were grown for 7 days on 
plates coated with a fixed concentration (10 g/ml) of CD137-Fc or Fc protein, and 
G-CSF was added daily at 0, 1, 10 or 100 ng/ml. In the absence of G-CSF two thirds 
of the cells expressed CD14 and/or F4/80 and 10% expressed Gr-1. With increasing 
concentrations of G-CSF the percentage of granulocytes increased and the percentage 
macrophages decreased (Fig. 3.40 A). However, G-CSF at 100 ng/ml did not induce 
more granulocytic differentiation than at 10 ng/ml, implying a saturation point 
between these two concentrations. In a parallel experiment G-CSF was kept constant 
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at 10 ng/ml, and the coating concentrations of CD137-Fc and Fc were varied from 0, 
5, 10 and 20 g/ml. In the absence of CD137 58.2% expressed Gr-1 and 5.8% 
expressed CD14 (Fig. 3.40 B). Increasing concentrations of CD137 reduced 
granulocyte and increased correspondingly macrophage numbers. The pattern was 
similar for F4/80, though the difference between 0 and 20 g/ml CD137 was less 




Figure 3.40. Dose response of the combination of G-CSF and CD137 protein. 
Cells were treated with a fixed concentration of CD137-Fc at 10 g/ml and varying 
the concentration of G-CSF at 0, 1, 10, or 100 ng/ml (A); or a fixed concentration of 
G-CSF at 10 ng/ml and varying the concentration of CD137-Fc at 0, 5, 10, or 20 
g/ml (B), and flow cytometry was performed for Gr-1, CD14 and F4/80 on day 7. 




The CD137-induced switch towards monocytic cell differentiation at the expense of 
granulocytes could also be verified by esterase staining. Naphthol AS-D chloroacetate, 
a substrate for specific esterase, stains cells of the granulocytic lineage purple, and 
these cells were predominant in fresh bone marrow cells (Fig. 3.41). Also clearly 
visible in fresh bone marrow cells are the ring-shaped nuclei, typical for murine 
neutrophils. After a 7-day exposure to immobilized CD137-Fc, most cells stained 
black with -naphthyl acetate, a substrate for non-specific esterase indicating 
differentiation towards the monocytic lineage. The concomitant increase in cell size 
and the kidney-shaped nuclei which are typical of monocytes further support 
CD137-mediated monocytic lineage differentiation. These results are in line with the 
data obtained by differential cell counting and flow cytometry (Fig. 3.39 A-D; Fig. 




Figure 3.41. Esterase staining. Fresh murine bone marrow cells, or cells which were 
cultured on plates coated with 10 g/ml CD137-Fc protein for 7 days, smeared on 
glass slides, fixed with citrate-acetone-formaldehyde solution, and stained for 
non-specific esterase (black, macrophages) and for specific esterase (purple, 
granulocytes). The slides were counterstained with hematoxylin and mounted with 
cover slips. Magnification: 630×. Scale bar: 25 m. This figure is a representative of 
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three independent experiments.   
 
 
Since bone marrow cells are a heterogeneous population of cells, we will investigate 
the function of CD137 and G-CSF in early myelopoiesis by using purified CMPs and 
GMPs in the future, and use Ly6G-specific Ab (clone 1A8) instead of Gr-1, which 
recognize both Ly6G and Ly6C.  
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3.4 CD137 supports Flt3L induced bone marrow derived monocytic DC 
differentiation 
In previous sections, we have shown that, at least in murine system, CD137 alone 
could not induce the differentiation of bone marrow cell to DCs (Section 3.2.7); and 
CD137 could not induce the proliferation of immature or mature DCs (Section 3.1.8 
and unpublished data from our lab). However, CD137 is reported to be able to mature 
and activate DCs (Wilcox et al., 2002; Kim et al., 2002; Laderach et al., 2003; Lippert 
et al., 2008). So we investigated whether CD137 had any effect on DC differentiation 
in the presence of Flt3L, which is a potent bone marrow derived DCs inducer (Naik et 
al., 2005). 
 
3.4.1 CD137 and Flt3L cooperatively induce morphological changes, survival and 
proliferation of murine bone marrow cells 
Bone marrow cells from BALB/c mice were treated with immobilized CD137-Fc or 
single dose of 100 ng/ml Flt3L, or with both. Cells treated with Fc or Fc + Flt3L were 
used as controls. Morphologically, the combination of Flt3L + CD137-Fc resulted in 
an increase of cell numbers, of both the adherent and suspension cells compared to 





Figure 3.42. CD137 and Flt3L cooperatively induce morphological changes of 
bone marrow cells. 2×10
6
 BALB/c bone marrow cells were cultured in wells that had 
been precoated with 10 g/ml CD137-Fc or Fc, in the presence or absence of 100 




More importantly, the combination treatment of Flt3L and CD137 on bone marrow 
cells showed additive effects on cell survival and proliferation. Flt3L could induce 
bone marrow cell proliferation as reported before (Jacobsen et al., 1995), and it 
showed a similar ability to maintain bone marrow cell survival and proliferation as 
CD137 (Fig. 3.43 A, B). When combined with immobilized CD137-Fc, the viable cell 
number on day 7 was slightly higher than the sum of that of Flt3L alone and 
CD137-Fc alone (3.5 × 10
5
 vs. (1.9+1.2) × 10
5
) (Fig. 3.43 A). The same situation 
could be found regarding to the cell proliferation (CPM: 1683.2 vs. (824.6+769.0)) 
(Fig. 3.43 B). There was no difference in cell numbers and proliferation between Fc + 
Flt3L and Flt3L alone indicating that the Fc domain of the CD137-Fc recombinant 




Fig. 3.43. Flt3L and CD137 additively induce survival and proliferation of bone 
marrow cells. (A) 2×10
6
 BALB/c bone marrow cells at a density of 10
6
 cells/ml were 
cultured in wells that had been precoated with 10 g/ml Fc or CD137-Fc, in the 
presence or absence of 100 ng/ml Flt3L. Cells were harvested on day 7, and cell 
counts were determined by trypan blue staining. Depicted are means ± SD of 4 
counts. (B) Bone marrow cells were cultured at 1×10
5 
per well for 7 days in 96-well 
plate that had been precoated with 10 g/ml of Fc or CD137-Fc in the presence or 
absence of 100 ng/ml Flt3L. Cells were labeled with 0.5 Ci 3H-thymidine for the 
last 24 h, and the rate of proliferation was determined with a scintillation counter. 
Depicted are means ± SD of triplicate measurements. *, p<0.05, **, p<0.01. This 




3.4.2 CD137 supports Flt3L induced MoDC differentiation from bone marrow cells 
The expression of the murine DC marker CD11c was used as a tool to assess the bone 
marrow derived DCs differentiation. Bone marrow cells treated with CD137-Fc or 
Flt3L alone resulted in 21.8% and 21.7% of CD11c
+
 cells, respectively. Interestingly, 
the combination of CD137-Fc and Flt3L could additively increase the CD11c
+
 
population to 37.7% (Fig. 3.44 A). MHC-II
+
 cells were also increased from 6.5% to 
49.5% on day 7 by addition of Flt3L (Fig.3.44 B). Therefore, CD137 supports Flt3L 
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induced bone marrow derived monocytic DCs differentiation. On the other hand, 
addition of Flt3L to CD137-Fc-treated bone marrow cells decreased CD14
+
 cells from 
43.9% to 34.6% and F4/80
+
 cells from 82.2% to 46.0% (Fig. 3.44 B). This indicated 
that Flt3L, suppressed CD137-induced macrophage differentiation from bone marrow 
cells. Flt3L may direct the monocytic cells to further differentiate to DCs rather than 
to macrophages. However, here we only examined the expression of murine DC 
surface marker CD11c together with MHC-II, which are not exclusively expressed on 
DCs. The functional analyses of CD137-Fc + Flt3L differentiated cells, such as 
allogeneic MLR, endocytosis assay and migration assay, need to be performed in the 
future. 
 
Fig. 3.44. CD137 supports Flt3L induced bone marrow derived DCs 
differentiation. 2×10
6
 bone marrow cells at a density of 10
6
 cells/ml were cultured in 
wells that had been precoated with 10 g/ml Fc or CD137-Fc, in the presence or 
absence of 100 ng/ml Flt3L. Cells were harvested on day 7 and subjected to flow 
cytometric analysis of CD11c (A), F4/80, CD14 and MHC class II expression (B). 
Depicted are the percentages of positive cells, with means ± SD of triplicates in (A); 
**, p<0.01. This experiment was performed three times with comparable results. 
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In summary, CD137 can work additively with Flt3L to promote proliferation and 
differentiation of bone marrow cells to phenotypically DC-like cells.  
 
 
3.4.3 CD137 does not further enhance Flt3L induced proliferation and 
differentiation of HSPCs 












 cells, in terms of cell proliferation (Fig. 3.45 A) and DC 





 is dominant and masks the effect of CD137, since in the bone marrow Flt3, 
the receptor of Flt3L, is only expressed by the progenitor cells, and Flt3L is known as 
a very potent growth factor and DC differentiation factor of HSC (Jacobsen et al., 
1995; Adolfsson et al., 2001).   
 
 












 cells were cultured for 7 days in wells that had been precoated with 10 
g/ml of Fc or CD137-Fc, in the presence or absence of 100 ng/ml Flt3L. (A) Cells 
were cultured in 96-well plate at 5×10
4
 cells/well, and labeled with 0.5 Ci 
3
H-thymidine for the last 24 h, and the rate of proliferation was determined with a 
scintillation counter. Depicted are means ± SD of triplicate measurements. **, 
p<0.01; n.s., not significant. (B) Cells were cultured in 12-well plates at 5×10
5
 
cells/well and harvested on day 7. The expression of CD11c was determined by flow 
cytometry.  
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3.5 CD137 expression is positively regulated during infection 
 
3.5.1 Bone marrow stromal cells may not be the source of CD137 in the bone 
marrow   
AA101 cells, a human bone marrow derived stromal cell line, were found to express 
CD137 (Fig. 3.46 A, B). The expression level was not homogenous among the cells, 
rather the expression correlated with the cell density (confluency) (Fig. 3.46 E; Table 
4). Interestingly, AA101 cells also express CD137L (Fig. 3.46 C, D) and its 
expression level was relatively stable (Fig. 3.46 E; Table 4). We tested two murine 
bone marrow stromal cell lines, ST-2 and MS-5. However, both of them expressed 




Figure 3.46. AA101 cells express CD137 and CD137L. AA101 cells, a human bone 
marrow derived stromal cell line, were stained with PE-conjugated anti-human 
CD137 mAb (Clone 4B4-1) (A) or PE conjugated anti-human CD137L mAb (Clone 
5F4) (C) or their isotype control PE-conjugated anti-mouse IgG1 (Clone MOPC-21), 
and analyzed by flow cytometry. Expression of CD137 mRNA (B) or CD137L mRNA 
(D) was determined by RT-PCR using cDNAs from two batches of AA101 cells. 
Cloned hCD137 plasmid or hCD137L plasmid were used as positive controls, 
respectively. Reactions with no template (water) or RNA from AA101 cells that was 
not reverse-transcribed served as negative controls. GeneRuler DNA ladder 
(Fermentas) was used as a size standard. PCR products were analyzed on a 1% TAE 
agarose gel. (E) AA101 cells were seeded in 6-well plate with the initial density at 1, 
2.5, 5, 7.5, or 10 ×10
5
 cells/ml. Cells were harvested after 2 days of culture and 
analyzed by flow cytometry with PE-conjugated anti-CD137 (Clone 4B4-1) and 
anti-CD137L (Clone 5F4). In (A), (C) and (E), Black line: Isotype, mouse IgG1 
(clone MOPC-21); Gray, filled curve: anti-CD137 (Clone 4B4-1) or anti-CD137L 
(Clone 5F4). These experiments were performed three times with similar results. 
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Table 4. CD137 expression on AA101 cells is proportional to the cell density. 







10 16.9 21.9 
7.5 15.8 25.2 
5 8.6 30.5 
2.5 5.2 34.5 




Figure 3.47. ST-2 and MS-5 cells express neither CD137 nor CD137L. ST-2 (upper 
panel) and MS-5 cells (lower panel), two murine bone marrow stromal cell lines, were 
stained with PE-conjugated anti-mouse CD137 mAbs (Clone 17B5 and 1AH2) or PE 
conjugated anti-mouse CD137L mAb (Clone TKS-1) or their respective isotype 
controls, and analyzed by flow cytometry. Black line: Isotype; Gray, filled curve: 
anti-CD137 (Clone 17B5) or anti-CD137L (Clone TKS-1). This experiment was 
performed three times with same results. 
 
 
3.5.2 Bacterial Bordetella pertussis infection increases the number of CD137
+
 cells 
in the bone marrow 
Despite the fact that the type of cells that expresses CD137 in the bone marrow is 
unknown, interestingly, we found bacterial infection could induce CD137 expression 
in total bone marrow cells (Fig. 3.25 D).  
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In bones of healthy BALB/c mice we could detect CD137 expression by 
immunocytochemistry but the number of CD137
+
 cells was increased more than 50% 
(from 4.2±0.4% to 6.4±1.5%) upon infection with wide type B. pertussis bacteria (Fig. 
3.48 A). More interestingly, when mice were infected with capsule gene knockout B. 
pertussis (CAPS-KO) strain, which was much less virulent than WT, the percentage of 
CD137
+
 cells were further increased to 12.1±3.5%. The regulation of CD137 
expression was confirmed by RT-PCR at mRNA level (Fig. 3.48 B). The 
immunohistochemistry staining of EDTA-decalcified formalin fixed paraffin 
embedded bone slides, which had less system background, also confirmed that B. 
pertussis infection increased CD137
+
 cells in the bone marrow (Fig. 3.48 C). This 
implied that the number of CD137
+
 cells in the bone marrow could be regulated the 
infection, and type and virulence of the infection may play a role in triggering the 






Figure 3.48. B. pertussis infection leads to an increase of CD137
+
 cells in the bone 
marrow. BALB/c mice were infected with B. pertussis wild type or capsule gene 
knockout (CAPS-KO) strain. Naïve BALB/c mice from the same batch were used as 
control. Mice were euthanized at day 3 post infection, and femur bones were 
harvested. (A) Immunocytochemical detection of CD137 expression (brown stain). 
Bone marrow cells were smeared onto glass slides and fixed with absolute methanol. 
Cell smears were stained with anti-CD137 mAb (clone 17B5) or its isotype control 
Syrian hamster IgG (BioLegend). Magnification: 200×. The numbers indicated are the 
percentages of stained cells in the total population as means ± SD of triplicates of 
countings. (B) Expression of CD137 mRNA was determined by RT-PCR using 
cDNAs from bone marrow cells. Cloned murine CD137 plasmid (pcDNA3.1-CD137) 
and cDNA from murine CD137 transfected CHO cells (CHO::mCD137) were used as 
positive controls. Reactions with no template (water) or RNA from WT B. pertussis 
infected bone marrow cells that was not reverse-transcribed served as negative 
controls. Comparable amounts of cDNA were verified by amplification of GAPDH. 
GeneRuler DNA ladder (Fermentas) was used as a size standard. PCR products were 
analyzed on a 1% TAE agarose gel. (C) Immunohistochemical detection of CD137 
expression (brown stain). Harvested femur bones were decalcified with EDTA, fixed 
with formalin, and embedded in paraffin. The sections were stained for CD137 using 
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the polyclonal goat anti-CD137 antibody (R&D Systems), and goat IgG was used as 
an isotype control. Magnification: 100×. These experiments were performed three 
times with comparable results.  
 
 
3.5.3 Virus Influenza A (H1N1) infection increases number of CD137
+
 cells in the 
bone marrow 
Next we looked at viral infection, and influenza A (H1N1) infection was used as a 
model. Similar as B. pertussis infection, the number of CD137
+
 cells in the bone 




Figure 3.49. Influenza A infection leads to an increase of CD137
+
 cells in the bone 
marrow. C57/BL6 mice were infected with Influenza A (H1N1). Naïve C57/BL6 
mice from same batch were used as control. Mice were euthanized at day 4 post 
infection, and femur bones were harvested. (A) Immunocytochemical detection of 
CD137 expression (brown stain). Bone marrow cells were smeared onto glass slides 
and fixed with absolute methanol. Cell smears were stained with anti-CD137 mAb 
(clone 17B5) or its isotype control Syrian hamster IgG (BioLegend). Magnification: 
200×. (B) Immunohistochemical detection of CD137 expression (brown stain). Femur 
bones were decalcified with EDTA, fixed with formalin, and embedded in paraffin. 
The sections were stained for CD137 using the polyclonal goat anti-CD137 antibody 
(R&D Systems), and goat IgG was used as an isotype control. Magnification: 100×. 
These experiments were performed two times with comparable results. 
 
 
3.5.4 I.p. injected LPS increases the number of CD137
+
 cells in the bone marrow  
We also investigate the situation of systemic inflammation by i.p. injection of LPS (E. 
coli 0111:B4). C57/BL6 mice that had been injected with 1 mg/kg or 5 mg/kg LPS 
had increased CD137
+
 cells in the bone marrow at 24 h post-injection compared to 





Figure. 3.50. I.p. injection of LPS leads to an increase of CD137
+
 cells in the bone 
marrow. C57/BL6 mice were i.p. injected with LPS from E. coli 0111:B4 (Sigma) at 
1 mg/kg or 5 mg/kg in 100 l PBS. Mice injected with 100 l PBS were used as 
controls. Mice were euthanized after 24 h, and femur bones were harvested. (A) 
Immunocytochemical detection of CD137 expression (brown stain). Bone marrow 
cells were smeared onto glass slides and fixed with absolute methanol. Cell smears 
were stained with anti-CD137 mAb (clone 17B5) or its isotype control Syrian hamster 
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IgG (BioLegend). Magnification: 200×. Scale bar: 100 m. (B) Immunohistochemical 
detection of CD137 expression (brown stain). Femur bones were decalcified with 
EDTA, fixed with formalin, and embedded in paraffin. The sections were stained for 
CD137 using the polyclonal goat anti-CD137 antibody (R&D Systems), and goat IgG 
was used as an isotype control. Magnification: 100×. These experiments were 
performed two times with comparable results. 
 
 
3.5.5 CD137 expressed on activated T cells can induce proliferation of bone marrow 
cells  
Since activated T cells are well known to express CD137, we would like to test 
whether there were T cells in the bone marrow, and whether they express CD137. 
Flow cytometric analysis of CD3 on total bone marrow cells in the healthy naïve 
BALB/c mice showed that, although the frequency was very low, about 1% nucleated 
bone marrow cells were T cells (Fig 3.27 B in Section 3.2.6).  
 
Next we checked the ability of activated CD137 expressing T cell in inducing 
proliferation of bone marrow cells. When bone marrow cells from wild type (WT) 
C57/BL6 mice were cocultured for 5 days with activated T cells, but not resting T 
cells, from both WT and CD137-deficient C57/BL6 mice (Fig. 3.51 A), the 
proliferation of bone marrow cells was triggered. The activated T cells from WT mice 
had significantly higher potential to induce bone marrow cell proliferation than their 
counterparts from CD137-deficient mice (Fig. 3.51 B). This indicates that activated T 
cells have ability to induce proliferation of bone marrow cells, and that CD137 plays a 
role in this process.   
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Combined with the fact that bacterial and viral infections and systemic inflammation 
increased the number of CD137
+
 cells in the bone marrow, we hypothesize that the 
CD137 expressing cells in the bone marrow are likely to be activated T cells that 
migrated there from inflammatory tissues or from draining lymph nodes, and that 
these activated T cells are able to induce hematopoiesis in the bone marrow through 




Figure 3.51. Activated T cells could induce bone marrow cell proliferation. (A) 
Splenocytes from C57/BL6 WT or CD137-deficient (KO) mice were cultured with 2.5 
g/ml Concavalin A for 48 h, and harvested and analyzed for CD137 expression by 
flow cytometry. (B) T cells were purified from splenocytes of WT or CD137-deficient 
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C57/BL6 mice by MACS using Pan T cell isolation kit (Miltenyi) and seeded into 
plate that had been precoated with 5 g/ml agonistic rat anti-mouse CD3 mAb (clone 
17A2) and 5 g/ml of anti-mouse CD28 mAb (Clone 37.51) or their isotype controls 
rat IgG2b and Syrian hamster IgG, respectively, both at 5 g/ml. After 48 h, the cells 
were harvested and cocultured with fresh bone marrow cells from wide type C57/BL6 
mice at the ratio of T : BM = 1:1 in round-bottom 96-well plate for another 5 days. 
The wells containing only bone marrow cells or activated T cells from WT or 
CD137-deficient mice were used as single cell type controls. The cells were labeled 
for the last 24 h with 0.5 Ci 3H-thymidine. The rate of proliferation was determined 
as 
3
H-thymidine incorporation with a scintillation counter. Depicted are means ± SD 
of triplicate measurements. *, p<0.05; BM, bone marrow cells; act, anti-CD3 and 
anti-CD28 activated; iso, isotype control antibody treated; WT, wild type C57/BL6 
mice; KO, CD137-dificient C57/BL6 mice. This experiment was performed three 
times with comparable results. 
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CHAPTER 4  DISCUSSION 
 
The CD137 receptor / ligand system is involved in a number of different immune 
activities (Sica et al., 2000; Croft, 2003; Watts, 2005), and reverse signaling by 
CD137L has been documented in monocytes, DCs, B cells and T cells where it has 
been shown to regulate activation, survival, proliferation and apoptosis (Schwarz, 
2005). Our current study adds hematopoietic progenitor cells to this list, and 
demonstrates that CD137L signals also regulate hematopoiesis. CD137 and its ligand 
are found to be expressed by bone marrow cells and progenitor cells, respectively; and 




4.1 What have we learned about the role of CD137L signaling in hematopoiesis? 
CD137 protein promoted survival (Fig. 3.3 A; 3.17), colony formation (Fig. 3.5; 3.22; 
3.23) and proliferation (Fig. 3.3 B, C; 3.4; 3.19) of hematopoietic progenitor cells, in 
both man and mouse. In the murine system, CD137 was more potent than G-CSF (Fig. 
3.17A). The activity of CD137 lasted for more than 3 weeks after a single dose, while 
the short half-life of G-CSF required it to be added daily. CD137-induced 




 cells resulted in an increase in 
cell numbers and in colony formation. The colonies formed in response to CD137L 
signaling were CFU-GM and CFU-M, i.e. myeloid precursor cells, indicating that 
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CD137-induced proliferation was accompanied by a differentiation of HSPCs towards 
the myelo-monocytic lineage. Myeloid differentiation was supported by the increase 
in CD11b expression.  
 
Members of the TNF and TNF receptor superfamilies are primarily known for their 
functions in the regulation of immune responses rather than their roles in 
hematopoiesis. However, several members of these two superfamilies have been 
shown to be involved in the growth and differentiation of hematopoietic progenitor 
cells. For instance, CD95 and TNF related apoptosis inducing ligand (TRAIL) are of 
critical importance for lymphopoiesis and myelopoiesis (Greil et al., 2003). TNF can 
induce or inhibit hematopoiesis, depending on its dose and interaction with other 
growth factors (Jacobsen et al., 1994). CD27 inhibits myelopoiesis and may so 
counteract the CD137L activity (Nolte et al., 2005). Our study adds CD137 and its 
ligand to this list. Support for this notion comes from the fact that mice injected with 
anti-CD137 antibodies have a 10-fold increased number of bone marrow cells with a 
hematopoietic stem cell phenotype (Niu et al., 2007). Further, mice deficient in 
CD137 have enhanced numbers of multipotential, erythroid, granulocyte macrophage 
progenitor cells in bone marrow, spleen and blood (Kwon et al. 2002). If one accounts 
the increase in myeloid progenitor cells to a missing differentiation signal which 
normally would be delivered by CD137 then these observations fit nicely to our data 
showing that CD137 induces differentiation to mature myeloid cells, i.e. monocytes 
and macrophages. This interpretation could also explain why transgenic mice 
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overexpressing CD137L on APC have a 3-fold elevated number of macrophages in 
the spleen (Zhu et al. 2001). However, Lee and colleagues reported recently that at 
steady state CD137 and CD137L limit myelopoiesis and the development of DCs by 
in vivo study in CD137-deficient mice. It seems contradictory to our studies and 
previous reports, but it may just reveal the two sides of CD137 in regulating the 
hematopoiesis based on the different immune activation states. This will be discussed 
in more detail in section 4.5.  
 
 
4.2 Into what lineage does CD137 drive differentiation of HSPCs? 
Like most other growth factors that induce proliferation, CD137L agonists also 
influence differentiation of hematopoietic progenitor cells, specifically to the myeloid 
lineage, and within the myeloid lineage to monocytes, as evidenced by the increased 
CD11b and CD14 expression (Fig. 3.6), respectively. We could observe no effect of 
CD137-Fc on erythroid, megakaryocytic or lymphoid differentiation, not even when 
cytokines were added which induce erythroid or megakaryocytic differentiation (Jiang 
et al., 2008b). Independent evidence against lymphoid differentiation comes from 
previous data where CD137 protein has been shown to induce cell death in T cells 
(Schwarz et al., 1996; Michel et al., 1999). Though CD137L signaling enhances 
proliferation of preactivated B cells, it has no effect on proliferation of resting B cells 
(Pauly et al., 2002). These data imply that CD137 is not a general hematopoietic 
growth factor. Rather, it leads specifically to an amplification of monocytic cells.  
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Monocytes can give rise to DCs or macrophages. It has already been demonstrated 
that recombinant CD137 protein or anti-CD137L antibodies can induce activation, 
survival and proliferation in peripheral monocytes (Langstein et al., 1998, 1999a, 
1999b; Ju et al., 2003). Our study extends these reports by showing that CD137 not 
only acts on mature monocytes but induces hematopoietic progenitor cells to grow 
and to differentiate to monocytes and macrophages. In man, macrophage 
differentiation is evidenced by increased phagocytosis, high IL-10 secretion, absence 
of IL-12 and dendritic cell markers (CD1a, CD83, CD209) (Smith et al., 1998). In 




 cells equal amounts of macrophages (CD14, F4/80) 
and DCs (CD11c) markers are induced by CD137 protein (Fig. 3.28), CD137L signals 
does not direct differentiation towards DCs, as shown by the inability of 
CD137-exposed cells to induce T cell proliferation in a MLR, and to secrete IL-12. 
Instead, high levels of IL-10 and increased phagocytic activity show that CD137L 
signaling induces macrophage differentiation in hematopoietic progenitor cells (Smith 
et al., 1998). The spindle-like morphology of the cells is also more consistent with a 
macrophage than a DC differentiation. The differentiative influence of CD137L 
signaling towards macrophages was specific since it did not enhance numbers of 
lymphoid, megakaryocytic or erythroid cells. 
 
CD137L crosslinking has been reported previously to support DC maturation. But in 
these studies DCs were derived from human umbilical cord blood CD34
+
 cells or 
peripheral monocytes via culture with cytokine cocktails for 1 to 7 days before 
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exposure to CD137 protein (Kim et al. 2002; Laderach et al. 2003; Lippert et al. 
2008). Our findings are not contradictory to these reports, rather they demonstrate 
wider biological activities of CD137 in myelopoiesis. While CD137 enhances 
maturation of immature DCs derived from hematopoietic progenitor cells, it will 
induce macrophage differentiation in hematopoietic progenitor cells when given as a 
first and sole signal. All these data suggest that CD137 may be a general growth and 
differentiation factor for monocytic cells, and are in line with the increased number of 
myeloid cells in a transgenic mouse overexpressing CD137 (Zhu et al., 2001).  
 
In addition, our data are partly in agreement with earlier studies which demonstrated 
that CD137 protein in combination with M-CSF increases proliferation of bone 
marrow-derived osteoclast progenitors but inhibits M-CSF + receptor activator of 
nuclear factor  ligand (RANKL)-induced osteoclast differentiation (Saito et al., 2004; 
Shin et al., 2006a). Some of the osteoclast progenitor cells that proliferated in 
response to CD137 together with M-CSF in the study by Saito et al. may also have 




 cell population of our study (Saito et al., 
2004). What is surprising however is that CD137 protein inhibited osteoclast 
differentiation while it promoted macrophage differentiation, since both cell types are 
closely related if not identical. This difference could be due to the different starting 




4.3 Is CD137 a general growth factor and activator for monocytic cells? 
By summarizing our results we found that CD137L agonist augment the proliferation 
of HSPCs and induce the differentiation to CFU-GM (GMP) in the first step (Fig. 3.5; 
3.23); and then induce further differentiation to macrophages at the expense of 
granulocytes (Section 3.1.6; 3.2.7; 3.3.4). Combination of CD137 with G-CSF and 
Flt3L cooperatively or additively induces survival and proliferation of bone marrow 
cells (Fig. 3.37; 3.43). CD137 and G-CSF antagonize each other in inducing 
differentiation of macrophages and granulocytes (Section 3.3.4), while CD137 
supports Flt3L induced DC differentiation (Fig. 3.44). Recent work from our lab also 
shows that CD137 alone can induce differentiation of human peripheral monocytes 
into DCs and can induce the maturation of the immature DCs (unpublished data from 
Shaqireen D/O K. M. M., and Schwarz H.).  
 
It seems that CD137L signaling generally sustains the process of myelopoiesis 
starting from CFU-GM. It supports the differentiation of macrophages, monocytes 
and DCs depending on the environment and especially the presence of other 
hematopoietic growth factors. A proposed schematic summary of CD137-induced 
myelopoiesis is depicted in Fig. 4.1. In addition, previous studies have shown that 
CD137 is able to induce activation and maturation of monocytes and DCs. Therefore, 
CD137 can be recognized as a general growth factor and activator for myeloid cells, 





Figure 4.1. Proposed schematic summary of CD137-induced myelopoiesis. (m), 





 bone marrow cells T cells? 
CD137 is expressed on a small subset of total bone marrow cells (Fig. 3.1 A; Fig. 3.25 
B, D), and the next important question we want to address was the nature of the 
CD137-expressing cells in the bone marrow.  
 
Since we have shown that CD137 expression in the bone marrow can induce 
hematopoiesis, or more specifically monocytopoiesis, we first looked at the bone 
marrow stromal cells, which are well known to provide a unique niche to support the 
hematopoiesis in the bone marrow (Heissig et al., 2005; Yin and Li, 2006). Although 
AA101 cells, a human bone marrow derived stromal cell line, expresses CD137 and 
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the expression seems to be under a certain regulation (Fig. 3.46), we could not detect 
CD137 expression on ST-2 and MS-5 cells, two murine bone marrow stromal cell 
lines (Fig. 3.47). This suggested that bone marrow stromal cells were unlikely the 
source of CD137 expression in the bone marrow. CD137 detected on AA101 cells 
may be an epigenetic effect of cellular transformation. CD137 may merely be a tumor 
antigen expressed by the AA101 cell line as its expression has been documented in 
several cancers, including osteosarcoma (Lisignoli et al., 1998), lung cancer (Zhang et 
al., 2007), non-Hodgkin’s lymphoma (Furtner et al., 2005), among others. 
 
We then turned to T cells, since CD137 was originally found on activated T cells, and 
activated T cell can quickly upregulate CD137 expression (Kwon et al., 1989; 
Schwarz et al., 1993). It is well known that T cell progenitors leave the bone marrow 
and enter the thymus at a very early stage of T cell development (Fowlkes and Pardoll, 
1989). CD137 expression on T cells is strictly activation dependent (Schwarz et al., 
1995), therefore, if the CD137-expressing cells in the bone marrow are T cells, they 
are likely to be circulating activated T cells that have been migrated back to the bone 
marrow.  
 
CXCR4 is an important chemokine receptor of HSCs for receiving homing signal to 
the bone marrow based on a gradient of CXCL12 (SDF-1) which is released by bone 
marrow stromal cells (Aiuti et al., 1997; Peled et al., 1999; Kollet et al., 2001). It has 
been shown that, during an infection, activated T cells also upregulate their CXCR4 
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expression to migrate back to the draining lymph nodes and thymus. And similar to 
HSCs and plasma cells, T cells can undergo transendothelial migration in response to 
CXCL12 in vitro, with memory T cells responding better than naïve T cells (Cinamon 
et al., 2001). Therefore, it is tempting and reasonable to speculate that 
CXCR4-expressing activated T cells, that also express CD137, could migrate back to 
the bone marrow too, based on the CXCL12 gradient, similar as the HSCs.  
 
In fact, some studies have already shown that activated CD4
+
 cells, migratory 
memory T cells, and FoxP3
+
 regulatory T cells could migrate back to the bone 
marrow compartment (Menteiro et al., 2005; Rosa and Pabst, 2005; Kim, 2006). Rosa 
and Pabst (2005) have shown that under physiological conditions, mature CD4 and 
CD8 T cells undergo extensive migration from blood to the bone marrow and vice 
versa, and that bone marrow can function as a secondary lymphoid organ for both 
CD4 and CD8 cells, as well as a preferential homing site for memory T cells (Rosa 
and Pabst, 2005). This is further proven by Li and colleagues (2007), who have shown 
that bone marrow is a preferential homing site for autoreactive T cells in type 1 
diabetes; and that bone marrow could serve as a reservoir for memory T cells (Li et al., 
2007). Monteiro and colleague (2005) have demonstrated that activated CD4
+
 bone 
marrow T cells produce hematopoietic-related cytokines and essential for 
hematopoiesis stimulation during infection and hematologic recovery after bone 
marrow transplantation. The authors therefore conclude that the “normal 
hematopoiesis” does not reflect a basal level bone marrow activity, but it is 
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antigen-induced state maintained by constant activation of bone marrow CD4
+
 T cells 
(Monteiro et al., 2005). The bone marrow T cells only comprise ~ 3 – 8% of nucleated 
bone marrow cells (Zeng et al., 2002; Westermann and Pabst, 1992), which correlates 
well with the low frequency of CD137
+
 cells in the bone marrow (Fig. 3.1 A; Fig. 
3.25 B).   
 
In our B. pertussis and Influenza A H1N1 infection models a direct effect of the 
pathogens on bone marrow cells can be excluded since both pathogens infect the lung 
and not the bone marrow. Instead, we hypothesize that T cells in the lung or in 
lung-draining lymph nodes become activated in response to the infection and induce 
expression of CXCR4 and CD137, which plays an important role in anti-pathogen 
immune responses in the lung (Lin et al., 2009; Harrison et al., 2006). These 
CD137-expressing T cells then migrate back to the bone marrow and interact with 
HSPCs and induce proliferation and myelo-monocytic differentiation. The newly 
generated monocytic cells may then leave the bone marrow and migrate to the 
inflammation site and assist in the clearance of the pathogens under the help of Th1 
cytokines.  
 
However, we could not exclude the possibility that the CD137-expressing cells in the 
bone marrow are other immune cells, such as NK cells or macrophages, which have 
been reported to express CD137 at low level (Melero et al., 1998; Lin et al., 2008; 
Kienzle and von Kempis, 2000). The true identity of CD137-expressing bone marrow 
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cell requires further studies in the future. A multi-color flow cytometric analysis will 
be a good start.  
 
 
4.5 Does CD137L signaling influence myelopoiesis differently during steady state 
conditions and during immune responses? 
As stated at the end of section 4.1, the function of CD137L signaling in myelopoiesis 
seems to be opposite at activated immune states and steady state conditions. 
 
4.5.1 CD137 induces myelopoiesis during infection 
CD137 activation is found to be associated with various immune activation 
conditions.  
 
Bacterial and mycobacterial infections are reported to induce CD137 expression. 
Upregulation of CD137 in osteoblastic cells was observed by infection with 
Mycobacterium bovis bacillus Calmette-Guérin (BCG), Escherichia coli, Salmonella 
typhimurium, and Staphylococcus aureus, and by treatment with lipopolysaccharides 
and heat-killed BCG in vitro (Saito et al., 2004). In vivo studies show that E. coli 






 cells in the bone 
marrow, and an increased number of CFU-GM (Zhang et al., 2008), which fits nicely 
to CD137-induced colony formation from HSPCs, with mainly CFU-GM (Fig. 3.5; 
3.22; 3.23). By using CD137-deficient mice, Lee and colleagues have shown that 
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CD137 is required for rapid clearance of Listeria monocytogenes infection by 
inducing rapid infiltration and activation of neutrophils and monocytes (Lee et al., 
2005, 2009). Curto and colleagues have showed that mycobacteria M. avium and M. 
tuberculosis could productively infect microglia, a macrophage-like cell in brain, and 
induce the expression of CD137. It is interesting that the expression of CD137 
appears much earlier and stronger, and is maintained longer with the more virulent 
mycobacterium (Curto et al., 2004). In line with these findings, our B. pertussis 
infection model also revealed that the expression of CD137 was upregulated in the 
bone marrow, and was correlated to the virulence of the bacterial strains (Fig. 3.48).   
 
During influenza viral infection, CD137 is reported to be induced on lung T cells, 
transiently or sustained depending on the severity of the infection. Endogenous but 
not transgenic over-expressed CD137L plays a critical role in protecting mice from 
severe effects of influenza disease (Lin et al., 2009). Mice infected with 
cytomegalovirus (CMV) showed defects in hematopoiesis in the bone marrow with 
increased numbers of progenitor cells (personal communication with Degli-Esposti M. 
A.). This observation may somehow relate to the CD137 expression, if we consider 
that influenza A infection causes an increased number of CD137-expressing cells in 
the bone marrow (Fig. 3.49), which could potentially induce the proliferation of 
HSPCs in the bone marrow.  
 
Our results show that inflammation induced by systemic administration of high levels 
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of endotoxin such as LPS from E. coli can increase the number of CD137-expressing 
cells in the bone marrow (Fig. 3.50). It is also reported that LPS preferentially induces 
CD137L expression on human MoDCs, and that the sorted CD137L
hi
 cells could 
potently augment T cell expansion and survival (Lee et al., 2003).  
 
Furthermore, inflammation caused by thermal injuries and sepsis often lead to 
monocytosis accompanied with neutropenia (Santangelo et al., 2001; Shoup et al., 
1998). Since CD137 is able to drive HSPCs away from granulocytic but towards 
monocytic differentiation (Fig. 3.39; 3.40; 3.41), perhaps CD137 plays an important 
role in burn induced inflammation. Interestingly, CD137 expression on human T cells 
is also upregulated by DNA damaging agents such as anti-cancer drugs, or 
γ-irradiation (Kim et al., 2002). 
 
The circumstances discussed above; including viral infection, bacterial infection, 
mycobacterial infection, high level of endotoxin, thermal injury, and DNA damage; 
can be recognized as danger signals or sensed as stress by the host. The immune 
system becomes activated in response to such danger signals. CD137 seems to play a 
significant role in initiating and sustaining the immune activation. Among all the 
events induced by CD137L signaling, the induction of myelopoiesis in the bone 
marrow by CD137
+
 cells seems to be an indispensable one.   
 
4.5.2 CD137 limits myelopoiesis and the development of DCs at steady state  
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Recently, Lee and colleagues (2008) found CD137L expression on HSCs, 
differentiating CMPs and GMPs, and CD137 expression was inducible on activated 
myeloid progenitors. They claimed that CD137 and CD137L had a function to limit 
myelopoiesis and the development of DCs by showing that steady-state numbers of 
GMPs, myeloid lineage cells, and mature DCs were higher in CD137- and 
CD137L-deficient mice; and absence of interaction between CD137 and CD137L led 
to enhanced differentiation into DC lineages (Lee et al., 2008).  
 
The discrepancies between Lee et al.’s and our study and previous studies may reflect 
the different function of CD137 / CD137L in regulation of hematopoiesis, particularly 
myelopoiesis and DC development at different physiological conditions. In order to 
allow clearance of the pathogen, CD137L signaling tends to induce myelopoiesis in 
an inflammatory condition, while it tends to inhibit myelopoiesis at steady state to 
maintain the balance and homeostasis. This is partially confirmed by the follow-up 
study on the consequence of CD137 on DC survival and function during an activated 
immune state. Choi and colleagues, (2009) reported that, during LPS induced 
inflammation and Propionibacterium acnes infection, CD137 functioned as a survival 
factor for DCs by maintaining high level of Bcl-2 and Bcl-XL (Choi et al., 2009). 
 
One very recent review has discussed this issue as well (Wang et al., 2009). The 
author was concerned about the differences between Lee et al.’s and our studies. Lee 
et al. (2008) tested the effect of CD137-Fc on myeloid progenitors over 4 days of 
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culture, and showed no effect of CD137-Fc on WT cells (Lee et al., 2008). However, 
we showed little effect of CD137-Fc on expansion of bone marrow cells in the first 
few days of culture, but CD137-Fc treatment resulted in a dramatically enhanced bone 
marrow cell expansion at 7-12 days of culture (Jiang et al., 2008a, 2008b). 
Nevertheless, we believe that different timing (early vs. late) may not be the main 
reason for the discrepancy. The transient signaling may come closer to the truth; 
because expression of CD137 at high level occurs only transiently during acute 
inflammation, which is likely the situation that our experiments mimick. In contrast, 
the experiments of Lee and colleagues dealt with the steady state situation with low 
and constant CD137 expression. 
 
 
4.6 Are HSPCs differentiated by CD137 regulatory macrophages or MDSCs? 
Our studies show that, by in vitro culture with immobilized CD137 protein for 7 days 





profile (Fig. 3.10; 3.11; 3.29; 3.31). In an 
allogeneic MLR, these cells cannot induce T cells proliferation (Fig. 3.12; 3.30), and 
more importantly, they suppress the T cell proliferation induced by allogeneic mature 
DCs (Fig. 3.33). These data suggest that in vitro CD137 expanded cells are 
immunosuppressive. There are three major groups of myeloid cells that possess 
immunosuppressive functions – tolerogenic DCs, regulatory macrophages and 
MDSCs. 
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Our results showed that CD137-treated cells are not likely DCs, ruling out the 
possibility that the cells are tolerogenic DCs.  
 
Macrophages are also important effector cells in tumor immunity besides CTL and 
NK cells. Depending on the phenotype, macrophages can either promote or prevent 
tumor progression. According to the traditional M1 / M2 classification, the so-called 





 phenotype, whereas alternatively activated macrophages are 




 phenotype (Gordon, 2003). 
According to the new grouping system based on homeostatic functions, the so-called 
regulatory macrophages produce high levels of the immunosuppressive cytokine 
IL-10, and also downregulate IL-12 production (Gerber and Mosser, 2001), and the 
ratio of IL-10 to IL-12 could be used to define regulatory macrophages (Mosser and 
Edwards, 2008). The morphology and phenotypes of CD137-differentiated HSPCs fit 
the description of regulatory macrophages or alternatively activated macrophages 
quite well. Moreover, since the differentiated cells produce high level of MCP-1 and 
IL-8 in the murine and human system (Fig. 3.32 A; 3.13), respectively, the cells are 
believed to be activated. However, they do not produce M-CSF and IL-6 (unpublished 
data from Tang Q. and Schwarz H.), which is usually seen in classical activated 
monocytes/macrophages. This in turn indicates that the differentiation and activation 
of murine monocytic cells by CD137 is not through the classical pathways.    
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Because there were immature myeloid cells in the culture of CD137-treated HSPCs, 
these cells could also be MDSCs. Movahedi and colleagues described MDSC can be 
divided into two subpopulations including monocytic cells and polymorphonuclear 
(PMN) cells (Movahedi et al., 2008). However, Gallina and colleagues showed that 
MDSCs are mainly inflammatory monocytes but not granulocytes (Gallina et al., 







and the MDSC have mixed M1 and M2 type characteristics (Umemura et al., 2007). 
These characteristics are quite similar to our CD137-treated cells. They are 
macrophage like cells, most of them are CD11b
+
, and some of them co-express 
CD11c (Fig. 3.28), and they can effectively suppress T cell proliferation induced by 
mature DCs. A study from our lab also indicated that the CD137-treated human 
monocytes exhibit mixed characteristics of M1 and M2 macrophages in terms of the 
prolife of cytokine secretion, signature gene expression, and surface receptor 
expression (unpublished data from Toh K. L. and Schwarz H.).  
 





 cells could partially suppress T cell proliferation in an 
allogeneic MLR too, but with less extent (unpublished data). This indicated that both 
soluble mediators and cell-cell interactions were essential for the suppressive function. 
In preliminary studies the neutralizing anti-IL-10 antibody has not shown any effect 
on reversing the suppressive function (unpublished data), suggesting that the classical 
immunosuppressive cytokine IL-10 may not be one of the soluble factors mentioned 
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above. The detailed immune suppressive mechanisms of CD137 differentiated HSPCs 
require further investigation.   
 
In shot, the cells augmented and differentiated in vitro from HSPCs by CD137L 
signaling could be regulatory macrophages or MDSCs or a mixture. However, we still 
don’t know whether this is also the case in vivo. If the answer is yes, then this 
population of regulatory macrophages or MDSCs could be a potential target for 
cancer immunotherapy. The patients should have better immune response against 
tumors by preventing the generation or by a direct depletion of these regulatory cells.  
 
 
4.7 Is CD137-induced myelopoiesis beneficial or deleterious for the host?  
As discussed and speculated above, after the host senses danger signals, the 
expression of CD137, probably on T cells, is upregulated. The activated 
CD137-expressing T cells migrate back to bone marrow and induce myelopoiesis. The 
newly generated monocytes then leave the bone marrow and enter the circulation. 
Whether these cells are beneficial or deleterious depends on their immunological 
phenotypes: immunostimulatory or immunoregulatory. 
 
As shown in Results under section 3.2.8, in vitro treatment of HSPCs with CD137 
leads to suppressive cells; however, in vivo the situation is very likely more complex. 
The characteristics of the differentiated cells usually depend on the microenvironment. 
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In a long lasting immune activation, e.g. a sustained infection, high levels of 
inflammatory cytokines such as TNF (Mosser and Edwards, 2008) are maintained at 
the inflammation site. Under the influence of these inflammatory cytokines and the 
associated microbial pathogens or cellular stress, the CD137-induced monocytic cells 
would go through maturation and activation and elicit anti-microbial effector 
functions. Of course, the myelopoiesis induced by CD137 in this situation is 
beneficial for the host in fighting the infection. On the other hand, if this happens in 
the context of an autoimmune reaction, the disease is getting worse with the influx of 
new differentiated inflammatory macrophages.    
 
However, in contrast to the situation of an infection and inflammation, in a tumor 
microenvironment, high levels of immunosuupressive cytokines such as IL-10 and  
TGF- are maintained by the tumor cells, tumor stromal cells, and / or tumor 
infiltrating immune cells, while the production of Th1 cytokines such as TNF and 
IL-12 is inhibited (Dumont and Arteaga, 2002; Sierra, 2005). In the tumor 
microenvironment, the CD137-induced cells would differentiate into regulatory 
macrophages or tumor associated macrophages (TAM), which dampen the immune 
response and in turn are beneficial for tumorigenesis. This may be one of the 
mechanisms that some tumor cells express CD137 as neoantigen, in order to induce 
the local myelopoiesis and yield more TAM to gain advantage for growth. 
Interruption of this process could lead to the inhibition or eradication of tumors. 
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In summary, CD137-induced myelopoiesis is an outcome of stress conditions. It is a 
natural response that the host requires more leukocytes to deal with these conditions. 
Whether the outcome is beneficial or deleterious for the host depends on the 
microenvironment and cytokine milieu that the newly generated cells would 
encounter after they enter the circulation.    
 
 
4.8 At what differentiation stage do HSPCs respond to CD137?  
Both the CD34
+




 cells in murine system 
contain progenitor cells of different stages of development ranging from multipotent 
long-term hematopoietic stem cells (LT-HSCs) to already committed progenitor cells 
(Ogawa et al., 1991; Adolfsson et al., 2001; Christensen et al., 2001). So the next 
question we asked was at what stage the progenitor cells start to respond to CD137.  
 
The most primitive cells are embryonic stem (ES) cells, and CD137 showed no 
significant impact on murine and human ES cells (Fig. 3.34; personal communication 
by Kadereit S.). 
 
Long-term HSCs (LT-HSCs) are defined by their ability to give rise to the lymphoid 
and myeloerythroid lineages for life after transplantation into lethally irradiated 
recipients while short-term HSCs (ST-HSCs) and committed CFUs have more limited 
self-renewal capacity and are capable to respond to stimuli within 6 – 14 days 
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(Christensen et al., 2001; Capmany et al., 1999). The fact that CD137 protein induced 
proliferation, colony formation and myeloid differentiation of CD34
+
 cells within 14 




 cells within 7 days, suggests that the responding cells were 
ST-HSCs and myeloid progenitor cells, including CFU-GM and CFU-M. Whether 
more primitive progenitor cells such as LT-HSCs can also be activated by CD137 will 
need to be determined in future studies.  
 
We found both G-CSF and CD137 are able to induce proliferation of hematopoietic 
progenitor cells and an increase in cell numbers with comparable potencies. The 
combination of G-CSF and CD137 generated significantly (p<0.05) more cells during 
a 7-day culture period than either factor alone but had neither a synergistic nor an 
additive effect on the number of live bone marrow cells (Fig. 3.37), which implies that 
either CD137 or G-CSF alone is sufficient for ensuring growth or survival of the 
responding progenitor cells, and the two factors are largely exchangeable for these 
effects. The nature of responding cell population is not known. The fact that CD137 
protein and anti-CD137L antibodies can influence differentiation of granulocytes, 
monocytes and DCs indicates that the target cell for CD137 is a progenitor cells 
which can give rise to all three cell types, which would be CFU-GM or an even more 
primitive progenitor cell. The fact that CD137 and G-CSF compete in determining 
differentiation pathways also suggest that the responding cell population is CFU-GM 
or earlier.  
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However, CD137 and Flt3L showed much weaker cooperative effects on the 




 cells than that of bone marrow cells 




 seems to be dominant and it 
masks the effect from CD137. Combined with the fact that Flt3, the receptor of Flt3L, 
is expressed mainly by the HSPCs in the bone marrow, the CD137 responding cells 
should be committed progenitor cells rather than the true stem cells.  
 
Our preliminary data showed that as early as CMPs and one of their direct progeny 
GMPs (equivalent to CFU-GM) can respond to immobilized CD137-Fc protein 
effectively in terms of morphological changes. We will investigate the details in the 
future and further look into multi-potential progenitors (MPPs) and ST-HSCs. 
 
 
4.9 How can a small population of CD137 and CD137L expressing cells in bone 
marrow cause such wide-spread functional effects? 
Only few cells in the bone marrow stained positive for CD137, and only 1 – 3% of 
CD34
+
 cells were found to express CD137L (Fig. 3.1). These low expression levels 
are contrasted by the comparatively large biological response of CD34
+
 cells upon 
crosslinking of CD137L.  
 
One possible explanation is that CD137L may be expressed on a small subpopulation 
of cells which can proliferate very potently upon CD137L crosslinking. Or 
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crosslinking of CD137L on the few cells which express it leads to secretion of soluble 
factors which then induce proliferation of a larger number of cells which do not need 
to express CD137L. IL-8 is likely to be one of the candidates among the various 
hematopoietic growth factors, since CD137L signaling leads to substantial IL-8 
release (Fig. 3.13), and neutralizing IL-8 partially blocked CD137-induced 
proliferation of CD34
+
 cells (Fig. 3.14). The partial dependency of CD137L signaling 
also indicates that besides IL-8 there are other signaling pathways involved, which 
require further investigation.  
 
Alternatively, the detection methods used were not sensitive enough, thereby 
underestimating expression levels of CD137 and CD137L. Similar to us, Lee and 
colleagues (2008) also showed that the expression level and the frequency of CD137 
on the hematopoietic progenitor cells were very low (Lee et al., 2008). It is a fact 
accepted among our peers that CD137L expression is difficult to detect, as its 
expression is transient, and it can be released from cells by metalloproteinase cleavage 
(Salih et al., 2001). Furthermore, Lin and colleagues (2009) have managed to show 
that the level of endogenous CD137L that is protective in severe influenza infection is 
very low, and below the limit of detection at the protein level by flow cytometry and 
immunofluorescent staining, although detectable at the mRNA level (Lin et al., 2009).  
 
Everything has its two sides and the immunity is not an exception. The balance of the 
immune system needs to be carefully considered when we apply immunotherapy. For 
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example, transfer of an optimal number of naïve T cells protects against an otherwise 
lethal dose of infection, but transfer of too many T cells results in disseminated 
inflammation and results in death likely due to CD8 T cell-mediated pathology. 
CD137 receptor / ligand system shows the same characteristic. Intranasal delivery of 
CD137L by recombinant adenovirus marginally improves survival of CD137L 
-deficient mice at low dose, but exacerbates disease at high dose (Lin et al., 2009).  
 
The expression of inducible costimulatory molecule pairs such as CD137 - CD137L is 
under tight regulation in vivo. Perhaps they have been acquired by the immune system 
to handle progressively more virulent infections, so as to maintain the effector CD8 T 
cell responses when required, but avoid excessive immunity when the danger signal is 
readily cleared. All these facts suggest that it is not the absence or presence of CD137 
/ CD137L causes all the effects, rather the magnitude of or the changes in CD137 / 
CD137L expression determines the outcomes. The subtle change in CD137 / CD137L 
expression level makes a huge impact on the balance of homeostasis and immune 
response. Thus, the positive regulation of CD137 expression in the bone marrow 
during infection and inflammation (Section 3.5.2 – 3.5.4) should be considered to be 
important for host defense.   
 
 
4.10 Future studies 
As we discovered that CD137L signaling plays a role in myelopoiesis more questions 
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emerged. Five main aspects are currently under investigation or going to be studied in 
future.  
 
First, we would like to further explore the function and underlying mechanisms of the 
immunosuppressive cells differentiated from HSPCs by CD137. Several possible 
mechanisms of regulatory macrophages or MDSC suppressing T cell activation have 
been proposed. 1) They have direct suppressive functions on T cells: e.g. they produce 
reactive nitrogen compounds (peroxynitrites) that nitrosylate CD8 and the TCR on T 
cells to block T cell activation (Nagaraj et al., 2007); 2) they express coinhibitory 
molecules such as PDL-1; 3) they release IL-10 to induce immature DCs becoming 
tolerogenic DC; 4) they suppress IL-12 release to abolish NK cell function; 5) they 
produce ROS or RNS to induce apoptosis in T cells.   
 
Second, the identity of CD137
+
 cells in the bone marrow need to be confirmed. In 
vivo transfer of activated T cells into WT or CD137-deficient mice will be a good 
attempt to start. The composition of the bone marrow, spleen and the peripheral blood 
of the hosts will be analyzed. At the same time, a methodology that can sensitively 
detect the low frequency of CD137
+ 
cells among the bone marrow cells in 
combination with other lineage markers needs to be established.   
 
Third, We are going to look at the function of CD137 in granulopoiesis, the other arm 
of myelopoiesis besides monocytosis. The antagonism of CD137 and G-CSF on each 
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other in inducing differentiation of GMPs will be analyzed in details using 
immnuofluorescent tracking system at the single cell level together with a collaborator. 




 cells in this project, 
the identity of the earliest responder cells among the progenitor cells at different 
stages will be explored as well.   
 





 cells, same as PBS controls (Fig. 3.17, 3.18, 3.19). However, since 
monocytes, macrophages and DCs express Fc receptors, Fc protein may have some 
influence on monocytic cell differentiation, as we have seen in Fig 3.6A and 3.27A. 
Therefore, a recombinant CD137 protein without the Fc part needs to be developed. 
To remove the Fc portion on CD137-Fc simply by enzymatic cleavage of the linker 
between them may not be a good choice, because the proteases are not specific 
enough to give a clean cut. This may lead to the cleavage of extracellular domain of 
CD137 too. For purification purpose, CD137 could be fused with other affinity tags, 
such as His-, HA-, or GST-tag. Other Fc-free systems, such as expressing CD137 on 
cell surface (Fig. 3.26B) or immobilizing CD137-Fc on protein A-coupled beads (Fig 
3.4B), could also be applied to figure out whether the differentiation of HSPCs is 
induced by CD137 alone or with the combinantion of Fc.   
 
Last but most important, We have to find a recipe to delivery CD137 in vivo. Since 
crosslinking CD137L requires oligomerized CD137, CD137 protein has to be 
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immobilized onto a delivery vector, which is small enough and stable enough to 
deliver CD137 into the bone marrow compartment. Functional efficacy need to be 
monitored in the animal models to evaluate the functions of CD137-induced 
myelopoieisis in vivo.     
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CHAPTER 5  CONCLUSION 
 
The detection of CD137 and CD137L expression in bone marrow, and the induction 
of proliferation, colony formation, increase in cell numbers and differentiation of 
HSPCs – CD34+ cells in the human system, and Lin-, CD117+ cells in the murine 
system – identify novel biological activities for CD137 and its ligand, indicating a 
role for this receptor / ligand system in hematopoiesis. This is further confirmed by 
demonstrating that the number of CD137
+
 cells in the bone marrow increases during 
viral and bacterial infection and inflammation. CD137 and G-CSF or Flt3L function 
cooperatively on promoting survival and proliferation of HSPCs, although they drive 
divergent differentiation pathways. This study extends previous knowledge that 
signals through CD137L induce activation, proliferation and survival in monocytes, 
and enhance maturation of DCs, and thereby shows that CD137 and CD137L regulate 
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Appendix I. Buffers and Solutions 
 
PBS (working concentration, 1×) 
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 in 1 L H2O, pH 7.4 
 
FACS buffer 
0.5% FBS, 0.02% NaN3 in PBS, pH 7.4 
 
MACS buffer 
0.5% FBS, 2 mM EDTA in PBS, pH 7.4 
 
RBC lysis buffer 
0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA in H2O, pH 7.4 
 
ELISA wash buffer (PBST) 
0.05% Tween-20 in PBS 
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Appendix II. List of antibodies used in the study 
 
 
Antibody Clone Source 
Rat anti-mouse CD137L (PE, biotin) TKS-1 eBioscience 
Hamster anti-mouse CD137 (PE) 17B5 eBioscience 
Armenian hamster IgG (PE, FITC, biotin) eBio299Arm eBioscience 
Hamster anti-mouse CD3e (PE, FITC) 145-2C11 eBioscience 
Rat anti-mouse CD4 (FITC) GK1.5 eBioscience 
Rat anti-mouse CD11b (PE) M1/70 eBioscience 
Rat anti-mouse CD11c (PE, FITC) N418 eBioscience 
Rat anti-mouse CD14 (PE) Sa2-8 eBioscience 
Rat anti-mouse CD19 (PE) 6D5 eBioscience 
Rat anti-mouse CD80 (PE) 16-10A1 eBioscience 
Rat anti-mouse CD86 (PE) PO3.1 eBioscience 
Rat anti-mouse CD117 (c-kit) (FITC) 2B8 eBioscience 
Rat anti-mouse CD117 (c-kit) (PE) 3C1 Miltenyi 
Rat anti-mouse Gr-1 (Ly6C/G) (PE, FITC)  RB6-8C5 eBioscience 
Rat anti-mouse Gr-1 (Ly6C/G) (biotin)  RB6-8C5 BioLegend 
Rat anti-mouse Ly6G (FITC) 1A8 BD Pharmingen 
Rat anti-mouse F4/80 (PE) BM8 eBioscience 
Rat anti-mouse MHC-II (I-A/I-E) (PE, FITC) M5/114.15.2 eBioscience 
Rat anti-mouse Sca-1 (Ly6A/E) (APC) D7 eBioscience 
Rat IgG2a (PE, FITC, biotin) eBR2a eBioscience 
Rat IgG2b (PE, FITC, biotin) eB149/10H5 eBioscience 
Rat anti-mouse CD3 (LEAF) 17A2 BioLegend 
Hamster anti-mouse CD28 (LEAF) 37.51 BioLegend 
Rat anti-mouse GM-CSF (LEAF) MP1-22E9 BioLegend 
Rat IgG2b (LEAF) RTK4530 BioLegend 
Syrian hamster IgG (LEAF) SHG-1 BioLegend 
   
Mouse anti-human CD137L (PE) 5F4 Biolegend 
Mouse anti-human CD137L (PE) C65-485 BD Pharmingen 
Mouse anti-human CD137 (PE) 4B4-1 BD Pharmingen 
Mouse anti-human CD137 (biotin) BBK-2 NeoMarkers 
Mouse IgG1 (unconjugated, PE) MOPC-21 Sigma 
Mouse IgG1 (FITC, APC) MOPC-21 eBioscience 
Mouse anti-human CD3 (PE) UCHT1 eBioscience 
Mouse anti-human CD11b (PE) ICRF44 eBioscience 
Mouse anti-human CD11b (PE) M1/70.15.11.5 Miltenyi 
Mouse anti-human CD14 (PE) 61D3 eBioscience 
Mouse anti-human CD19 (PE) HD37 eBioscience 
Mouse anti-human CD34 (PE, FITC) AC136 Miltenyi 
Mouse anti-human CD41 (PE) HIP8 eBioscience 
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Mouse anti-human CD45 (PE) 5B1 Miltenyi 
Mouse anti-human CD68 (PE) Y1/82A eBioscience 
Mouse anti-human CD83 (PE) HB15e eBioscience 
Mouse anti-human CD209 (DC-SIGN) (FITC) eB-h209 eBioscience 
Mouse anti-human CD235a (PE) HIR2 eBioscience 
Mouse anti-human HLA-DR (APC) LN3 eBioscience 
Mouse anti-human IL-8 (unconjugated) 6217.11 Sigma 
Goat anti-human IgG (Fc specific) (FITC) polyclonal Sigma 
   
Streptavidin (HRP) - Sigma 
Extravidin (Cy3) - Sigma 
Goat anti-rat IgG (Cy2) polyclonal Millipore 
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Appendix III. Primers and cycling conditions for RT-PCR 
 
 








mCD137-F: 5’-ATG GGA AAC AAC TGT TAC AAC G-3’ 
57 40 518 
mCD137-R: 5’-ACA GAA ATG GTG GTA CTG GGA G-3’ 
m CD137L 
MurCD137L-SEN.F: 5’-GCA CTG AAA GCT TGC CGC 
CAT GGA CCA GCA CAC ACT T-3’ 
55 30 961 
MurCD137L-SEN.R: 5’-GAA GGA GAA TTC TCA TTC 
TCA TTC CCA TGG GTT GTC GGG-3’ 
m GAPDH 
GAPDH-F: 5’-TGG TAT CGT GGA AGG ACT CAT GAC-3’ 
57 25 190 
GAPDH-R: 5’-ATG CCA GTG AGC TTC CCG TTC AGC-3’ 
h CD137 
CD137 SEN.F HindIII: 5’-TGT GCA AGC TTC CAC CAT 
GGG AAA CAG CTG TTA CAA C-3’ 
57 40 793 
CD137 SEN.R EcoRI: 5’-ACT GAA TTC TCA CAG TTC 
ACA TCC TCC TTC-3’ 
h CD137L 
hCD137L-F: 5’-GGA ATA CGC CTC TGA CGC TT-3’ 
57 40 650 
hCD137L-R: 5’-TGT GAA GAT GGA CGC CCA G-3’ 
h FcR 
FCGR1A-F: 5’-ATG TGG TTC TTG ACA ACT CTG C-3’ 
56 40 550 
FCGR1A-R: 5’-GAC AGA TAT TCC TGC TGA TGT G-3’ 
h TCF7L2 
TCF7L2-F: 5’- GAT GAC CTA GGC GCC AAC GA-3’ 
59.5 40 585 
TCF7L2-R: 5’- TTT GGG GTC TAC GTC GGC TG-3’ 
h WNT5A 
WNT5A-F: 5’-AGA AGT CCA TTG GAA TAT TAA GCC 
C-3’ 56 40 666 
WNT5A-R: 5’-CGT TGT TGT GCA GGT TCA TGA-3’ 
h FcR1A 
FCER1A-F: 5’-CTC CTG CCA TGG AAT CCC CT-3’ 
59.5 40 607 
FCER1A-R: 5’-AGC CAG TAC TTC TCA CGC GG-3’ 
h Fibronectin 
FN1-F: 5’-ACG GGA GCC TCG AAG AGC AA-3’ 
59.5 40 737 
FN1-R: 5’-TTC CAC TCT CCT CGG CCG TT-3’ 
h SOCS1 
SOCS1-F: 5’-GGT AGC ACA CAA CCA GGT GGC A-3’ 
61.5 40 618 
SOCS1-R: 5’-AAG GAG CTC AGG TAG TCG CGG A-3’ 
h TGF- 
TGFA-F: 5’-CCT GTT CGC TCT GGG TAT TGT G-3’ 
59.5 40 428 
TGFA-R: 5’-CGG TTC TTC CCT TCA GGA GG-3’ 
h Cyclophilin 
cyclophilin-F: 5’-GTC CAG CAT TTG CCA TGG AC-3’ 
55 30 200 
cyclophilin-R: 5’-GAC AAG GTC CCA AAG ACA GC-3’ 
m = mouse, h = human, TA = annealing temperature. 
 
 192 
Appendix IV. The antibody list and the map of cytokine antibody array 
 
 
 A B C D E 
1 POS POS POS POS Blank 
2 NEG NEG NEG NEG Blank 
3 Eotaxin-2  FAS ligand  Fractalkine  G-CSF  GM-CSF  
4 Eotaxin-2  FAS ligand  Fractalkine  G-CSF  GM-CSF  
5 IL4 IL5  IL6 IL9 IL10 
6 IL4 IL5  IL6 IL9 IL10 
7 Lymphotactin MCP-1  MCP-5  M-CSF  MIG 
8 Lymphotactin MCP-1  MCP-5  M-CSF  MIG 
9 SDF-1-alpha  TARC  TCA-3  TECK  TIMP-1  
10 SDF-1-alpha  TARC  TCA-3  TECK  TIMP-1  
 F G H I J 
1 axl BLC CD30L CD30/TNFRSF8 CD40 
2 axl BLC CD30L CD30/TNFRSF8 CD40 
3 IFN-gamma  IGF-BP-3  IGF-BP-5  IGF-BP-6  IL1-alpha  
4 IFN-gamma  IGF-BP-3  IGF-BP-5  IGF-BP-6  IL1-alpha  
5 IL12-p40/p70 IL12-p70  IL13  IL17 KC 
6 IL12-p40/p70 IL12-p70  IL13  IL17 KC 
7 MIP-1-alpha  MIP-1-gamma  MIP-2  MIP-3-beta  MIP-3-alpha  
8 MIP-1-alpha  MIP-1-gamma  MIP-2  MIP-3-beta  MIP-3-alpha  
9 TNF-alpha  sTNF RI  sTNF RII TPO VCAM-1 
10 TNF-alpha  sTNF RI  sTNF RII TPO VCAM-1 
 K L M N  
1 CRG-2  CTACK CXCL16 Eotaxin  
2 CRG-2  CTACK CXCL16 Eotaxin  
3 IL1-beta  IL2  IL3  IL3 Rb   
4 IL1-beta  IL2  IL3  IL3 Rb   
5 Leptin R Leptin LIX  L-Selectin  
6 Leptin R Leptin LIX  L-Selectin  
7 PF4  P-Selectin RANTES SCF   
8 PF4  P-Selectin RANTES SCF   
9 VEGF Blank Blank Blank  
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